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The opportunistic pathogen Pseudomonas aeruginosa is the leading cause of morbidity and 
mortality in Cystic Fibrosis (CF) patients. Extensive genomic adaptation of this organism 
facilitates its emergence as a dominant organism within the lung microbial community and to its 
ability to chronically persist within the CF airways. The environmental and host factors 
contributing to the success of this species in vivo have been the subject of intensive research 
efforts. Gastro-oesophageal reflux (GOR) has recently emerged as a major co-morbidity in CF 
and a range of other respiratory conditions and is associated with the presence of bile acids in the 
lungs of CF patients, a consequence of micro-aspiration of refluxed gastric contents. This thesis 
aimed to investigate the impact that bile exerts on the global lung microbiota and the key CF 
associated pathogen P. aeruginosa.  
The detection of bile acids in paediatric CF patients using liquid chromatography mass 
spectrometry (LC-MS) analysis correlated with a reduction in lung microbial biodiversity and the 
emergence of dominant respiratory pathogens including P. aeruginosa. Bile acids may contribute 
to the progressive restructuring of the lung microbiota towards a pathogen dominated state 
associated with worse clinical outcomes. Bile and the active component bile acids were found to 
be capable of triggering P. aeruginosa to transition to a chronic, antibiotic tolerant lifestyle 
through a combination of transcriptional and phenotypic responses. Functional screens based on 
biofilm formation and growth on bile identified key two component systems mediating the 
biofilm response to bile with a connection to central metabolism becoming apparent. The latter 
screen identified the glyoxylate shunt as a key breakpoint in the suppression of redox potential as 
part of the bile response. Bile was also found to be capable of selecting for genetic variants in an 




derivatives emerged exclusively in the presence of bile with genome sequencing identifying 
single nucleotide polymorphisms (SNPs) in quorum sensing (lasR) and both the pyocyanin 
(phzS) and pyomelanin (hmgA) biosynthetic pathways. These mutations have been previously 
described in various clinical isolates of P. aeruginosa. Loss of Pseudomonas Quinolone Signal 
(PQS) production in the pigmented variants underpinned the loss of redox suppression in 
response to bile, perhaps a consequence of the anti-oxidant/pro-oxidant activities attributed to the 
PQS signalling molecule. Bile is therefore capable of influencing the evolutionary trajectory of 
this respiratory pathogen, a key finding in understanding the emergence of genotypic and 
phenotypic heterogeneity within the lungs of patients with respiratory disease.  
Collectively, this research supports the role for bile in the progression of chronic infection in CF 
through its impact on P. aeruginosa and other respiratory pathogens. Therefore, the early 
detection and profiling of bile acids utilising rapid point of care devices could lead to the 
identification of high risk paediatric patients and to the development of increasingly effective 
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1. The Antibiotic Crisis  
The discovery of penicillin in 1928 by Sir Alexander Fleming reshaped the landscape of modern 
medicine, revolutionizing the treatment of bacterial infections and saving the lives of countless 
millions in the process (1). Since then, a wide array of antibiotics have been discovered (2). 
However, this has coincided with the rapid emergence of antimicrobial resistance with resistance 
strategies described for almost all developed antibiotics (Fig. 1) (3). This challenge represents 
perhaps the greatest threat to modern medicine with urgent action required. The problem of 
resistance could be combatted, at least in part, by the development of novel antibiotics and the 
implementation of appropriate stewardship practices. However, there has been a significant 
reduction in pharmaceutical investment for the research and development of novel 
antimicrobials, with 15 of the 18 largest pharmaceutical companies abandoning this field of 
research which has contributed to the drying up of the antibiotic pipeline (4-8). Furthermore, the 
global over-reliance and over prescription of antibiotics has exacerbated the problem, increasing 
the rate of emergence of antibacterial resistant isolates. All of which was predicted and 





Figure 1. Timeline of the explosion in novel antibiotic discovery accompanied by the years in which there was reports 
of bacterial antimicrobial resistance. This highlights that for every new antibiotic introduced, the target bacteria 
evolved resistance strategies ensuring their survival. Adapted from Fair and Tor, 2014 and Ventola, 2015 (2,3).  
1.1 Challenges in the Clinical Control of Infection caused by ESKAPE Pathogens  
Epidemiologists have become particularly concerned about combatting nosocomial infections 
caused by the “ESKAPE” pathogens (11). This group encompasses both gram positive and gram 
negative bacteria and comprises Enterococcus faecium, Staphylococcus aureus, Klebsiella 
pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa and Enterobacter species. More 
recently, inclusion of Escherichia coli has been proposed under the acronym ESKAPEE (12). 
Members of the ESKAPE club are notorious for the numerous strategies of antimicrobial 




mechanisms which could subsequently be exploited for the development of new therapeutic 
strategies (11, 13).  
In 2017, the World Health Organisation (WHO) outlined a list of 12 priority pathogens, which 
included ESKAPE pathogens, designating them as either a critical, high or medium threat (Table 
1)(14). The threat posed by these pathogens is immediate, representing a significant clinical and 
economic challenge, as uncontrolled infections by these organisms can often be fatal. Though 
clinical control of infection is still manageable, there is now strong evidence to suggest we are 
rapidly approaching the onset of a post antibiotic era which may severely limit our capacity to 
treat currently controllable infections. Of particular concern is the increased incidence of chronic 
disease globally (15) and with it, the refractiveness of persistent chronic infections to 
conventional antibiotic treatments. The eradication of pathogens which have transitioned from an 
acute to chronic lifestyle and become established in the patient can be clinically challenging if 
not entirely impossible. Understanding the basis of this transition is a key focus in overcoming 










Table 1; WHO list of priority pathogens for the research and development of novel 
antimicrobials. 










Priority 2: High  
Enterococcus faecium 

















Priority 3: Medium 
Streptococcus pneumonia 









2. Chronic Respiratory Disease  
In recent decades, there has been an increase in the morbidity and mortality arising from chronic 
disease. Current estimates have placed chronic disease as the third leading cause of death 
worldwide (28), with the incidence projected to rise with the age profile of the global human 
population. Chronic respiratory diseases, including Cystic Fibrosis (CF), Chronic Obstructive 
Pulmonary Disease (COPD), asthma, idiopathic pulmonary fibrosis and non CF-Bronchiectasis, 
are rapidly emerging as a major global health problem (29). Economic losses linked to chronic 
respiratory disease can be primarily attributed to expenses associated with long term disease 
management and loss of productivity due to disability (30). In the European Union (EU) alone 




estimated €48.4 billion due to COPD alone and €33.9 billion due to asthma (30). The European 
Respiratory Society (ERS) reports that the economic costs associated with CF are in the region 
of 600 million per annum with mutation type shown to influence the cost of CF associated care 
(30, 31). It is expected with the advent of new and expensive therapeutics that this figure will 
increase substantially. Whilst the underlying pathophysiology of these respiratory diseases is 
unique, disease progression is often mediated by chronic infection or chronic inflammation 
which is accompanied by a gradual loss of lung function (32, 33). In fact, for COPD, CF and non 
CF-bronchiectasis, the “vicious cycle” hypothesis has been proposed whereby infection or 
inhalation of toxic substances, such as tobacco smoke, impairs the innate immune system within 
the lung. This induces an overt immune response resulting in chronic inflammation which further 
perpetuates chronic airway infection (32-34). 
2.1 Overview of the Pathophysiology of CF 
CF is the most common autosomal recessive genetic disease within the Caucasian population, 
affecting more than 70,000 people worldwide (35). This genetic condition results from a 
mutation in the Cystic Fibrosis Conductance Regulator (CFTR) gene encoding an Adenosine 
Triphosphate (ATP) driven chloride pump (36, 37). This protein is embedded in the cell 
membrane of all epithelial cells including the cells lining the lungs and gastrointestinal tract (GI 
tract). The mutation results in a defective CFTR protein which impairs normal airway clearance 
and results in the accumulation of a viscous mucus on the lining of epithelial cells, hence CF is 
considered to be a multisystem disorder (Fig. 2). The disease is found to affect the pancreas, 
resulting in pancreatic insufficiency, and the digestive tract causing gastrointestinal 
malabsorption and malnutrition. Hepatic defects are also common with a third of patients 





Figure 2. An overview of the pathophysiology of CF. CF results from a genetic defect in the CFTR gene resulting in 
abnormal chloride and water transport in and out of epithelial cells. The subsequent accumulation of a viscous mucus 
on the lining of the cell leads to a perpetual cycle of infection and inflammation culminating in a progressive loss of 
lung function. Taken from Boeck and Amaral, 2016 (58). 
2.2 CF and the Respiratory System 
The pathophysiology of CF is primarily considered to be respiratory in nature. The reduced 
airway surface hydration and build-up of viscous mucus on the lining of lung epithelial cells 
impairs mucociliary clearance in the airways. This defective mucociliary clearance has been 
proposed to be central to the progression of lung disease due to the ineffective clearance of 
pathogenic microorganisms from the lungs which are capable of causing airway infections (40, 
41). This results in the generation of an overt immune response culminating in prolonged 
inflammation in the lungs (42, 43). The heightened pro-inflammatory response to pathogens 
further exacerbates the problem (Fig. 2) (44). It has recently been shown, however, that 




Inflammation was detected prior to the onset of bacterial infection, which could be correlated 
with bronchiectasis at 1 years old (45, 46). Furthermore, mutation of the CFTR gene itself has 
been shown to lead to a dysregulation of host inflammation leading to bronchiectasis further 
promoting persistent airway infection. CFTR defects have been shown to generate a more acidic 
pH in the lungs which has been proposed to reduce the action of the pH sensitive innate immune 
system (47). What is clear is that infection drives inflammation and that inflammation can 
predispose to infection with these perpetual cycles of infection and inflammation underpinning 
bronchiectasis and progressive lung decline, the leading cause of morbidity and mortality in the 
CF cohort (35, 48, 49). 
2.3 Genetic Basis of CF 
The genetic basis of CF was first elucidated in 1989 (37). Since then over 2,000 mutations have 
been described in the CFTR gene with only 150 of these known to be definitive causative disease 
associated mutations (50, 51). These mutations can be classified in to six different categories 
depending on the functional consequence of the mutation in the gene on the protein (Fig. 3) (52). 
Consequently, a spectrum of disease severity ranging from mild to severe is evident in CF 
depending on the type of mutation present, a major determinant of clinical status. The presence 
of one partially functioning CFTR gene has been shown to dramatically reduce disease severity 




Figure 3. Genetic mutations in the CFTR gene can be categorized into 6 broad categories on the basis of the molecular 
defect in the CFTR protein arising from the mutation. The class of mutation present significantly affects disease 
severity and therapeutics available for treatment. Taken from Quintana-Gallego et al, 2014 (52). 
2.3.1 Classes of CFTR Gene Mutation 
The classes of CFTR gene mutation are outlined in the review by Veit et al. (55). Class I 
mutations result in the introduction of a stop codon into the messenger RNA leading to the 
production of a non-functional protein by the ribosome during translation. Class II mutations 
result in the production of a misfolded protein that is not transported to the cell surface and is 
therefore targeted by the cell for proteasomal degradation. This class encompasses the most 
common CFTR gene mutation, a deletion mutation of phenylalanine at position 508 (ΔF508), 
yielding a misfolded protein which is targeted for degradation in the cell. Approximately 90% of 
CF patients present with at least one copy of this mutation (56). Class III mutations cause the 
permanent closing of the CFTR channel, preventing any ion transport across the cell membrane. 
Class IV mutations decrease the conductance of chloride ions through the CFTR channel. Class 
V mutations reduce the number of CFTR proteins present on the cell surface meaning that even 




mutations affect the stability of the CFTR protein so that its half-life is reduced. A new 
classification system was recently proposed which takes into account the possible corrective 
therapies available, in addition to severity and mode of action of the mutation (57, 58).  
2.4 Prevalence of CF 
The availability of prenatal diagnosis and new-born screening has affected the global incidence 
and prevalence of CF and has resulted in earlier patient diagnosis and improved patient 
prognosis. As stated previously, CF is the most common genetic disease in Caucasian 
populations with Canada, UK and Ireland all having particularly high rates of CF births (Fig. 4) 
(59, 60). Ireland has the highest incidence of CF worldwide with approximately 1 in 19 Irish 
people carrying a mutation in the CFTR gene and approximately 1 in 1,400 live births presenting 
with CF (60-62). Though the life expectancy of affected patients has significantly increased with 
medical advancements, the estimated life expectancy of 40 years still falls far below average (63, 
64). Diagnosis at birth represents a unique opportunity to monitor disease progression which may 










Figure 4. Global prevalence of CF with green denoting low birth prevalence, orange denoting intermediate birth 
prevalence and red denoting high birth prevalence. The most common mutations identified in each country are also 
outlined.  Ireland has the highest worldwide prevalence of CF. Adapted from Seyed Bashir et al, 2017 and O’Sullivan 




2.5 Clinical Treatment for the Symptomatic Control of CF 
A variety of treatments exists for the daily management of CF in an attempt to improve the quality 
of life of affected individuals. These therapies are primarily targeted to the symptomatic 
consequences arising from CFTR mutation. Clinical strategies consist of a combination of chest 
physiotherapy to clear excess mucus from the lungs, bronchodilators and/or corticosteroids to 
relieve symptoms of breathlessness and intensive antibiotic therapy to control frequent airway 
infections with the primary goal of preventing the onset of chronic bacterial infection (65-67). 
Inhalation of antibiotics is indicated for patients with chronic P. aeruginosa infection; either the 
nebulized aminoglycoside tobramycin or the inhaled β- lactamase aztreonam (68, 69).  The 
macrolide antibiotic azithromycin is regularly administered to CF patients. However, it has been 
proposed to function as an anti-inflammatory rather than as an anti-infective (70-72). Anti-
inflammatories, including oral corticosteroids are important in the reduction of airway dilation 
(73). As the build-up of mucus within the lungs significantly impacts lung function it represents a 
significant interventional target in the clinical control of CF. Routine sessions of chest 
physiotherapy are directed to the reduction of airway obstruction with the goal of improving mucus 
clearance from the lungs (74, 75). The use of handheld vibratory devices such as the FLUTTER 
device can further aid airway clearance (76). Mucolytic therapies such as dornase alfa reduce the 
viscosity of mucus which has been shown to reduce the number of airway exacerbations (77-79). 
Additionally, hydrator therapies utilizing hypertonic saline solutions improves mucociliary 
clearance in an attempt to reduce the frequency of airway infections (80, 81). Unfortunately, the 
lack of compliance and adherence to recommended treatment plans has serious consequences on 
patient welfare and prognosis. Generally, as the patient transitions into adult there is a decrease in 




Whilst patient life expectancy and quality of life has undoubtedly improved, these conventional 
therapies are largely ineffective in modulating disease progression (83-85). In cases of severe lung 
damage a patient may be required to undergo lung transplantation (86). However, several 
contraindications exist in the selection criteria for lung transplant such as infection with the 
pathogen Burkholderia cenocepacia (87). As such many CF patients do not qualify as candidates 
and are excluded from this last resort treatment (88). Additionally, recolonization of the lower 
airways following lung transplant by P. aeruginosa residing in the host is common and is 
associated with poor clinical outcome (89).  
The rapid spread of antibiotic resistance through bacterial populations resulting in the emergence 
of multi drug resistant pathogens means many antibiotics currently utilised are becoming 
ineffective in the control of infectious disease particularly pulmonary disease (90). This is further 
confounded by the fact that antibiotics become largely redundant once respiratory pathogens adopt 
a chronic biofilm lifestyle (91, 92). These developments signify the urgent need for alternatives to 
antibiotics. As we enter a new era of medicine it is hoped that treatment will shift from 
management of symptoms to early treatment interventions in order to prevent deterioration.  
2.6 Molecular Therapeutics for the Treatment of CF 
As our understanding of the genetic basis of CF has progressed, so too has our application of 
molecular therapeutic treatments to alleviate symptoms. This is particularly evident in the 
targeted therapies that aim to correct the effects of CFTR gene mutation allowing for the 
restoration of protein functionality. There are three main classes of drugs currently utilized to 





2.6.1 Premature Stop Codon Suppressors 
Premature stop codon suppressors are used in the treatment of class I mutations, which represent 
approximately 10% of all presenting CF cases, where a stop codon is introduced into the 
sequence which interferes with translation (93). The aminoglycoside category of antibiotics such 
as gentamicin and tobramycin were found to be effective in the induction of translational read 
through so that the ribosome ignored the introduced premature stop codon and continued on to 
produce a complete functional protein (94-96). However, long term administration of such 
antibiotics is not advised due to toxicity complications (94, 96). This led to the production of a 
functionally similar synthetic alternative ataluren which also allows the ribosome to skip the 
premature stop codon (97, 98).  
2.6.2 CFTR Correctors 
CFTR correctors are used in the treatment of class II mutations in which the CFTR protein is 
misfolded and not transported to the cell surface. As this class encompasses the most common 
CFTR mutation it has been the subject and focus of much clinical research. Correctors have been 
shown to improve the trafficking of the protein to the cell surface (99). The first corrector 
compound to be introduced onto the market was lumacaftor however clinical trials revealed little 
improvement in patient symptoms (100, 101).  
2.6.3 CFTR Potentiators 
The third category of molecular therapeutics; CFTR potentiators are used in the treatment of all 
other classes of CFTR mutations. Potentiators improve the functionality of the CFTR protein at 
the cell surface (102). Ivacaftor is one such potentiator introduced onto the market in 2012 for 
the G551D mutation (103, 104). Interestingly, the administration of either lumacaftor (CFTR 




mutation revealed no significant improvement in patient clinical status (105, 106). However, the 
administration of a combination of lumacaftor and Ivacaftor, referred to as Orkambi on the 
market, resulted in a 30% increase in cellular chloride transport in patients (101). This is 
proposed to be due to the combined action of the drugs resulting in an increase in both the 
delivery of the CFTR protein to the cell surface and enhanced channel opening. The efficacy of 
Orkambi in vivo may also be related to the ability of lumacaftor to stimulate phagocytosis and 
killing of P. aeruginosa by macrophages (107). A significant limitation of these therapies, 
however, is the age at which treatment can commence. Up until recently Orkambi treatment has 
only been approved for use in patients greater than 6 years of age (108). In January 2018 the 
FDA and the EU expanded the approval for the use of Orkambi in children as young as 2 (108). 
Unfortunately, by this time irreversible lung damage has been shown to have already occurred 
(109, 110). Additionally, bacterial infections can have also become established, a negative 
prognostic marker for the effectiveness of Orkambi (111, 112). Furthermore, longer term studies 
are required to establish the efficacy of these CFTR repair treatments in the prevention of 
symptomatic decline as patient’s age.  
2.6.4 Gene Therapy 
Gene therapy/editing is emerging as a new approach in the management of genetic disease. 
However, despite early progress, many significant obstacles remain which continue to delay the 
development of this strategy as a viable treatment for CF. Evidence from pre-clinical trials have 
demonstrated modest improvements in lung function as measured by Forced Expiratory Volume 
(FEV1), however there was no coinciding increase in the quality of life of affected patients (113, 
114). Additionally, the numerous risks that accompany the application of gene therapy must be 




As medical research has advanced at such a fast pace, many have suggested that we are 
approaching the age of personalised medicine in the treatment of genetic diseases such as CF. 
However, response to treatment plans has been shown to drastically vary between patients, even 
for those individuals with the same mutation (116). Therefore, several challenges must be 
addressed if personalised medicine is to become a reality. Though, the aforementioned combined 
corrective and potentiating therapies have considerable potential, it is clear that focus should 
shift to early intervention strategies. The objective of such strategies should ultimately be the 
prevention of lung function decline in paediatric CF patients. The identification of factors 
promoting chronic inflammation and the emergence and persistence of chronic pathogens that 
contribute to this decline is fundamental in the design and eventual implementation of novel 
treatment regimens.  
3. Lung Microbiome Composition in Patients with Chronic Respiratory Disease 
Whilst the development of chronic respiratory disease is multifactorial, the interactions between 
the host and colonising microbes is central to the pathophysiology of disease progression.  
Therefore, it follows that a potential alternative strategy could emerge from the study of the 
underlying microbiology of chronic respiratory disease, particularly how respiratory pathogens 
residing in the lung are triggered to adopt a chronic biofilm lifestyle. 
Several studies have investigated the microbiological basis of chronic pulmonary disease and 
have revealed that the lungs of both healthy and diseased individuals harbour diverse 
communities of bacteria and are not sterile environments as was previously believed (117-122). 
A comprehensive knowledge of the differences between microbial communities (known as the 
microbiota) residing in the lungs of healthy and diseased patients could further enhance our 




microbiota has been shown to be determined by three primary factors; (1) the degree of 
microbial immigration, (2) the rate of microbial elimination and (3) the growth rate of the 
constituent members. The contribution and balance of each of these factors to the respiratory 
microbiota should be considered when studying differences that may exist between health and 
disease (123). The lower airways of healthy individuals have been shown to harbour diverse, 
though low abundance communities of bacteria (124-126). In contrast, the lower airways in 
respiratory disease consists of highly diverse and highly abundant bacterial communities (Fig. 5) 
(127-133). These differences in abundances between health and disease can potentially be 
attributed to a higher bacterial burden and ineffective bacterial clearance from the lungs due to 
impaired mucociliary clearance in pulmonary disease (134). The source of these lower airway 
communities are thought to be the upper airways and the gastrointestinal tract (135-139). These 
reservoirs of bacteria can be transmitted via inhalation, micro-aspiration and direct mucosal 
extension (123, 125). Reports of perturbations of these communities in samples from patients 
with chronic respiratory disease are frequently described in the literature. Additionally, insights 
into the influence of host physiological factors that shape the dynamics of these populations 





Figure 5. Summary of common microbiota associated with healthy vs CF lungs. Commonly identified taxa are 
illustrated and the factors governing the dynamics of these communities are presented. Microbes such as the anaerobes 
Veillonella and Prevotella are routinely isolated from healthy lungs. While Staphylococcus and Haemophilus are 
known to be early colonisers of the lungs of paediatric patients with CF, Pseudomonas ultimately achieves a dominant 
position within the lung microbiota.  The balance between microbial immigration and elimination has been described 
as a primary influence on the community structure of a healthy lung. In contrast, regional growth conditions within 
the lung microenvironment have been shown to drive population diversification. 
3.1 Sampling Techniques for the Identification and Characterisation of the Lung 
Microbiome 
In order to examine the microbial communities residing in the lung, the lung must first be 
sampled with specific consideration given to the location of sampling and the level of 
invasiveness (140). There are four types of sample that can be used; 1) bronchoalveolar lavage 
fluid (BALF), 2) induced or expectorated sputum sampling, 3) deep throat swab and 4) analysis 




3.1.1 BALF Sampling 
The gold standard for sampling the lung microbiota is BALF sampling. BALF is obtained during 
a surgical lung bronchoscopy during which various regions of the lung can be sampled (124, 
133, 141). In adults, this procedure is considered to be minimally invasive requiring the 
administration of local anaesthetic and sedative (142, 143). In contrast, this procedure is 
considerably more invasive in paediatric patients as a general anaesthetic is required with an 
increased risk of unintentional trauma to the airway epithelium (144, 145). As many microbiota 
studies encompass paediatric patients, the level of invasiveness should be a primary concern 
when choosing a sample type. Furthermore, this option can often become prohibitively expensive 
for use on a wide scale basis in large clinical cohorts (146). 
3.1.2 Sputum Sampling 
The preferred alternative to BALF sampling is the use of expectorated or induced sputum samples. 
Sputum comprises the thick mucus that is coughed up by patients from the lower airways; with 
expectorated sputum generated solely by coughing and induced sputum obtained by administration 
and inhalation of a hypertonic saline solution (147-149). The use of sputum, both expectorated and 
induced, has numerous advantages; it is safe, non-invasive, can be routinely carried out and is 
relatively inexpensive (150). Therefore, it is the most widely practiced technique of sampling the 
lung microbiota. Initially, the primary disadvantage associated with the use of sputum was the 
potential risk of cross-contamination by microbial communities present in the upper respiratory 
tract (151). However, several studies have identified distinct microbial communities in the upper 
airways/oropharyngeal tract when compared to that of the lower respiratory microbiota with 




3.1.3 Explanted Lung Sampling 
Lastly, in patients who present with end stage lung disease, a lung transplantation may be required. 
In these cases microbial sampling of the explanted lungs can be undertaken. Analysis of these 
microbial communities has provided further evidence confirming that BAL and sputum are 
effective means of sampling the lung environment (127). Interestingly, these studies of explanted 
lungs highlighted that significant bacterial community heterogeneity exists throughout the lung. 
The spatial heterogeneity present within the lung, a product of environmental gradients within the 
lung, may be the basis for the formation of distinct communities of bacteria in different regions of 
the lungs (123, 154-156).   
3.2 Culture Dependent versus Culture Independent Analysis of the Lung Microbiome 
What has become increasingly apparent from microbiota analysis of various regions throughout 
the body is that the use of culture dependent techniques alone is insufficient in providing a fully 
representative overview of the complexity of microbial communities present. Furthermore, the 
practice of species-specific cultivation techniques for the identification of pathogenic species has 
further biased the view of the diversity present within the lung. The primary limitation associated 
with culturing is that only a small percentage (1%) of bacteria were believed to be culturable. 
This phenomenon coined the “plate count anomaly” by Staley and Konopka in 1985 described 
the apparent inability to culture many microbes visible under the microscope (157). To culture 
this 1% is both challenging and time consuming (158). However, a study by Sibley et al. 
demonstrated that the majority of bacteria present in the CF airways are readily cultured through 
an enrichment of conventional microbiology techniques. A combination of culture dependent and 
culture independent techniques increased the sensitivity of bacterial detection within the CF lung 




better understanding of the complexity of the human microbiota (160, 161). Next Generation 
Sequencing (NGS) including Illumina HiSeq/MiSeq and PacBio, has become more affordable 
allowing increased species level identification offering a more representative view of the lung 
microbiome (131, 162). The emergence of third generation sequencing technologies such as 
Oxford nanopore technologies and ion torrent require just a single molecule of DNA to sequence 
which could potentially translate into faster and cheaper sequencing of lung microbiomes (163). 
The availability of such a wide array of technology means studies conducted on the lung 
environment generates a vast amount of information. However, inter-study comparisons should 
be interpreted cautiously as standardised practices have yet to be established. This includes 
choice of sample type, method of DNA extraction and sequencing technology; all of which can 
introduce biases into microbiome studies. Hence, what is critical for this rapidly emerging field 
is the design of standardised practices, an issue that must be addressed for future research. 
Nevertheless, microbiota studies have been conducted for many respiratory conditions with a 
pervasive microbiome reported for CF which has been correlated with patient disease status 
(128). Signature microbiota profiles are currently being investigated for other respiratory 
diseases including COPD, asthma and bronchiectasis (164, 165).  
4. A Pervasive Lung Microbiome Exists in CF Patients 
The lungs of CF patients harbour diverse microbial communities with independent studies 
detecting up to 100 genera of bacteria (Fig. 5) (166-168). This is significantly more diverse than 
previously estimated and is unsurprising considering the CF lung is a warm, humid environment, 
organically rich with defective mucociliary clearance favouring the exponential proliferation of 
microbial communities without removal. This favourable niche is exploited by a plethora of 




to Proteobacteria, Bacteroidetes, Fusobacteria and Firmicutes (166, 168). The signature CF 
microbiome is reported to be heavily dominated by the classical CF-associated pathogens; P. 
aeruginosa, S. aureus, Haemophilus influenzae and B. cepacia complex (36, 42, 128, 171). It is 
thought that there is a general pattern of colonization of the CF lung; first by H. influenzae and S. 
aureus succeeded by P. aeruginosa, Stenotrophomonas and Burkholderia (Fig. 6) (35, 171).  
 
 
Figure 6. General pattern of microbial colonisation within the CF airways with S. aureus a primary coloniser of the 
paediatric CF lung and P. aeruginosa a primary coloniser of the adult CF lung. Taken from CFF Annual data report, 
2014 (1). 
It has been shown that these pathogenic bacteria can represent a tiny portion of the total 
microbiota in early stage lung disease with evidence that Streptococcus, Porphorymonas, 
Prevotella, Veillonella, Rothia, Actinomyces, Gemella, Granulicatella, Fusobacterium, and 
Neisseria comprise the core microbiota with a relatively high proportion of both facultative and 
obligate anaerobic bacteria present (168, 172). The presence of anaerobes may be explained by 
the thick mucus present on lung epithelial cells which is anoxic in nature due to the slow 
diffusion of oxygen and rapid utilisation of available oxygen by aerobic bacteria. This results in 




strict and facultative anaerobes (169, 170, 173). The discovery that strict anaerobes are 
commonly present in the CF lungs further highlights the limitations of conventional 
microbiology as these bacteria went largely undetected due to difficulties culturing within 
clinical settings (168, 172). 
4.1 Polymicrobial Communities and Age Associated Decline in Diversity are Observed in 
CF Microbiomes 
The previously held view that respiratory infections in CF are of a mono-microbial nature has 
been challenged by the growing understanding of the microbiological basis of the disease. This 
has highlighted that a limited number of pathogenic species are not solely responsible for 
infection. Rather, pulmonary exacerbations, described as a temporary decline in lung function, 
are driven by multiple microbial species with community composition also impacting antibiotic 
efficacy (174, 175). These observations have shifted our attention to the role of polymicrobial 
communities and inter-kingdom interactions in infection and in the factors contributing to the 
restructuring of these communities throughout disease progression (130, 176-182). These studies 
have also highlighted the limitations associated with treatment strategies based solely on the 
identification of pathogenic bacteria through routine culturing. Therefore, analysis of the 
microbiota as a whole is becoming increasingly important (121, 130, 159, 177). Ecological 
networking strategies have played an important role in deciphering microbial community 
dynamics throughout the infection process (178). 
Findings from numerous cross-sectional studies have revealed progressive increases in the 
diversity of bacterial communities as a patient ages (129, 166, 183). However, as patients transition 
to adulthood, there is a gradual decrease in diversity where communities become dominated by a 




age of 25 (129, 132, 166, 183). Whilst the microbiome is relatively constant in clinically stable 
patients, patients experiencing an exacerbation display dynamic changes in community structure 
referred to as microbial dysbiosis though there is no coinciding significant change in bacterial load. 
This dysbiosis is characterised by a shift towards a low diversity, pathogen dominated microbiota 
with the infection process beginning as early as infancy, further highlighting the importance of 
community diversity in the maintenance of lung health (184-188). The “Keystone pathogen 
hypothesis” could explain this observation. This attempts to describe the role of polymicrobial 
interactions within the lung whereby low abundance members of the community such as the 
Gemella genera, play a major role in the remodelling of the microbiota towards that of a dysbiotic 
pathogenic community (185, 189, 190). There is evidence of early homeostatic disruption to the 
CF lung microbiota when compared to healthy controls, indicating the occurrence of a fundamental 
disturbance at an early age (191). The similarity in community composition between paediatric 
and adult microbiota further supports the finding that microbial dysbiosis becomes established 
early on in life and is maintained throughout disease progression (135).  
The trend towards reduced microbial diversity is characterised by a reduction in evenness and 
richness of microbial populations and is negatively correlated with clinical status and pulmonary 
function. This observation is becoming a predominant feature of many chronic inflammatory 
conditions (192, 193). Furthermore, microbial communities in older patients are composed of more 
phylogenetically related populations which are potentially resistant to antimicrobial treatment 
strategies (166, 194). Whilst data generated from these studies are informative, they are 
significantly limited by their cross-sectional study design and small sample size (186, 195). A 




term as these studies would provide insights into microbiome evolution with respect to patient 
aging.  
The association of microbial community diversity and disease status has been previously described 
for several human conditions. A reduction in biodiversity and consequential alteration of the 
functional capabilities of the microbial community are evident in the gut microbiota for 
inflammatory diseases and diabetes and in the oral cavity microbiota with periodontitis (196, 197). 
The recurrent administration of antibiotics during exacerbations has been proposed to contribute 
to the age-related decline in diversity in CF. Whilst some studies have proposed significant 
determining effects (132, 198), others have demonstrated only transient effects (128, 199). 
However, the microbiota has been shown to recover to baseline level after exacerbations and 
antibiotic treatment (186, 200). In addition to antibiotics, the environment and inflammation have 
been proposed to play a role in the shaping of the lung microbiota. However, the relative 
contribution of each of these factors is unknown, in particular that of the influence of antibiotics 
(132, 198-202). It is clear, however, that the frequent disruptions to these communities are 
associated with increased morbidity and mortality. Even with the emergence of new treatments 
such as Orkambi (203-205) which have revolutionised the clinical management of CF, 
understanding the CF microbiota in terms of both low and high abundance genera, as well as the 
relative importance of fungal species and viruses, remains a key research question. Particularly, as 
those receiving treatment will have a degree of pre-existing airway destruction and an increased 
risk of infection (171, 206).  
5. P. aeruginosa Pathogenesis & CF 
Pathogenic domination of the CF lung microbiota is largely due to the emergence of P. aeruginosa, 




the lung such as reduced oxygen tension promotes the outgrowth of P. aeruginosa. Chronic 
infection by P. aeruginosa is a primary indicator of poor clinical prognosis and is correlated with 
a lower FEV1, a clinical measurement of lung function (207, 209). A recent study has highlighted 
that chronic infection with the key CF pathogen P. aeruginosa drives pulmonary dysbiosis rather 
than the existence of prior dysbiosis facilitating the emergence of this opportunistic pathogen 
(210). The ability of  P. aeruginosa to adopt a biofilm mode of growth which is refractive to 
antibiotic therapy and to chronically infect the CF lung is widely considered to be the primary 
driver of progressive lung disease in CF (91).  
P. aeruginosa is a gram negative rod belonging to the family Pseudomonadaceae. It is capable of 
occupying a wide range of niches with its high degree of genome adaptability facilitating rapid 
adaptation to new environments (211). It is considered an opportunistic human pathogen with the 
WHO classifying it as a priority one critical pathogen for the development of novel antibiotics 
(14). P. aeruginosa can cause life threatening infections in immunocompromised patients and 
patients suffering from respiratory conditions such as CF with colonisation found to occur within 
the first three years of life (212). Significant advances have been made in CF clinical care, in 
particular early eradication strategies and the prevention of cross patient transmission which has 
reduced the frequency of chronic colonisation by P. aeruginosa and has resulted in an 
improvement in patient outcome and increased life expectancies (69, 213-219).  
5.1 Acute versus Chronic Lifestyle of P. aeruginosa 
The large proportion of transcriptional regulators (representing approximately 10% of all genes 
present) within the 6.3 Mb P. aeruginosa genome facilitates the survival of this microbe under 
the range of stressful conditions it encounters such as oxygen stress and nutrient limitation (220). 




and optimal growth at 37˚C underpins its role as a human pathogen (221). The process of airway 
infection involves an initial acute phase characterised by the production of a suite of virulence 
factors facilitating invasion and survival in the host (222). During this acute stage of 
pathogenesis, the pathogen is highly motile, secreting a variety of toxins and proteases with the 
type three secretion system of particular importance. This lifestyle stage is characterised by 
severe and significant damage to target host cells. Acute infections are evident in patients with 
ventilator associated pneumonia, urinary tract infections, infections in immunosuppressed 
patients and wound infections in burn patients (223). As the organism transitions towards 
chronicity and long term persistence, there is a reduction in acute virulence factor production 
which contributes to the successful evasion of this pathogen from the host immune system (222, 
224, 225). The emergence of hyper-mutator strains of P. aeruginosa increases the ability of the 
pathogen to adapt to these new host conditions and is central to the success of P. aeruginosa as a 
human pathogen (226, 227). The occurrence of alginate overproducing strains is associated with 
the development of mucoid strains arising from a loss of function mutation in the mucA 
transcriptional regulator (228, 229). This event is thought to signify the switch to chronic 
infection and is important in the long-term survival of this organism within the host. Although 
there is currently no universally accepted clinical definition of chronic P. aeruginosa infection 
(208, 230, 231), the phenotypic changes that occur during the transition have been well 
characterized in this organism. The acute to chronic switch as outlined by Moradali et al. (Fig. 7) 
involves the suppression of key acute virulence determinants such as the Type Three Secretion 
System (T3SS), phenazine production, and swarming motility, while the chronic persistent 
lifestyle is adopted through increased biofilm formation and the production of chronic virulence 




layers of regulation, including the quorum sensing (QS) signalling pathway and classical two 
component signalling systems (220).   
 
Figure 7. The acute to chronic behavioural lifestyle switch encompasses a wide array of phenotypic and signal 
transduction changes facilitating persistence within the CF lung enivronment. This includes a combination of clsssical 
two component systems, transcriptional regulators and virulence factors. Taken from Moradali et al, 2017 (220). 
5.1.1 Quorum Sensing 
P. aeruginosa employs quorum sensing signalling systems in order to mediate the collective 
behaviour of communities. These regulatory systems enable coordination of cooperative gene 
expression to environmental signals.  P. aeruginosa encodes two classical Acyl-Homoserine 
Lactone (AHL) QS systems (LasIR and RhlIR), as well as an Alkyl Quinolone (AQ) system 




systems involving an autoinducer synthesis gene and a cognate regulatory gene. There is also an 
emerging role for the IQS system, although its interconnection with the classical systems remains 
to be established (232). These are complex, interconnected pathways mediating the response to a 
variety of input signals. All three of these systems are involved in cell to cell communication 
with the AQ system in particular shown to have a role in biofilm formation and persistence 
(233). Quorum sensing is linked to the production of a wide range of virulence factors, including 
the redox active phenazine pyocyanin, an important virulence factor in the establishment and 
persistence of infection in vivo. Phenazines are respiratory pigments that play a role in 
extracellular electron transport which facilitate survival by mitigating the stress of electron 
acceptor limitation (234). Pyocyanin has also been shown to contribute to the success of P. 
aeruginosa as the dominant organism within the lung microbial community through its inhibition 
of respiration of competing microorganisms such as S. aureus (235). Quorum sensing has also 
been implicated in the pathogen’s interaction with the host, with PQS shown to induce oxidat ive 
stress and repress expression of the anti-oxidant enzyme Heme oxygenase-1 in lung epithelial 
cells (236). Hence, these signalling molecules are central to P. aeruginosa pathogenicity.  
5.1.2 Secretion Systems 
There are a range of secretion systems facilitating the interaction between P. aeruginosa, the host 
and co-colonising resident micro-organisms. Two of the primary secretion systems are the Type 
Three Secretion System (T3SS) and the Type Six Secretion System (T6SS) which are capable of 
injecting effector proteins into host cells and neighbouring bacteria, respectively. The T3SS is 
employed by P. aeruginosa to manipulate the cells of its eukaryotic host. This system is encoded 
by 36 genes located on 5 operons and consists of a phage needle like structure with the ExsB 




Upon assembly of the needle like structure effector proteins encoded by approximately 6 
additional genes can be injected into the host cell. These effectors include ExoS, ExoT, ExoU 
and ExoY which can induce cell death, inhibit DNA synthesis and disrupt the actin cytoskeleton 
(238, 239). It is thought that these toxins prevent phagocytosis of the organism with a functional 
T3SS increasing disease severity. Hence, as the organism transitions to chronicity there is a 
dampening down of the activity of this system. A study by Subedi and colleagues further 
confirmed this with CF isolates shown to not possess the exoU gene while acute isolates 
recovered from anterior eye infections and microbial keratitis contained exoU which correlated 
with increased antibiotic resistance (240). 
 The T6SS also uses a phage-like needle machinery and is utilised by P. aeruginosa to 
manipulate competing bacterial cells through a ‘tit for tat’ interaction, ultimately inhibiting their 
growth (241). The T6SS is encoded by three distinct gene clusters; Hcp1 secretion island (HSI)-
I, HSI-II and HSI-III. The activity of this system potentially facilitates the dominance of P. 
aeruginosa further enhancing its fitness within the polymicrobial CF lung microbiome.   
5.1.3 Antibiotic Resistance 
P. aeruginosa displays a high level of resistance to a range of antibiotics (Fig. 8). The antibiotic 
resistance of this organism can be attributed to a combination of natural resistance afforded by (i) 
the presence of the outer membrane for which a range of antibiotics cannot permeabilise; (ii) 
intrinsic resistance systems, including an array of efflux systems and regulated porins; and (iii) 






Figure 8. High percentage of P. aeruginosa isolates display combined antibiotic resistance to clinically relevant 
antibiotics throughout Europe. This highlights the effectiveness of this organism at combatting the stress represented 
by antimicrobials and its numerous strategies to increase its resistance (1). 
P. aeruginosa employs a range of mechanisms for efficient antibiotic resistance (Fig. 9), 
including the production of antibiotic degrading enzymes such as β-lactamases, synthesis of 
antibiotic modifying enzymes, reduced outer membrane permeability and increased activity of 
efflux systems (242, 243). MexAB-OprM is one such efflux system contributing to P. 
aeruginosa resistance to β-lactam antibiotics. In clinical isolates, mutations in the regulatory 
genes of efflux systems have been demonstrated to result in the hyperexpression of the efflux 
pumps contributing to increased resistance to antibiotics in the clinic (244, 245). Though 
increased resistance to antibiotics is well described, a recent finding of the acquisition of 




worrying (246). The implications of enhanced P. aeruginosa antimicrobial resistance are far 
reaching not only in terms of the detrimental impact on patient’s quality of life but also the 
financial burden of clinical management strategies. 
 
Figure 9. P. aeruginosa employs a range of antibiotic resistance strategies to increase its tolerance and resistance to 
antimicrobials ensuring its persistence within the CF lung. This includes production of a biofilm hindering the 
penetration of antibiotics, antibiotic modification to prevent its activity and active efflux of antibiotics. Taken from 
Sherrard et al, 2014 (243). 
5.1.4 Biofilm formation 
The ability of P. aeruginosa to produce a biofilm, a community of microbes residing in a 
protective matrix of Extracellular Polymeric Substances (EPS), is one of the primary 
mechanisms underpinning its tolerance to antibiotics within the CF lung (247). The EPS matrix 




249). The architecture of the biofilm changes throughout biofilm maturation as described in 
Figure 10 below (250).  
 
Figure 10. The stages of biofilm development in P. aeruginosa involving initial then irreversible attachment, 
microcolony formation, macrocolony formation and eventually dispersal of the biofilm. The architecture of the 
resulting biofilm can vary with the 3D mushroom like biofilm typical.  Taken from Whitters and Stockley 2011 (250). 
P. aeruginosa is known to produce three main polysaccharides; alginate, Pel and Psl which 
determine biofilm stability, with Pel and Psl required for early stage biofilm formation (251, 
252). The modulation of polysaccharide production during chronic infection promotes the 
strength of biofilms during infection (253). Extracellular DNA (eDNA) is essential for biofilm 
formation, with degradation of eDNA shown to block the production of a biofilm (254). 
Additionally, eDNA contributes to biofilm maturation through its impact on motility and its role 
as nutrient source to bacteria within the biofilm (255, 256). The production of a biofilm involves 
the coordinated action of several regulatory systems including but not limited to quorum sensing, 
two component systems (GacS/GacA, RetS/LadS) and the bacterial second messenger cyclic-di-




Cyclic-di-GMP has been widely recognised for its importance in biofilm formation and 
swarming motility, behaviours which are proposed to be inversely regulated. The production of 
c-di-GMP involves synthesis by GGDEF domain containing diguanylate cyclase proteins and 
breakdown by EAL and HD-GYP domain containing phosphodiesterase proteins, for which P. 
aeruginosa is known to encode approximately 41 (258).  The pools of c-di-GMP in the cell have 
been shown to modulate the production of polysaccharides, with high levels of c-di-GMP 
inducing polysaccharide biosynthesis and low levels of c-di-GMP promoting motility (259-262). 
Interestingly, a recent study has proposed a role for c-di-GMP in the ability of P. aeruginosa to 
evade the host immune system through its interactions with the methyltransferase, WarA (261). 
The regulatory control of biofilm development has been linked to quorum sensing (263). The Las 
system has been implicated in the structural development of a biofilm with LasR involved in the 
regulation of Psl and PQS linked to the release of eDNA (264-266). Furthermore, the connection 
between quorum sensing and cellular motility indirectly impacts upon biofilm architecture (267). 
The GacS/GacA two component system consisting of a transmembrane sensor kinase and 
response regulator has been demonstrated to be a global regulator of QS biofilm formation (268-
270).  
The complexity of systems governing P. aeruginosa virulence and pathogenesis serves to 
highlight the challenges faced in elucidating the factors that signal the transition from an acute to 
chronic lifestyle. Many of the regulatory systems that are involved in controlling multi-cellular 
behaviour, biofilm formation, motility and secretion are well characterised. Molecular 
mechanisms have been proposed for a number of these systems and yet the factors responsible 




therefore is to elucidate the niche factors that cause P. aeruginosa and indeed other pathogens to 
adopt a chronic antibiotic tolerant biofilm in patients with respiratory disease. 
5.1.5 Adaptive Evolution 
The persistence of P. aeruginosa has been proposed to be due in part to its ability to rapidly 
adapt to novel conditions with several studies reporting phenotypic and genotypic diversification 
both in vitro and in vivo (271-281). This adaptive evolution, proposed to be underpinned by 
recombination, is evidenced in the recovery of a range of distinct clinical isolates from the 
sputum of CF patients, a product of spatial heterogeneity within the lung (154, 155, 275, 282, 
283). From the genomic perspective, these studies have identified several loci that are frequently 
mutated, which has led to them being classified as pathoadaptive mutations. The evolutionary 
pathways through which these mutations emerge are distinct between studies, notwithstanding 
the fact that convergent evolution is proposed to occur (284, 285). Pathoadaptive mutations 
frequently occur in genes including the global regulators lasR, rpoN, mucA, mexT, retS, exsD, 
and ampR as reviewed by Winstanley et al. (286). The consequence of these mutations is the 
emergence of phenotypic variants which display reduced virulence factor production, enhanced 
antibiotic resistance, enhanced siderophore production and auxotrophy. The non-uniform nature 
of P. aeruginosa populations and the significant genotypic and phenotypic heterogeneity present 
means that there should be careful interpretation of data generated from clinical isolates. Though 
there is still not a full understanding of the drivers of pathoadaptation, several factors may 
contribute to the positive selection on these genes including, iron acquisition (287, 288), 
antibiotic administration (289-293), sputum conditions (277, 290, 294), biofilm conditions (295, 
296) and presence of phage (277, 297). Further investigation is required to unravel the 




also be taken into consideration, as it can provide valuable insights into the connections between 
metabolic specialisation and adaptive phenotypic traits (298). Collectively, this research has the 
potential to provide new knowledge that may be useful in hindering the establishment of chronic 
Pseudomonas infections.  
6. Factors Modulating the Progression of Chronic Respiratory Infection 
The microbiota is profoundly shaped by clinical intervention though the importance of host and 
environmental factors in disease progression has yet to be fully established. Knowledge of the 
role of host factors is vital to understanding (i) how remodelling of the CF microbiota occurs and 
(ii) how pathogenic bacteria emerge to chronically dominate the local microbial community. 
This would underpin the design of novel strategies with the purpose of breaking the vicious cycle 
of chronic infection and inflammation to prevent progressive respiratory decline. As a result 
there have been several investigations attempting to identify environmental or host factors 
correlating with disease progression and clinical outcome (32, 299). Several factors, including, 
antibiotics, anaerobic conditions, mucin and short chain fatty acids have been demonstrated to 
influence both the microbiota and the immune response. 
6.1 Antibiotic Administration 
The repeated administration of antibiotics to CF patients from a very young age has been 
proposed to significantly contribute to the remodelling of microbial communities within the CF 
airways (185, 198-200, 300). The utilisation of broad-spectrum antibiotics which alter the global 
polymicrobial community may underpin these effects. However, no consensus has been reached 
regarding the long term impact of antibiotics on the airway microbiota with some studies 
suggesting significant effects (198), while others observed that the microbiota is only transiently 




some evidence that supports the contribution of antibiotic usage to the restructuring of the 
microbiota, it does not appear to have a determining effect hence other factors must also be at 
play.  
6.2 Hypoxic Environment 
The accumulation of viscous mucus, a consequence of airway hypersecretion and airway surface 
liquid dehydration, results in the generation of steep oxygen gradients throughout the lung (169, 
301). These hypoxic conditions function as an environmental signal to potential colonising 
anaerobic microbes particularly P. aeruginosa (169, 302). P. aeruginosa has been shown to 
respond to hypoxic conditions by increasing production of the polysaccharide alginate, a 
significant biofilm component, further increasing anoxic regions within the lung (169, 303). S. 
aureus has also been shown to transition from a non-mucoid to mucoid phenotype in response to 
anaerobic conditions (304).  In addition to the impact on the microbiota, hypoxic conditions have 
been demonstrated to trigger an inflammatory response with elevated levels of macrophages, 
neutrophils and cytokines detected in BALF exposed to hypoxic conditions (305). Neutrophilic 
inflammation is a key factor in the pathophysiology of CF lung disease (306) with hypoxic 
conditions shown to contribute to this (307).   
6.3 Mucin 
The primary component of the viscous mucus present on the lining of airway epithelial cells are 
mucins; high molecular weight glycoproteins which represent a favourable nutrient source to 
colonising microbes as a reservoir of carbon and nitrogen (301, 308). Mucin degradation has 
been shown to occur within the CF lung microbiota with co-colonisation of residential anaerobes 
essential to this process. This facilitates the outgrowth of opportunistic pathogens potentially 




production of Short Chain Fatty Acids (SCFA) and amino acids, products which are detected at 
high concentrations in CF sputum (312, 313). There is evidence to suggest that mucin 
degradation can support the high carbon demands of P. aeruginosa, though this organism is 
capable of utilising multiple carbon sources in vivo (314, 315). Hence, the catabolism of host 
mucin by residential microbes may contribute to the initial progression of lung disease, with its 
relative importance possibly diminishing as the microbiota becomes dominated by a single 
organism such as P. aeruginosa which cannot efficiently utilise mucin as a sole carbon source in 
a monoculture (309, 316).  
6.4 Short Chain Fatty Acids 
SCFAs as stated above are by-products of microbial fermentation by facultative anaerobes within 
the hypoxic lung environment and are regularly detected in CF sputum (317). SCFA’s contribute 
to the host inflammatory response through its impact on cytokines GM-CSF, IL-6 and IL-8 (318, 
319). Hence, SCFA’s may enhance the recruitment of neutrophils to the CF airways contributing 
to the heightened pro-inflammatory response which results in the development of bronchiectasis. 
Though high concentrations of SCFA’s impaired P. aeruginosa growth (320) lower 
concentrations were found to transiently enhance growth in mid-log phase (318). Therefore, this 
key microbial metabolite has a dual impact on both pathogen growth and airway inflammation.  
6.5 Co-morbidities in CF 
As the life expectancy of CF patients continues to increase, this brings with it new challenges for 
the clinical management of the disease. Factors arising from co-occurring morbidities now need 
to be considered when assessing the progression of CF. It has recently been proposed that there 
will be a 75% increase in the number of adults with CF by 2025 (321). This figure does not 




potentiator therapies described above. A detailed and comprehensive review of the co-
morbidities associated with CF has been recently published by Ronan and colleagues (322). As 
might be expected from a multisystem disease, these include pulmonary, pancreatic, 
hepatobiliary, renal, genitourinary, coronary, bone, malignancies, and gastrointestinal disorders. 
The latter has received considerable attention in recent years arising from the growing 
appreciation of the connectivity of the gut-lung axis.   
6.5.1 Gastro-oesophageal Reflux and Lung Disease 
A significant correlation has emerged between gastro-oesophageal reflux disease (GORD/GERD 
in the USA) and chronic respiratory disease (323-328). In patients diagnosed with GORD, a 
variety of pulmonary manifestations have been observed, including chronic cough, bronchitis, 
bronchial asthma, bronchitis, pneumonia and interstitial fibrosis (329). This has led to 
suggestions that GORD is an underlying host factor modulating chronic respiratory disease 
though the exact mechanism through which it elicits this effect has not been thoroughly 
investigated.  
GORD is a condition resulting in the transition of the contents of the stomach in to the 
oesophagus. It is ultimately a clinical manifestation resulting from the disruption of a normal 
physiological process where the barriers that control reflux are impaired and no longer function 
effectively (327, 330, 331). GORD is a spectrum disease comprising three broad categories, 
where patients exhibit mild to severe disease symptoms; i) non-erosive reflux disease, where 
there is no evidence of mucosal damage, ii) erosive esophagitis and iii) Barrett’s oesophagus, 
where there is evidence of damage to the mucosa (332, 333). Many physiological risk factors 
contribute to the development of GORD, such as a defective lower oesophageal sphincter (LOS), 




commonly present in patients with underlying respiratory conditions such as CF and COPD and 
are found to be exacerbated by daily chest physiotherapy treatment regimens (334-336). 
Typically, diagnosis depends on patient presentation with clinical symptoms such as heartburn, 
acid regurgitation and stomach pain however, up to 50% of patients do not present with these 
characteristic symptoms making clinical diagnosis a challenge (327, 337-339). Furthermore, 
GOR diagnosis is hindered by asymptomatic or silent GOR, therefore diagnosis based solely on 
symptomatic presentation is inadequate with recommendations that patients be monitored and 
tested for reflux. 
The co-morbidity of GORD with chronic respiratory disease is now widely accepted, however, 
the mechanisms through which this lung damage is incurred has yet to be elucidated. It was first 
proposed in 1975 that GORD contributes to progressive lung decline with GORD positive 
patients exhibiting more severe respiratory disease (340). The correlation between the presence 
of GORD and increased severity of lung disease led to suggestions that GORD contributes to 
progressive lung decline. A strong correlation between GORD-derived reflux, pulmonary 
aspiration, and increased lung damage extends to a wide range of respiratory diseases (341). This 
includes advanced lung damage following lung transplantation (342, 343), ventilator associated 
pneumonia (344), Barrett’s oesophagus and oesophageal adenocarcinoma (345) and Bile Acid 
Pneumonia in neonates (346).  Based on previous associations between GORD, poor pulmonary 
function and early acquisition of key lung pathogens in CF patients, GORD is potentially a key 
factor in the acceleration of CF disease progression (347). It has been reported that up to 80% of 
CF patients exhibit symptoms of GORD, though this figure may be an under estimation of the 
prevalence within these populations due to limitations regarding diagnosis and the prevalence of 




Table 2; Co-morbidity of GORD with a range of respiratory conditions. 
Respiratory Condition Clinical Presentation Reference 
Cystic Fibrosis Reflux (327, 328, 349-356) 
Reflux/aspiration (326, 338, 357-361) 
COPD Reflux (362-373) 
Reflux/aspiration (374, 375) 
Asthma Reflux (376-385) 
Reflux/aspiration (386) 
Chronic cough Reflux (387-394) 
Reflux/aspiration (395-397) 
Idiopathic pulmonary fibrosis Reflux (398-403) 
Reflux/aspiration (404, 405) 
 
6.5.1.1 Clinical Diagnosis of GOR 
Clinically, there are several methods available enabling GOR diagnosis including endoscopy, 
manometry, proton pump inhibitor testing (PPI), and multichannel intraluminal impedance pH 
monitoring. Endoscopic diagnosis is routinely used to visualise mucosal damage, however, its 
low sensitivity of detection has limited its diagnostic value (406). Alternatively, manometry is 
effective in investigating oesophageal and LOS functioning. This technique is conventionally 
performed in the evaluation of a patient’s suitability for anti-reflux surgery (407). The 
prescription of PPI drugs and the evaluation of patient responsiveness to treatment is another 
diagnostic strategy routinely used (408). However, PPI testing is an ineffective strategy for the 
diagnosis of GORD due to subjectivity in the assessment of patient responsiveness and 
symptomatic resolution. The gold standard for the accurate diagnosis of GORD is intraluminal 
oesophageal impedance pH monitoring which detects both acid and non-acid reflux. The 
procedure involves placing a pH catheter into the oesophagus and monitoring oesophageal pH 




of biomarkers such as pepsin is currently under investigation as a diagnostic tool for GORD 
(374). 
6.5.1.2 Clinical Management of GORD 
Acid Suppression Therapy 
The current treatment plans of choice for GORD focus on acid suppression therapy through the 
use of PPIs and Histamine 2 receptor antagonists also known as H2 blockers. Both function 
through interference with the gastric acid secretion pathway (410). H2 blockers are effective at 
decreasing gastric secretion after meals and are useful in the treatment of mild forms of GORD. 
PPI’s are much more potent and function through the irreversible binding of the H+K+ATPase. 
Though daily therapy is the recommended treatment strategy which controls the majority of 
patients symptoms, up to 30% of patients have been reported to not respond to therapy and 
continue to experience symptoms (411-413). As the rate of refractory GORD is so high with 
those receiving PPI treatment still experiencing respiratory decline, alternative therapeutic 
management strategies must be sought for the successful control of GORD. In severe cases of 
GORD, where symptoms cannot be controlled by medicinal intervention surgical treatment may 
be required.  
Surgical Intervention 
The most common surgery for the resolution of GORD is known as a Nissen fundoplication 
which involves wrapping the upper curve of the stomach around the oesophagus in an attempt to 
strengthen the lower oesophageal sphincter muscle which, if successful, prevents recurring 
reflux. This can be a complete 360 degree wrap or a partial wrap with varying degrees of 
wrapping (414, 415). This surgery has evolved from an open surgical procedure to a laparoscopic 




avoiding the need for any incisions and is known as a transoral incisionless fundoplication (418-
420). Surgery has the primary advantage of addressing the underlying physiological 
complication of GORD and although it is invasive, it is quite effective in the control of GORD. 
Patients who undergo this surgery have been shown to display significant improvements in lung 
function which further reinforces that GORD and potentially aspiration of gastric contents into 
the lungs is contributing to pulmonary decline (421-424).  
Endoscopic Interventions for the Control of GOR 
Endoscopic techniques have been developed and are currently being tested for their effectiveness 
in the management of GORD. The goal of such endoscopic techniques is the reduction in the 
long term reliance on medication or surgical interventions through the creation of a barrier to 
reflux with very promising results to date. These techniques include radio frequency energy 
ablation; the most widely utilised technique, endoluminal gastroplasty and numerous implant 
techniques (417, 425). Radiofrequency ablation also known as the Stretta procedure is one major 
alternative to surgical intervention. This procedure involves the delivery of consecutive rounds 
of thermal energy to the LOS through the use of a 4 channel radio frequency generator and 
catheter system. This is an attractive alternative to medication and surgery as the procedure can 
be carried out as an outpatient under mild sedation in roughly 35 minutes. Though the 
mechanism of action is still not fully understood it has been shown to be a safe and effective 
technique for the control of chronic GORD. The wide scale application of this approach is 
limited by the age at which treatment can commence as candidates must be over 18 years of age 
to qualify for the procedure (426, 427). Endoluminal gastroplasty is a technique developed by 
Bard Endoscopic technologies which is trademarked as Endocinch. This device uses sutures to 




this procedure has been associated with complications and moderate side effects such as 
haemorrhaging, chest pain and dysphagia (428, 429). The effectiveness of surgery and 
endoscopic techniques in controlling GORD suggests that the aspiration of gastric contents in to 
the lungs is possibly responsible for the underlying pathophysiology linking GORD to chronic 
respiratory disease and not necessarily the effect of acid reflux.  
7. Bile acids in the Lungs are associated with GORD-induced Lung Damage 
The ineffectiveness of therapeutic controls such as PPIs and H2 antagonists and the high 
incidence of GORD in CF cohorts led to further investigations regarding the underlying 
causative factor(s) of GORD induced lung damage (430). This led researchers to investigate 
biomarkers of GORD in the lungs of CF.  Bile acids were detected in sputum and BALF samples 
of CF patients as a result of these studies. Bile acids are just a biomarker of aspiration of gastric 
contents, including bile which is a complex mixture. Physiologically relevant concentrations of 
bile acids have been detected in both BALF and sputum of CF patients (324, 357-360, 431). 
These concentrations have been shown to be capable of inducing lung damage and inflammation 
in cultured lung epithelial cells (432, 433). It has been proposed that the source of these bile 
acids is the gastric contents which are refluxed and aspirated into the lungs during periodic 
episodes of GOR (324, 358, 360, 431). Evidence for this source is supported by the effectiveness 
of the surgery Nissen Fundoplication in slowing down progressive lung disease potentially 
through the control of reflux and aspiration (434, 435). However, alternative sources of bile acids 
in the lungs have been proposed as evidenced by transmission in the circulatory system of 
neonates and de-novo biosynthesis within the lungs in pulmonary arterial hypertension (346, 
436). The frequency of bile aspiration is estimated to be as high as 80% in CF patients (359). The 




Bronchiolitis Obliterans Syndrome (BOS) and increased colonisation by P. aeruginosa (437, 
438). Administration of the macrolide antibiotic azithromycin to lung transplant recipients has 
been shown to reduce the level of aspiration with an improvement in clinical outcome observed. 
Mechanistically, this was proposed to be due to enhanced oesophageal motility and accelerated 
gastric emptying, however, their role in the control of GORD and bile aspiration in respiratory 
disease requires further investigation (439). 
7.1 Quantification and Profiling of Bile Acids in the Lungs 
In order to assess patients effectively for bile aspiration, high resolution technologies for the 
detection of bile must be designed. Detection techniques have evolved from methods based on bile 
acid identification in other matrices such as blood.  Currently, there is a lack of protocols in the 
literature describing the direct identification of bile acids from lung fluids, therefore advancements 
in this area are required to fully elucidate the emerging role of bile acid aspiration in chronic lung 
disease.   
7.1.1 Enzymatic Detection 
An enzymatic reaction using 3-α hydroxysteroid dehydrogenase (3-α HSD) linked to 
spectrophotometric analysis has been described to measure total bile acid levels present in BALF 
samples (440). 3-α HSD catalyses the oxidation of the hydroxyl group at position 3 of the bile 
acid steroid ring. In the presence of the coenzyme nicotinamide adenine dinucleotide (NAD), 3-α 
HSD converts bile acids into 3-keto steroids and NADH which react with nitrotetrazolium blue 
to form the dye formazan which can be measured spectrophotometrically at an OD495nm. Thus, 
allowing for the calculation of total bile acids concentration. This enzymatic approach has 




transplantation. These increased levels have been linked to the development of bronchiolitis 
obliterans syndrome (441). 
7.1.2 Liquid Chromatography-Mass Spectrometry 
Enzymatic assays are useful in the calculation of total bile acid levels however concentrations of 
individual bile acids and bile acid profiles cannot be obtained using this technique. High 
resolution liquid chromatography–mass spectrometry (LC-MS) is currently one of the most 
accurate technologies available for bile acid quantification.  Most methods rely on reverse phase 
chromatography with a variety of flow rates and column dimensions (442, 443). LC-MS (and 
MS/MS)  is capable of detecting bile acids from a variety of matrices including, blood serum 
(444), human bile (445), stool (446), and the brain (447). A highly sensitive and specific LC-MS 
method was developed to investigate the presence of bile acids in the lungs of paediatric CF 
patients and to examine its influence on chronic respiratory infection (324). This method has 
been successfully applied to the analysis of sputum samples from a cohort of paediatric CF 
patients for the detection and accurate profiling of bile acids. Bile acid profiles have also been 
measured in airway secretions collected from intubated and mechanically ventilated patients. The 
increased bile acid levels were shown to be associated with detrimental ventilator-associated 
pneumonia (344). Direct electrospray ionization mass spectrometry can also be utilised 
successfully to identify bile acids in the lower airways of adult CF patients with robust detection 
limits (0.01 µmol/L) (358). However, it has been suggested this method is not the most suitable 
for many biological matrices due to their complexity (448). Studies investigating the potential 
use of exhaled breath condensate for the diagnosis of bile aspiration are currently underway. 




it is just an indicator of GORD (449), and therefore would not give an accurate measurement of 
bile acid levels in the lungs.   
7.2 The Impact of Bile Acids on the CF Microbiome 
The existence of a pervasive CF microbiota, along with emerging evidence for a signature COPD 
microbiota (450, 451) prompted a pilot microbiota study encompassing 10 paediatric patients 
attempting to delineate the role of aspirated bile in the lungs of CF patients (324). Stratification of 
paediatric patient cohorts based on detected bile acid concentrations in sputum revealed a 
significant reduction in biodiversity and richness with the emergence of dominant Proteobacterial 
pathogens such as Pseudomonas, Stenotrophomonas and Ralstonia which when present could 
account for up to 98% of the microbial sample in patients with high bile acid levels (324). Clinical 
parameters such as age, gender, antibiotics and hospitalisation did not explain the observed shift 
in the microbiota. It was noteworthy that, in spite of the reduced biodiversity, these patients did 
not exhibit a decreased FEV1. In contrast, patient samples in which bile acids were not detected 
exhibited increased microbial biodiversity relative to bile acid positive samples. This diversity was 
underpinned by species more associated with a ‘healthy non-CF lung’ such as the anaerobes 
Veillonella and Prevotella (128). More recently, evidence of an aerodigestive route to P. 
aeruginosa acquisition has been proposed, further evidence of a link between the pulmonary and 





Figure 11. Aspirating patients display a reduction in both biodiversity and richness (Shannon and Chao index) with 
an emergence of Proteobacterial pathogens such as members of the family Burkholderiaceae and Pseudomonadaceae, 
adapted from Reen et al, 2014 (324). 
7.2.1 Bile Triggers Respiratory Pathogens to Adopt a Chronic Lifestyle 
While bile acid signalling has long been associated with a broad spectrum of diseases such as 
diabetes, gastrointestinal disease and obesity (453), the possibility that bile is potentially a 
signalling molecule in respiratory disease has not been previously considered. The strong 
correlation between the presence of bile acids and the emergence of dominant Proteobacterial 
pathogens within the CF lung microbiota suggests that bile might impact directly on the 
behaviour of the pathogen itself. Studies on the influence of bile on the human microbiota have 
been restricted to enteric pathogens associated with gastroenteritis and gut infections as well as 




enteric bacteria would appear to employ species-specific mechanisms in response to exogenous 
bile. For instance, the T3SS was reduced in Salmonella enterica in response to bile (458) while it 
was increased in Shigella flexneri, Vibrio parahaemolyticus (459-461) and in the protozoan 
pathogen Cryptosporidium spp (462). Furthermore, while motility was decreased in S. enterica it 
was found to be increased in V. cholera (463). Therefore, the impact of aspirated bile on the 
respiratory microbiota in the lung may be similarly diverse. Studies on the mechanisms 
underpinning the response of gastrointestinal bacteria to bile have recently led to the 
identification of a bile ‘sensor’ in Listeria monocytogenes (464), while a role for two component 
systems has also been reported in S. enterica (465). However, until recently, no information was 
available on the influence of bile on respiratory pathogens, which are likely to encounter 
reduced, non-toxic levels of bile through aspiration. This would be analogous to the recent 
finding that sub-inhibitory concentrations of antibiotics elicit specific adaptive responses in 
pathogens, distinct from the response to higher toxic levels (466). 
7.2.2 Bile and P. aeruginosa Pathogenesis 
Consistent with the association between aspirated bile and Proteobacterial pathogens, bile was 
shown to elicit a chronic persistent biofilm lifestyle in a broad spectrum of respiratory disease 
pathogens. Studies on P. aeruginosa in particular revealed that, once exposed to physiologically 
relevant concentrations of bile, the pathogen adopted a chronic lifestyle, suppressing virulence 
systems associated with the acute phase of infection, and adopting a signal rich biofilm mode of 
growth (323). This switch from acute to chronic is characteristic of P. aeruginosa behaviour in 
respiratory diseases such as CF, where the chronic behaviour of this primary pathogen underlies 
the morbidity and mortality that underpin the pathophysiology of this disease. Indeed, chronic 




faster decline in FEV1 despite optimal respiratory management, higher mortality rate and shorter 
median survival (467). Once P. aeruginosa changes its lifestyle from an acute virulent phenotype 
to a chronic biofilm mode of growth clinical management through antibiotic administration 
becomes largely ineffective (468, 469). Therefore, there is an urgent need to understand the 
molecular mechanisms through which this and other respiratory pathogens adopt the chronic 
biofilm lifestyle.  
Addition of exogenous bile significantly increased biofilm formation and repressed the swarming 
motility of P. aeruginosa. In addition, production of all three P. aeruginosa quorum sensing 
(QS) signals, which have been detected in biofilms and CF sputum (470, 471), was increased in 
the presence of bile (323). Furthermore, promoter activity of the tssA1 gene encoded within the 
chronic associated HSI-I T6SS (472, 473) was induced 3-fold in response to bile, while the 
acute-associated T3SS (474-477) was repressed. The ability of P. aeruginosa to thrive in acid 
suppressed stomachs of patients receiving proton pump inhibitors for the treatment of GORD is 
of concern due to suggestions of the existence of an aero-digestive microbiota (136, 452, 478). 
This is of particular relevance, as bacteria may have prior exposure to bile with the resultant 
aspiration allowing for the introduction of pre-adapted isolates into the lungs (136, 479). These 
pre-adapted isolates may therefore have an additional competitive advantage over residential 
members of the lung microbiota. 
The impact of bile was not restricted to P. aeruginosa with bile also found to influence the 
behaviour of other respiratory pathogens such as B. cepacia complex, A. baumanii, and the 
emerging pathogen Pandoraea sputonum towards a biofilm mode of growth. In contrast, 
exposure to bile appeared to strongly repress biofilm formation in some isolates of S. aureus and 




mechanism through which bile shapes the respiratory microbiota triggering the emergence of 
dominant Proteobacterial pathogens. It certainly supports the hypothesis that bile directly 
influences the lung microbiota through modulation of pathogen behaviour. Indeed, the 
modulation of both PQS signalling and T6SS is highly significant in light of their role in 
interspecies and inter-kingdom communication (241, 480-482). Induction of these compounds in 
the presence of bile may therefore influence the interactions between P. aeruginosa and 
competing organisms in the bile acid positive lungs of CF patients. The changes in population 
dynamics observed in bile aspirating patients may likely arise from the dual action of bile itself 
and that of the bile induced interspecies signal molecules, although these interactions are sure to 
be complex and difficult to define.  
7.3 Bile and Inflammation 
As stated earlier, cycles of infection and inflammation are key to the pathophysiology of CF and 
other respiratory diseases. Colonisation by pro-inflammatory pathogens in the CF lung has been 
shown to lead to a dysregulated and heightened pro inflammatory response by the host immune 
system (44, 483). This results in the recruitment of neutrophils and elevated levels of 
inflammatory cytokines. Hence, bile promotes the colonisation of pathogens which results in the 
initiation of inflammation leading to bronchiectasis and progressive loss of lung function. While 
a role for pro-inflammatory pathogens in instigating inflammation is well accepted, some studies 
suggest that airway inflammation can occur in infancy, prior to the onset of bacterial colonisation 
of the lung (45). Hence, in addition to the direct correlation between bile acids and chronic 
colonisation, the accumulation of bile acids in the lungs has been directly linked with the host 
inflammatory response and increased airway inflammation. Increased levels of alveolar 




levels of bile acids. Furthermore, bile acid aspiration has also been associated with increased 
BALF tumour necrosis factor alpha (TNF-α) in a rodent model of chronic aspiration (484). 
Neutrophil dominated inflammation is a characteristic pathophysiology of CF, with bile acids 
shown to mediate this process in intestinal cells (485). D’Ovidio and colleagues reported a link 
between the aspiration of gastric reflux and the development of BOS following lung transplant. 
Increased levels of both neutrophil elastase and IL-8 were detected in BALF with elevated levels 
of bile acids. The same pattern of inflammatory marker induction in the presence of bile acids 
has also been described in patients with ventilator assisted pneumonia (344), where the primary 
bile acid chenodeoxycholic acid (CDCA) was associated with elevated levels of IL-8. Bile acids 
have been found to act as signalling molecules through activation of dedicated receptors such as 
the nuclear receptor Farnesoid X Receptor (FXR) and the membrane-bound receptor Takeda-G 
protein Receptor 5 (TGR5). In addition, bile acids can also activate other receptors, such as the 
Pregnane X Receptor which has recently been shown to mediate gut dysbiosis in response to 
statin therapy (486). In vitro reports have described how bile acids modulate production of pro-
inflammatory markers, including FXR-dependent elevated levels of IL-6 production in lung 
epithelial cells (487-489). This suggests that bile aspiration alone is enough to drive 
dysregulation of the inflammatory response.  
Bile acids are also capable of modulating the host immune response by targeting the Hypoxia-
Inducible Factor (HIF)-1 transcription factor. This transcription factor is important in the 
mounting of an effective host response to infection with bile acids found to destabilise the HIF-
1α subunit in an FXR and TGR-5 independent manner (489). HIF-1 has been previously shown 
to be required for the resolution of acute inflammation in mice (490). This destabilisation could 




in patients with respiratory disease. Interestingly, the bile acid induced AQ, PQS has also been 
shown to destabilise HIF-1α in lung epithelial cells (432) suggesting a dual targeting of this key 
host transcriptional checkpoint in the P. aeruginosa infected bile acid positive lung environment. 
Indeed, PQS is known to be produced at high levels in the lungs of P. aeruginosa positive 
paediatric CF patients, particularly in isolates obtained from patients under the age of three 
(471). In contrast, PQS could not be readily detected in adult CF sputum samples by 
metabolomic analysis (491). Destabilisation of HIF-1α in these patients may further contribute to 
the ability of P. aeruginosa to avoid host clearance (492) 
The molecular mechanisms underpinning bile acid induced changes in the inflammatory 
response are yet to be fully defined, although mechanistic insights into the role of bile acids as 
host signals continue to emerge (485, 486). It is likely that the impact of bile acid aspiration on 
lung inflammation results from the dual targeting of the host cells with direct activation of 
inflammatory markers, as well as the indirect targeting of pro-inflammatory pathogens such as P. 
aeruginosa. 
Summary and Thesis Objectives 
Respiratory disease is the third leading cause of death worldwide. CF is Ireland’s most common 
life-threatening inherited disease, characterised by chronic lung infections that are practically 
impossible to eradicate. P. aeruginosa, one of the top three global nosocomial pathogens, is the 
primary agent associated with morbidity and mortality in CF patients. Once established in the 
lung, eradication of this pathogen is almost impossible due to intrinsic antibiotic resistance and 
its biofilm mode of growth. Aspiration of bile into the lungs of patients with respiratory disease 
may be a leading cause underlying the establishment of chronic behaving dominant species, 




therapies to combat chronic lung infections, particularly those found in CF patients. The overall 
aim of this thesis was to elucidate the pathways through which P. aeruginosa emerges as a 
dominant chronic pathogen in the bile positive lungs of CF patients. An integrated approach was 
undertaken in order to understand the impact of bile acid aspiration on the establishment and 
progression of chronic infections in CF. This thesis investigated the impact of bile acids on the 
lung microbiota, both from a cross sectional and a longitudinal perspective. Molecular 
approaches were employed to uncover the pathways through which P. aeruginosa responds and 
adapts to exogenous bile and bile acids, and to identify the factors underpinning the molecular 
mechanism. By furthering our understanding of the influence of bile on pathogen behaviour and 
on the population dynamics within the lungs of patients with CF there is the potential to develop 
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The microbiology of the lower airways is a major contributor to the progression of respiratory 
disease in Cystic Fibrosis (CF). The acquisition and chronic colonisation of the CF lower 
airways occurs early in life and is associated with progressive pulmonary inflammation and 
bronchiectasis. The shift observed in the CF respiratory microbiota towards that of chronic 
pathogen-dominated microbiota, as a patient transitions to adulthood, is associated with negative 
clinical outcomes. However, the key host factors which mediate and facilitate the emergence of 
disease associated microbiota remains to be elucidated. Recent evidence suggests a role for bile 
acids as a host trigger of chronic respiratory infection. Therefore, a cross-sectional and 
longitudinal study of an Australian paediatric patient cohort was undertaken to determine 
whether the accumulation of bile acids in the lower airways contributes to the restructuring of the 
microbial communities towards that of a low diversity, pathogen dominated state. These studies 
revealed that the presence of bile acids was associated with increased levels of host immune 
factors associated with inflammation and a reduction in microbial diversity with the emergence 
of dominant pathogens. Collectively, these data support the hypothesis that the presence of bile 
acids in the lungs of paediatric patients with CF correlates with a progressive restructuring of the 
lung microbiota, promoting a reduction in diversity and the emergence of chronic pathogens. 
Therefore, the early detection and profiling of bile acids in paediatric patients could lead to more 









Cystic Fibrosis (CF) is an autosomal recessive genetic disorder characterised by frequent airway 
infections and chronic respiratory inflammation. These recurrent cycles of airway infection and 
inflammation lead to the development of structural lung disease, most notably bronchiectasis, 
bronchial wall thickening, gas trapping, and pulmonary hypo-perfusion (1). Structural lung 
disease, including bronchiectasis, contributes to the progressive loss of lung function and 
eventually results in respiratory failure and death in approximately 90% of CF patients. Recent 
reports have highlighted the rapid development of bronchiectasis in the first three years of life 
with the majority (50-70%) of children with CF already displaying signs of bronchiectasis before 
they enter school (2). Chronic respiratory infection is the leading cause of morbidity and 
mortality within CF cohorts. There has been a paradigm shift from interventions based upon the 
amelioration of lung disease to one that emphasises disease prevention through early intervention 
based on evidence from the Australian Respiratory Early Surveillance Team for Cystic Fibrosis 
(AREST CF) and other key CF centers (3).  Therefore, the identification of factors capable of 
initiating early, progressive, neutrophil dominant airway inflammation and contributing to the 
development of chronic airway infections is of critical importance in the effective clinical 
management of lung disease in CF (4, 5). 
Though the lungs were previously considered to be a sterile environment, there has been a 
growing appreciation for the diverse communities of microorganisms that colonise the airways of 
both healthy and diseased individuals collectively referred to as the lung microbiota (6-8). A 
signature respiratory microbiota has been described for CF patients, with early acquisition and 
succession of pathogens such as Staphylococcus aureus, Haemophilus influenzae, Moraxella 




bronchiectasis (3, 9-11) and exaggerated neutrophilic inflammation (9, 12). Furthermore, as 
patient’s transition towards adulthood there is evidence for the emergence of a single dominant 
Proteobacterial pathogen, most frequently P. aeruginosa. These chronic infections are the 
leading cause of morbidity and mortality in CF patients due to the development of structural lung 
disease and progressive lung function decline. However, the factors that result in the emergence 
of these pathogens and trigger a transition to chronicity of infection are unknown. Identifying the 
factors that initiate the shift in the CF lung microbiota towards this disease associated state 
would underpin the development of more effective early intervention strategies. While many 
studies have examined the development and impact of factors such as age, inflammation and 
antibiotic administration on the microbiota (7, 13-22), no consensus has been reached regarding 
the individual contribution of each of these factors in the determination of the structure of the CF 
microbiota.  
Bile acids have recently emerged as a key host factor promoting chronic respiratory disease, with 
physiologically relevant concentrations capable of inducing both an immune response and a 
behavioural response in pathogens (23-30).  Bile acids have been shown to trigger the key CF 
associated pathogens P. aeruginosa and S. aureus to transition to a chronic lifestyle (24, 27). 
Previous cross-sectional studies have highlighted that bile acids are detected in sputum and 
bronchoalveolar lavage fluid samples of both paediatric and adult CF patients (23, 31-37). The 
presence of bile acids in paediatric patients has correlated with the emergence of dominant 
proteobacterial pathogens and a reduction in diversity, associated with the pervasive CF 
microbiota (23, 30). From the host inflammatory perspective, bile acids are associated with 




physiologically relevant µM concentrations found to destabilise HIF-1α and elicit increased 
levels of IL-6 in human airway cells (26, 30, 39).  
The objective of this study was to investigate whether the occurrence of bile acids in the lungs of 
children with CF patients is associated with the establishment of chronic pathogen dominated 
respiratory microbiota over time. Establishing a longitudinal perspective on changes in the 
microbiota over time would allow stronger correlations to be made based on bile acid profiles in 
those samples. The elucidation of the impact that bile acids exert on the dynamics of the lung 
microbiota would represent a potential novel biomarker for the identification of high-risk 





















Materials and Methods 
BALF Cohort, Sampling and Storage 
Cross-sectional Study 
Randomly selected BALF samples from a cohort of children (n=91) enrolled in AREST CF as 
part of a unique early surveillance program were collected according to the AREST-CF standard 
operating procedure and were available for this study (10). BALF retrieval involved lavaging of 
the right middle lobe (RML) with three washes of saline and one lavage of the most affected lobe 
determined by CT scan. To reduce the risk of contamination, the bronchoscope was applied 
through a laryngeal mask airway and suction was only applied once the bronchoscope tip had 
reached the lower airways. These patients had previously undergone surveillance bronchoscopy 
and chest CT starting soon after diagnosis (3-6 months), and yearly thereafter when clinically 
stable. Ethical approval (Ref. 1762/EPP) was previously granted to the AREST CF program by 
the Princess Margaret Hospital for Children, Perth ethics committee and committee and consent 
was obtained to participate from parents/guardians. Clinical data including culturable microbial 
history, antibiotic regimens and clinical symptoms and measurements were available through the 
ongoing multi-centre AREST CF program (40).  
Longitudinal Study 
Twenty patients who were enrolled in the initial cross-sectional study outlined above were 
selected for longitudinal analysis (n=77 BALF samples). In order to examine the potential 
progressive loss and/or recovery of diversity over time, ten patients with low Shannon Index (SI) 
diversity measurements (SI <1.8) and ten patients with high SI diversity measurements (SI >2) 




over the course of eight years with samples ranging from 11-88 months with a minimum of two 
samples and a maximum of 7 samples present per patient (Appendix Table 2). Based on these 
criteria one patient had to be excluded as only 1 sample could be provided. BALF retrieval was 
undertaken as outlined in the cross sectional study above. Ethical approval (Ref. 1762/EPP) was 
previously granted to the AREST CF program by the Princess Margaret Hospital for Children, 
Perth ethics committee with consent to participate obtained from parents/guardians. Clinical data 
including culturable microbial history, antibiotic regimens and clinical symptoms and 
measurements were available through the ongoing multi-centre AREST CF program 
Bile Acid Profiling and Cohort Categorisation 
Sample processing was performed using a method adapted from Tagliacozzi et al. (41) BALF 
samples were treated with equal volumes of Sputolysin (Calbiochem) and vortexed for 30 s prior 
to centrifugation at 5000 rpm for 15 min. The supernatant was removed into a sterile container 
and 250 µL removed for bile acid analysis. A 900 µL aliquot of acetonitrile (Sigma-Aldrich) was 
added to each 250 µL sample which was vortexed for 1 min and centrifuged at 13,600 rpm for 10 
min. A 900 µL aliquot was transferred to a clean container and the sample was evaporated under 
nitrogen to dryness. The sample was then resuspended in 250 µL MeOH:H2O (1:1) and 
subsequently analysed by LC-MS. This process has been described previously by Reen et al. (23, 
42). Each BALF sample was analysed for the presence of 12 principal bile acids (Cholic acid 
(CA), Chenodeoxycholic acid (CDCA), Deoxycholic acid (DCA), Lithocholic acid (LCA), 
Ursodeoxycholic acid (UDCA), Glycodeoxycholic acid (GDCA), Taurochenodeoxycholic acid, 
(TCDCA), Taurodeoxycholic acid (TDCA), Taurocholic acid (TCA), Glycocholic acid (GCA), 
Taurolithocholic acid (TLCA) and Tauroursodeoxycholic acid (TUDCA)) compared to purified 




where BALF retrieval volume as a proportion of instilled volume was found not influence bile 
salt concentrations (r2=0.004) suggesting variability due to dilution is unlikely to be a major 
factor when stratifying the population based upon levels of bile acids. For stratification of the 
patient cohort on the basis of bile acid concentrations the HB lower cut-off value correlated with 
a mean BA value of 0.0025 µM (SEM +/- 0.001), while the LB upper cut-off value correlated 
with a mean BA value of 0.00125 µM (SEM +/- 0.0006).  The LB categorisation was chosen to 
reflect the lower quartile (0.01307 µM) of bile acid concentrations, while the HB lower limit was 
set at twice the LB cut-off. For robustness, MB samples were also included in the analysis, 
representing those samples that fall in between the LB and HB categories. 
Bile acid profiling undertaken for the longitudinal microbiota analysis established inter patient 
differences with respect to the presence and concentration of bile acids. Patients were categorised 
based on total bile acid concentration of samples as either Bile Acid positive >0.015 µM (BA+, 
n=3, 11), Bile Acid negative <0.015µM (BA-, n=8, 30) or Transitioning (T, n=8, 34) if patient 
samples contained both BA+ and BA- samples. While a trend was observed with a reduction in 
the percentage of BALF retrieved as a proportion of instilled volume correlating with increased 
bile acid concentration, no statistical difference was observed between the transitioning cohort 
and the BA- cohort suggesting BALF processing may have minimal contributions to cohort 
stratification.  
Genomic DNA extraction 
The low level of infection and dilute nature of the BALF samples from the paediatric cohort has 
implications for downstream microbiome analysis (43, 44). BALF supernatant was centrifuged at 
13,000 rpm for 10 min with genomic DNA extracted from the resulting pellet. DNA extracted 




instructions. A minor modification was included in the recommended protocol consisting of an 
overnight incubation with proteinase K to ensure optimal and unbiased representation of DNA 
from all the bacterial groups present in BALF. Genomic DNA was re-suspended in sterile water 
with the gDNA concentration and quality (260/280) recorded via a nanodrop spectrophotometer. 
Quantification of the concentration and quality (260/280) of gDNA was also recorded by Qubit 
fluorometer. The extracted gDNA was stored at -20oC. 
Next Generation Sequence (NGS) Analysis 
PCRs were commenced running a pre-amplification for 20 cycles using GM3 and 1061R. One 
µL of this PCR was transferred to the second 20µl PCR which was done using the standard 
primers and was run for another 20 cycles. Subsequent PCRs included 5 ng of DNA extract, 15 
pmol of each forward primer 341F 5’-NNNNNNNNNNTCCTACGGGNGGCWGCAG and 
reverse primer 785R 5’- NNNNNNNNNNTGACTACHVGGGTATCTAAKCC in 20 µL 
volume of 1 x MyTaq buffer containing 1.5 units MyTaq DNA polymerase (Bioline) and 2 µL of 
BioStabII PCR Enhancer (Sigma). This provided coverage of the V3-V4 region for microbiome 
analysis. For each sample, the forward and reverse primers had the same 10-nt barcode sequence. 
PCRs were carried out for 30 cycles using the following parameters: 2 min 96°C pre-
denaturation; 96°C for 15 s, 50°C for 30 s, 70°C for 90 s. DNA concentration of amplicons of 
interest was determined by Gel electrophoresis. About 20 ng amplicon DNA of each sample 
were pooled for up to 48 samples carrying different barcodes. The amplicon pools were purified 
with one volume AMPure XP beads (Agencourt) to remove primer dimer and other small mis-
priming products, followed by an additional purification on MinElute columns (Qiagen). Each 
purified amplicon pool DNA (100 ng) was used to construct Illumina libraries using the Ovation 




preparative Gel electrophoresis. Sequencing was done on an Illumina MiSeq using V3 Chemistry 
(Illumina).  
Microbiome profiling and population analysis 
All sequence reads were processed by the NGS analysis pipeline of the SILVA rRNA gene 
database project (SILVAngs 1.3) (45, 46). Reads were aligned using the SILVA Incremental 
Aligner (SINA SINA v1.2.10 for ARB SVN (revision 21008)) (47) against the SILVA SSU 
rRNA SEED and quality controlled (46). All reads shorter than 350 aligned nucleotides and 
reads with more than 2% of ambiguities, or 2% of homopolymers, respectively, were excluded 
from further processing. In addition, putative contaminations and artefacts, reads with a low 
alignment quality (50 alignment identity, 40 alignment score reported by SINA), were identified 
and excluded from downstream analysis. 
Following this, identical reads were identified (dereplication), the unique reads were clustered 
(OTUs) on a per sample basis, and the reference read of each OTU was classified. Dereplication 
and clustering was done using cd-hit-est (version 3.1.2; http://www.bioinformatics.org/cd-hit) 
(48) running in accurate mode, ignoring overhangs, and applying identity criteria of 1.00 and 
0.98, respectively. Classification of each hit was performed by local nucleotide BLAST search 
against the non-redundant version of the SILVA SSU Ref dataset (release 123; http://www.arb-
silva.de) using BLASTN (version 2.2.30+; http://blast.ncbi.nlm.nih.gov/Blast.cgi) with standard 
default settings applied (49). The classification of each OTU reference read was then mapped, 
yielding quantitative information (number of individual reads per taxonomic path), within the 
limitations of PCR and sequencing technique biases, as well as, multiple rRNA operons. Reads 
without any BLAST hits or reads with weak BLAST hits, where the function “(% sequence 




(50). Sequence data from the microbiome community table were rarefied to 1502 sequences per 
sample using the R package vegan., comparable to recent studies on paediatric BALF from 
patients with CF (51). Negative control samples were processed using the same DNA extraction 
method in parallel with the test samples yielded 1-295 sequence reads.  
Statistical Analysis 
All clinical and diversity data were analysed using Prism version 5.0 (GraphPad, San Diego, CA, 
USA), or the R statistical package, for significance. Linear regression analysis was performed 
using GraphPad. Mann Whitney and one way ANOVA with post-hoc corrective testing were 
applied as appropriate and in all cases differences <0.05 were considered statistically significant. 
Experimental data presented is the average of at least three independent biological replicates. 
Statistical analysis was performed by paired student’s t-test (* p≤ 0.05, ** p≤ 0.005, *** p≤ 0.001). 
Table 1; An outline of strains utilised in this study; a combination of clinical isolates recovered 
from paediatric patients attending Cork University Hospital (CUH) and typed lab strains. 
Strain/Plasmid Description Source 
Staphylococcus aureus NCDO949 Typed strain isolated from pleural fluid Shinfield, UK 
Staphylococcus aureus CUH-E Paediatric clinical isolate from CUH This study 
Staphylococcus aureus CUH-T Paediatric clinical isolate from CUH This study 
Staphylococcus haemolyticus CUH-M Paediatric clinical isolate from CUH This study 
Staphylococcus haemolyticus CUH-D (LB) Paediatric clinical isolate from CUH This study 
Staphylococcus epidermidis CUH-D (MS) Paediatric clinical isolate from CUH This study 
Staphylococcus epidermidis CUH-K (LB) Paediatric clinical isolate from CUH This study 
Ralstonia CUH-242 Pigmented paediatric clinical isolate from CUH This study 
Ralstonia CUH-229 Non pigmented paediatric clinical isolate from CUH This study 
Stenotrophomonas maltophilia CUH-B (PIA) Paediatric clinical isolate from CUH This study 
Stenotrophomonas maltophilia CUH-C (PIA) Paediatric clinical isolate from CUH This study 
PA14 WT Wild Type (52) 
Pseudomonas aeruginosa CUH-A (PIA) Paediatric clinical isolate from CUH This study 






Overnight cultures were adjusted to an O.D600nm 0.05 in TSB in the presence and absence of bile 
or bile acids. Aliquots (1 mL or 200 µL) were transferred in to 24-well plates or 96 well plates 
respectively and incubated at 37˚C overnight. Biofilm formation was measured by removing 
culture by pipetting. Wells were washed with water by pipetting to remove any unattached 
biofilm. Attached biofilm was measured by staining for 30 min with 1 mL/ 200 µL of 0.1% (w/v) 
crystal violet. 100% (v/v) ethanol was used to solubilise the crystal violet followed by a 






















Sample preparation for bile acid profiling and genomic DNA extraction 
A batch of 91 BALF samples was received for the cross-sectional study and a batch of 77 
samples was received for the longitudinal analysis. These were prepared for bile acid profiling 
(assisted by David Woods) and genomic DNA extraction as outlined in Figure 1 below.  
 
Figure 1. Method of sample preparation of Australian BALF samples. Samples were prepared for bile acid profiling 
and gDNA extraction as outlined in the materials and methods. Bile acid profiling was conducted using LC-MS 
analysis with extracted gDNA sent for sequencing. 
Bile acid profiling and genomic DNA extractions was successfully undertaken for the 91 cross 






Table 2; gDNA concentrations from cross sectional BALF samples. 
Sample ng/µl 260/280 Sample ng/µl 260/280 
1 13.7 2.05 45 6.8 2.13 
2 7.2 1.97 46 25.6 1.84 
3 1.3 2.56 48 4.6 2.03 
4 3.5 2.31 49 2.6 2.22 
5 7.3 2.16 50 113.4 1.34 
6 6.2 1.75 51 8.7 1.43 
7 4.7 2.70 52 5.1 1.07 
8 6.1 2.55 53 4 1.32 
9 4.8 2.26 54 27.9 1.87 
10 10.5 1.56 55 4.2 1.55 
11 7.2 1.12 56 6.6 1.53 
12 7.6 1.30 57 7.8 1.34 
13 19.7 1.57 58 9.2 1.45 
14 11.8 1.39 61 3.2 1.07 
15 15.3 1.46 62 4 1.34 
16 4 1.53 63 4.5 1.09 
17 16.7 1.00 64 7.5 1.48 
18 16.4 0.86 65 5.3 2.12 
19 43.1 1.52 66 6.8 1.94 
20 46.4 1.12 67 4.8 1.51 
21 22 1.03 68 1.1 0.67 
22 3.2 0.79 69 5.7 1.86 
23 1.5 0.40 70 9.5 1.86 
24 2.8 3.79 71 15.4 1.92 
25 1.7 0.40 72 23.7 1.28 
26 4.9 2.28 73 1.4 1.27 
27 107.6 1.14 74 10.6 1.87 
28 6.3 1.91 75 8 1.76 
29 6.8 2.86 76 5.7 2.36 
30 3.9 3.47 77 25.3 1.87 
31 5.2 2.57 78 5.9 2.04 
32 6.9 1.52 79 12.7 1.90 
33 4.9 3.30 80 7.2 1.47 
34 4.8 1.82 81 17.3 1.73 
35 7.3 2.15 82 7.5 3.01 
36 11.3 1.48 83 56.4 1.50 
37 6 2.05 84 7.3 2.19 
38 4.8 2.05 85 5.2 2.02 
39 9.1 2.15 86 10.3 1.86 
40 17.2 1.86 87 10.8 1.56 
41 3.8 3.69 88 5.5 0.66 
42 8.2 1.66 89 15.1 2.04 
43 7.7 1.92 90 8.7 1.96 





The patient cohort ranged in age from 2-5 years and were representative of the AREST CF 
cohort with regards demographic and clinical features (Appendix Table 1) (51, 53). There was a 
technical fault in the processing of samples 47, 59 and 60 so these samples were no longer 
available for analysis. Bile acid profiles of twelve individual bile acids generated through LC-
MS analysis are illustrated in Figure 2. The concentrations of bile acids detected, although lower 
than those detected by our group and others in sputum or saliva (23, 37), were in line with 
previous reports from BALF (31). Glycodeoxycholic acid (GDCA) and Glycocholic acid (GCA) 
were particularly abundant bile acids in this cohort. It was clear however that inter-patient 
differences existed in terms of the concentrations of bile acids detected.  
 
Figure 2. Bile acid (BA) profiling for 88 patients with key denoting both individual bile acid (BA) and total bile acid 
(TBA) concentrations. Each BALF sample was analysed for the presence of 12 principal bile acids; Cholic acid (CA), 
Chenodeoxycholic acid (CDCA), Deoxycholic acid (DCA), Lithocholic acid (LCA), Ursodeoxycholic acid (UDCA), 
Glycodeoxycholic acid (GDCA), Taurochenodeoxycholic acid, (TCDCA), Taurodeoxycholic acid (TDCA), 





Bile acids correlate with a reduction in microbial diversity in CF lung microbiomes  
Lower respiratory infections, even from as early as the first weeks of life, are strongly associated 
with the development of pulmonary inflammation and bronchiectasis. Furthermore, changing 
dynamics of the lung microbial community structure is emerging as a critical factor in the 
pathophysiology of CF. Microbial profiles of the paediatric BALF samples were established 
based on the V3-V4 region of 16S rDNA with 5 samples excluded as microbiome analysis could 
not be completed. Shannon Index (SI) as a measure of lung biodiversity was determined for each 
sample with lower SI indices appearing to correlate with the presence of bile acids (Fig 3A). The 







Figure 3. (A) Stacked chart analysis of the lung microbiota of the 88 patient samples with genera >1% identified. 
Analysis is overlaid with diversity of the microbiota as measured by SI and concentrations of bile acids present 
highlighting a correlation between the presence of bile acids and a reduction in biodiversity. (B) Stratification of the 
patient cohort on the basis of bile acid concentrations detected into high bile (HB >0.03 µM), moderate bile (MB 
0.015-0.3 µM) and low bile (LB <0.015 µM) further highlights the correlation between the presence of bile acids and 
the reduction in diversity with HB trending towards a statistically significant difference to LB.  
Stratification of the patient cohort into three categories on the basis of quartile bile acid 
concentrations; high bile (HB >0.03 µM, upper quartile), moderate bile (MB 0.015-0.3 µM) and 
low bile (LB <0.015 µM, lower quartile) further highlights the correlation between the presence 
of bile acids and the reduction in SI with the difference between the HB and MB categories to 




respectively)  (Fig 3B). Inflammation of the CF lung is dominated by neutrophils that release 
oxidants and proteases, particularly elastase. Neutrophil elastase (NE) in the CF airway 
secretions precedes the appearance of bronchiectasis, and correlates with lung function 
deterioration and respiratory exacerbations. Stratification of the cohort based on bile acid status 
revealed a correlation with NE levels, with no NE detected in LB samples (Figure 3B). 
Although HB (one tailed t-test, p=0.0702) and MB (one tailed t-test, p=0.0567) samples trended 
towards higher levels of NE when compared with LB samples the difference between the groups 
were not statistically different. Importantly, these three categories were indistinguishable based 
on age, gender and antibiotic regimens (Appendix Figure 1). 
The previous observation that BAs in the lungs correlate with changes in the microbiology of the 
lung led us to investigate whether the presence of BAs in patients could explain the shift in the 
dynamics of the microbiota over time. In order to investigate whether the progressive loss and/or 
recovery of diversity over time is associated with the accumulation of bile acids in these patients, 
10 patients with the lowest SI (<1.8 with the exception of two samples 5 and 36) values (5, 14, 
16, 36, 40, 51, 77, 87, 89, 90) and the same number of patients with the highest SI (>2) values (6, 
9, 10, 15, 22, 41, 50, 70, 75, 76) were enrolled from the cross-sectional study for longitudinal 
analysis. 77 BALF patient BALF samples were obtained which spanned over the course of eight 
years with samples ranging from 11-88 months with a minimum of two samples and a maximum 
of 7 samples present per patient (Appendix Table 3). Based on these criteria one patient had to be 
excluded as only 1 sample could be provided. Bile acid profiling, gDNA extraction and 
microbiome analysis was undertaken as described above. On the basis of low read values (Table 
3), the following samples were excluded from analysis; 5e, 7c, 13d, 16e, 18e as well as one 




Table 3; gDNA concentrations from longitudinal BALF samples. 
ID  ng/µl 260/280 Reads ID  ng/µl 260/280 Reads 
1 C 5 1.42 120029 11 A 0.4 0.36 3918 
 D 316.3 1.84 219713  C 22 1.89 4807 
 F 19.9 1.84 263960 12 B 1.1 0.70 36780 
 G 292.1 1.87 195093  C 3.8 1.27 54919 
2 B 2.3 1.58 1807  D 1.4 1.61 3908 
 C 3.8 1.56 3619  E 3.5 1.32 6668 
 G 3.6 2.25 135513  F 3.6 2.26 5878 
3 B 14.8 1.91 10985  G 2.1 1.05 9174 
 C 1.7 1.41 10919 13 C 2 1.04 4942 
 E 14 2.16 251502  D 0.9 1.19 697 
4 A 32.5 1.63 126434  E 2.2 1.98 2099 
 D 38 1.96 243494  F 15 2.23 20828 
 E 22.4 2.07 293621  G 27.9 1.91 9557 
5 B 1 2.44 46963  H 8 2.08 16773 
 C 3.4 1.88 14668 14 D 2.2 1.64 15858 
 D 7.5 1.37 155175  E 2.5 0.78 17342 
 E 0.8 -0.89 327 15 B 0 0 35340 
 F 15.6 1.91 71908  E 4.8 2.42 19336 
 G 14 2.09 14223 16 C 13.4 2.08 19045 
6 B 3.1 3.09 35567  D 2 3.64 55950 
 D 29 1.70 60616  E 2.4 2 625 
 E 48.8 1.74 15450  F 1.5 1.16 25691 
 F 7 1.90 273565  G 3.6 1.03 6828 
 G 20.6 1.83 163260 17 B 3.2 1.70 2905 
 H 96.6 1.82 157699  C 0.8 0.51 1934 
 I 64.7 1.74 137271  D 156.9 1.24 5341 
7 B 0.8 1.28 8086  E 4.8 2.63 1979 
 C 0 0.16 459  F 0.5 1.51 1216 
 D 11 1.75 279670 18 C 0.4 2.41 2995 
8 C 5.7 1.09 63475  C 0.2 0.30 22101 
 D 2.6 1.50 11806  D 1.3 2.04 1507 
 E 2 1.19 11504  E 3.6 1.85 948 
 F 9.3 1.42 5291 19 D 0.4 0.27 46775 
9 D 11.1 2.22 2876  E 4.4 2.08 5991 
 E 7.8 2.22 166964  F 96.7 1.91 27151 
 F 45.7 1.66 4485 20 C 2.5 0.86 15570 
10 B 2.3 1.99 13638 
 C 12.2 1.88 73715 
 D 7.8 1.37 98326 
 E 4.7 2.92 1691 
 F 2.5 2.24 15 
 
Following on from previous studies and the initial cross sectional which demonstrated that BAs 
are present in both BALF and sputum of paediatric patients, BA profiling of the longitudinal 




acids with patients categorized as Bile Acid+ (BA+) if bile acids were consistently present in all 
patient samples (TBA >0.015 µM), Bile Acid- (BA-) if patient samples had low to no bile acids 
present (TBA <0.015 µM) and transitioning patients having bile acids present intermittently 
(patient samples contained a mixture of BA+ and BA- samples) (Fig. 4). Glycocholic acid 
(GCA) and Taurocholic acid were abundant in BA+ patients. While there was no significant 
difference in age and antibiotic administration between the three groups, there were more female 
patients in the BA+ category compared to the BA- category. This could be attributed to the 
overrepresentation of females in the initial cross-sectional study (Appendix Figure 1).  
 
Figure 4. Bile acid profiling of 77 longitudinal patient samples with a minimum of 2 samples per patient and a 
maximum of 7. As such 1 patient had to be excluded from further analysis as only 1 sample could be provided. Patients 
were categorised based on the presence of bile acids over time with patients designated BA+ consistently having bile 






Age-associated reductions in biodiversity  
Microbiome analysis of the paediatric BALF samples was undertaken based on the V3-V4 
region of 16S rDNA with SI measurements completed for each patient sample. Characterisation 
of patients on the basis of SI measurements over time revealed three broad categories: (i) patients 
in which the microbiome consistently remained stable over time (2.035 +/ 0.439), (ii) patients in 
which the microbiome fluctuated between high diversity and low diversity samples over time 
(1.371 +/- 0.791), and (iii) patients whose microbiome crashed over time with no recovery in 
diversity suggesting the emergence of a dominant organism (1.178 +/- 0.881) (Figure 5). 
Figure 5. Longitudinal analysis of the diversity of the microbiomes of 19 patients’ revealed patients could be 
categorised into three broad categories; (A) Highly diverse, stable microbiomes (B) Fluctuating diversity microbiomes 
and (C) Crashed microbiomes. 
Interestingly, while an age associated decline in the diversity of microbial communities has been 
described in CF patients, this did not apply to category A where the patient’s lung microbiota 
remained relatively diverse and stable over time. This raised the question as to what factors 
underpinned the differences in SI observed between groups of patients, which cannot solely be 





Bile acid positivity promotes changes in the CF paediatric microbiome 
Principal component analysis based on the microbial profiles of the total patient cohort revealed 
the presence of two primary clusters. Correlation analysis with the SI categories described in 
Figure 5 revealed that cluster 1 was predominantly a composite of samples from the crashed 
microbiome category while cluster 2 was predominantly composed of samples from the highly 
diverse stable microbiomes. There was a potential third cluster present, however this cluster was 
found to not separate completely from cluster 1 and 2. This suggested that, apart from the 
diversity score, the signature taxonomic profile was being shaped by some host or environmental 
factor. 
 
Figure 6. PCA of the global microbiome from the total patient cohort revealed separation into two primary clusters 
with patient samples from the crashed microbiome category predominantly located in cluster 1 while patient samples 
from the highly diverse, stable microbiome found in cluster 2.  
Correlation of the PCA analysis with BA profiling revealed cluster 1 to be dominated by samples 




Samples from the transitioning cohort were found to be distributed between the two clusters. 
This was further supported by hierarchical clustering using the Bray Curtis dissimilarity Index in 
which two primary clusters; 1 (A & B) and 2, were once again observed (Fig. 7). The samples 
contained within cluster 1 were predominantly BA+ while samples in cluster 2 were primarily 
BA-. Clustering was found to be independent of either age or augmentin regimes (Appendix 
Figure 2).  
 
Figure 7. Hierarchical clustering based on the bray Curtis dissimilarity index highlighting bile acids underpin 
microbial community remodelling. 
Bile acids are linked to a progressive reduction in diversity 
The previously reported transition towards low microbial diversity over time was not evident in 
all patients tested in this study (Fig. 5). Therefore, the central question to be addressed here was 
whether the presence of bile acids underpinned the age associated reduction in diversity. Global 
linear regression analysis of the total patient cohort revealed a significant decrease in Shannon 




Index (pathogen dominance). However, the stratification of the total patient cohort into the 
assigned bile acid categories highlighted that these age associated effects are only evident in the 
transitioning patients shifting towards BA positivity (Fig. 8). In contrast, the BA- cohort 
maintained a highly diverse microbiomes over time while the BA+ cohort trended towards low 
diversity and increased pathogen dominance though was not significant. This was potentially due 
to the consistently high concentrations of bile acids over time, resulting in the prior 
establishment low diversity scores. The reduction in diversity was significant in the transitioning 
cohort where the accumulation of bile acids correlated with a reduction in diversity indexes.  
 
Figure 8. Diversity measurements of the total patient cohort and stratification into BA+, T and BA- cohorts. (A,B) 
Significant reduction in Shannon Index and Simpson Index diversity measurement over time in total patient cohort, 
only evident in the T cohort. (C) Significant increase in Berger-Parker pathogen dominance Index over time in total 




Bile acids promote pathogen acquisition and chronic colonisation 
The presence of bile acids is associated with the persistent infection by the pathogenic organisms 
Pseudomonas, Inquilinus and Haemophilus in this paediatric cohort. Once acquired by patients, 
these pathogens become established and dominate the microbiota of the BALF samples analysed. 
In general, the earlier samples from all patients in this study displayed a relatively diverse 
microbiota populated by Veillonella, Neisseria and Streptococcus (Figure 9A). In patients that 
transition towards BA+, the subsequent acquisition and establishment of pathogenic organisms 
such as Pseudomonas, Staphylococcus, Haemophilus, Stenotrophomonas and Achromobacter is 
evident. This is in direct contrast to BA- patients which retain a highly diverse microbiota 
including the health associated organisms such as Neisseria, Veillonella and Prevotella. The 
organisms Propionibacterium and Sphingomonas are also found to be more abundant in this 
cohort of patients. In instances where a pathogen emerges such as Pseudomonas in patient 13 or 
Haemophilus in patient 9, these do not appear to persist or become the dominant member of the 
microbial community. In patient 13 though the relative abundance of Pseudomonas initially 
increases to 69% and 89%, the following year this is reduced to 47%. Hence, even though the 
bug is still present, it has not retained its position strongly as dominant organism. In patient 9, 
though Haemophilus is acquired and is detected at a relative abundance of 78%, the following 
year the organism has completely cleared and is not detectable in the patient samples. In a bile 
negative environment the data suggests that the infection is capable of being successfully cleared 






Figure 9. (A) Stacked chart denoting the microbial composition present in BA+, T and BA- patient samples. BA+ and 
T samples display a reduction in biodiversity and increased levels of dominance of the microbiota by individual 
genera. In contrast, BA- samples are generally more diverse.  (B) Culturable data from the clinical data of samples 
obtained in the two years post-microbiome study confirms the hypothesis that the presence of pathogens is associated 
with the presence of bile acids as can be seen in BA+ and T patients. 
Furthermore, analysis of culturable data from the AREST clinical database in the two years post 
sampling for microbiome analysis demonstrates that pathogenic organisms are more routinely 
cultured in BA+ and transitioning patients (Figure 9B). This is consistent with the hypothesis of 
persistent colonisation by CF associated pathogens in the presence of bile acids. However, this 
analysis must be viewed in the context of limited availability of follow-on patient samples. 
Interestingly, although Pseudomonas was present in the microbiome of BA- patient 18, a follow-




the infection. This contrasts to BA+ patients where colonisation of the lung with a pathogen is 
persistent and cannot be resolved.  
 
Figure 10. A summary overview of the longitudinal study. BA+ patients display elevated bile acid levels, reduction 
in diversity as measured by SI, increased pathogen dominance of the microbiota and elevated levels of the pro-
inflammatory cytokine IL-8. In contrast, BA- patients displayed reduced bile acid levels, generally higher levels of 
diversity, reduced pathogen dominance and lower levels of the cytokine IL-8. The transition category in which patient 
samples consist of both BA+ and BA- samples is an intermediate between the two categories in terms of the parameters 
assessed. 
In conclusion, BA+ patients were found to display elevated levels of bile acid with a reduction in 
diversity as measured by SI, increased pathogen dominance of the microbiota and elevated levels 
of the pro-inflammatory cytokine IL-8 also observed. In contrast, BA- patients were found to 
display reduced bile acid levels, generally higher levels of diversity, reduced pathogen 
dominance and lower levels of the cytokine IL-8. The transition category in which patient 




acid categories (Fig. 10). This is the first longitudinal study that points to the association 
between bile acids and the restructuring of the lung microbial communities.  
Phenotypic profiling of clinical isolates of a range of respiratory pathogens 
The growing appreciation for the extent of species phenotypic heterogeneity within the CF lung 
led us to further investigate whether the response of lung microbiota associated microbial species 
to bile is uniform. Therefore, a range of bacterial isolates, outlined in Table 1, were tested in 
order to investigate whether bile is capable of modulating the behaviour of clinical isolates in the 
same manner as previously investigated typed strains. The strains tested were a combination of 
clinical isolates recovered from paediatric patients attending Cork University Hospital previously 
collected in the BRC and typed lab strains. Interestingly, not only was there a differential 
response to bile between the typed lab strains and clinical isolates, there was apparent variation 
in the bile response between clinical isolates. As mentioned above, this is unsurprising in light of 
reports describing phenotypic heterogeneity of strains residing in the CF lung (54-56). In Staph 
aureus, the most prevalent early coloniser in paediatric patients with CF, initial studies reported 
that bile repressed biofilm formation in the typed strain NCDO949 (24). However, in a marked 
contrast, it was found to stimulate biofilm formation in the two clinical isolates (CUH-T and 
CUH-E) (Fig. 11A). In Staph haemolyticus, one of the isolates (CUH-M) tested did not exhibit 
any change in biofilm in response to bile, while a slight but significant reduction in biofilm 
formation was observed in the other Staph haemolyticus isolate (CUH-D LB) (Fig. 11B). In the 
two Staph epidermidis strains tested (CUH-D MS & CUH K LB) bile significantly increased 
biofilm formation. In the emerging respiratory pathogen Ralstonia, a dark brown pigmented 
isolate (CUH-242) significantly increased biofilm formation in response to bile. In contrast, a 




two Stenotrophomonas maltophilia strains tested (CUH-B PIA & CUH-C PIA) were non 
responsive to the presence of bile, again in contrast to the typed strain tested previously (24). In 
P. aeruginosa, the biofilm response to bile was conserved relative to the typed lab strain in one 
of the clinical isolates tested (CUH-A PIA) with an apparent hyper response to bile. However, 
biofilm formation was not significantly altered in another clinical isolate tested (CUH-B McC) 
further highlighting phenotypic heterogeneity amongst isolates (Fig. 11D). This data confirms 
that phenotypic diversity with regards to bile responsiveness is present in our clinical isolate 
collection. This suggests that potential strain specific adaptations may occur in a bile positive CF 
lung environment, a hypothesis which will be further explored in chapter 3. In order to confirm 
this, further investigations would be required encompassing bile acid profiling and the isolation 







Figure 11. Biofilm formation in clinical isolates and typed strains of a range of respiratory pathogens. (A) Staph 
aureus, (B) Staph haemolyticus and Staph epidermidis, (C) Ralstonia and Stenotrophomonas maltophilia and (D) P. 














The CF lung has been shown to harbour distinct microbial communities with dysbiosis evident 
throughout disease progression characterised by a shift towards a low diversity, pathogen rich 
microbiota (13-15, 57-59). The polymicrobial nature of CF infections has highlighted the 
importance of community structure and interactions between members and their contribution to 
the pathogenesis of respiratory disease. Of particular importance, is the knowledge of host 
factors which shape these microbial communities facilitating the establishment of chronic 
infections; the primary cause of morbidity and mortality in the CF population. The aim of the 
clinical studies outlined in this chapter was to undertake a cross-sectional/longitudinal analysis of 
the microbiology of the lower respiratory tract of paediatric patients with CF, and to establish if 
correlations existed between bile acids and pathogen dominated microbiomes.  
The cross-sectional study encompassing 91 patient samples revealed inter-patient differences in 
both the concentrations of bile acids and in the microbial profiles and diversity present. This 
initial study indicated a potential correlation between the presence of bile acids and reshaping the 
microbial communities present. This evidence appeared to position bile acids as a key player in 
the modulation of the respiratory microbiome towards a low diversity, chronic pathogen 
dominated state commonly observed in end stage lung disease. In order to further investigate this 
hypothesis 20 patients were selected from the cross-sectional analysis for a longitudinal study.  
Several reports have described a reduction in microbial biodiversity of the CF lung as patient’s 
transition into adulthood (7, 13, 14, 22, 60) . However, the factors underpinning this age 
associated decline remain unclear. Additionally, the fact that not all patient’s exhibit these 
decreases in diversity is worthy of investigation. Within our cohort of 19 patients, 8 patients 




fluctuated over time and the diversity of 7 patient’s microbiotas crashed over time. PCA analysis 
on the global microbiota of the total patient cohort revealed separation into two primary clusters. 
As recent findings have identified a role for bile acids in the progression of chronic lung disease 
(28, 35-37, 61), we wanted to investigate whether the presence of bile acids in these paediatric 
patients could explain this separation.  
A hierarchical clustering tree based on the Bray Curtis dissimilarity matrix revealed that the 
clustering could be attributed to the presence of bile acids. The majority of BA+ samples were 
found in cluster 1 and the majority of BA- samples were found in cluster 2. While a selection of 
patient samples were found clustered together and certain early year samples clustered together, 
this was not the case for the majority of the samples and could not explain the global clustering.  
The administration of the antibiotic augmentin did not affect clustering. These results support the 
association between bile acids and the reshaping of microbial communities towards low diversity 
populations. Analysis of three commonly utilised diversity measurements Shannon Index, 
Simpson Index and Berger-Parker Index confirmed the age associated reduction in diversity and 
age associated increase in dominance of organisms in the total patient cohort (7, 13, 14, 22, 60). 
However, only patients transitioning towards bile acid positivity display this signature CF effect. 
This firmly supports the hypothesis that the appearance of bile acids in the lungs triggers a 
programmed switch in the microbiota whereby theirs is a reduction in diversity and an 
overgrowth of single dominant organisms. 
From a clinical perspective, understanding how bile acids transition to the lungs of these patients 
is crucial. A role for gastro-oesophageal reflux (GERD) and aspiration has been proposed in 
recent years underpinned by evidence from in vitro and in vivo studies of microbial pathogenesis, 




association between aspiration and airway inflammation in children with CF is evident from 
examination of bronchoalveolar fluid (64). Importantly, only low concentrations of bile salts are 
required to change microbial communities and phenotypes (23, 24, 27, 42), and therefore micro-
aspiration rather than overt GERD may be sufficient to significantly shape the lung microbiome 
in early CF (43). Both chronic cough and asthma have also been reported to result in increased 
bile acid levels in sputum (37), and studies are ongoing to determine the incidence of reflux and 
aspiration in these cohorts. Alternatively, de-novo synthesis of bile acids has been speculated to 
occur in pulmonary arterial hypertension (65), and to reach the lung by the circulatory system in 
neonates (28). Therefore, further studies will be needed to address the complexity of how bile 
acids are able to accumulate in the lungs of patients with CF. 
The in-depth characterisation of the microbiota revealed the presence of several key CF-
associated pathogenic organisms in BA+ and transitioning patients. This included Pseudomonas, 
Haemophilus, Stenotrophomonas and Staphylococcus. Interestingly though it is not yet known if 
bile acids influence the acquisition of these organisms, upon emergence of these organisms 
within the microbiome bile acids influenced the ability of these organisms to chronically 
colonise and persist in the lung with pathogens persisting for several years. In contrast, the 
microbiota of BA- patients were highly diverse containing members of the healthy associated 
microbiota including Neisseria, Prevotella and Veillonella. Interestingly, where acquisition of a 
pathogen such as Pseudomonas was observed in the BA- cluster, microbiome analysis of 
subsequent samples revealed the pathogen did not become a dominant member of the microbial 
community hence no evidence of chronic colonisation was observed. This suggests a potential 




support the hypothesis of a centralised role for bile acids in facilitating chronic colonisation of 
the CF lung by P. aeruginosa and other Proteobacterial pathogens. 
This study is the first paediatric longitudinal study examining a role for bile acids in the onset of 
the disease associated microbiota in CF. However, this and other respiratory microbiota studies 
should be carefully interpreted with consideration given to the numerous limitations that exist 
with regards to sample collection, processing and sequencing. The primary issue when dealing 
with paediatric BALF samples is the risk of low bacterial load thereby increasing the risk of 
background contamination, particularly from DNA extraction kits (66-68). This should be kept in 
mind with respect to this study in which there was both low volumes of BALF available and low 
bacterial load. The collection and processing of such low bacterial load samples is therefore 
critical with proactive measures required to ensure that no exogenous DNA is introduced 
throughout the handling of samples. The inclusion of negative controls during processing is 
essential in the monitoring of background contamination levels, with several negative controls 
including DNA kit controls and water controls in place during the processing of these samples 
(69). The lack of a bronchoscope control in this study is not ideal, a gap which should be 
addressed going forward as any background contamination introduced during sample collection 
could be misinterpreted as residents of the respiratory microbial community. Sequencing of such 
controls leads to the identification of background contamination facilitating their exclusion from 
data analysis with numerous exclusion strategies outlined by Marsh et al. (70). The choice of 
DNA extraction kit employed has also been shown to significantly impact the bacterial DNA 
yields obtained, with different extraction kits reported to harbour contaminating microbiomes 
referred to as the “kitome” (67, 68). In this study, increased DNA concentrations were yielded 




(260/280) obtained using this extraction method could impact upon downstream analysis. 
However, the internal quality controls of LGC deemed these samples of sufficient quality for 
sequencing. Even after employing an optimised DNA extraction method, there may still be a 
problem in the generation of sufficient amplicons for sequencing. In these instances, such as for 
this study, nested PCR reactions may be used to enhance amplicon yield for downstreaming 
sequencing (71). However, use of nested PCR requires the additional liquid handling steps which 
increases the risk of the introduction of exogenous DNA (70). Enhanced PCR cycles may also 
increase amplification errors and increase the detection of background contamination (68). The 
exclusion of low read sequencing data, as applied in this study, which may not be reliable should 
be undertaken in order to not confound the interpretation of the data or the potential biological 
significance.  Hence, while this study has provided some valuable insights into the impact of bile 
acids on the paediatric lung microbiota, they must be viewed in the context of the challenges 
encountered in the processing and sequencing of the samples.  
In conclusion, this study establishes that the presence of bile acids in the lung is accompanied by 
a loss of diversity, emergence of a dominant pathogen which is often Pseudomonas and from a 
clinical perspective higher levels of the pro-inflammatory cytokine IL-8 (Figure 10). While this 
study aims to establish a causal role for bile acids in the progression of respiratory disease, the 
limited number of samples available restrict the outputs to strong associations. Further 
comprehensive longitudinal analysis, including potential animal models, will be required to 
make a convincing case for causality. These findings provide new knowledge on what could 
represent both a potential biomarker for the identification of high risk patients and a potential 
therapeutic target for the development of novel therapeutics, providing an opportunity for 
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Appendix Figure 1. Comparison of age, patients on augmentin and gender across the HB, MB and LB categories. 
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54 2 3.39 F508del I
I 
II  1 
55 1 3.30 R560T I
I 
III  1 
56 2 3.67 P67L 
I 
IV  0 
57 1 3.20 c.3121G-A 
I 
  1 
58 2 4.44 G551D I
I 
III  1 
61 2 3.13 R347P 
I 
IV  0 
62 1 2.56 F508del 
I 
II  1 
63 1 3.25 1585-1G>A I
I 
I  1 
64 1 3.63 F508del I
I 
II  0 
65 1 3.44 F508del 
I 
II  1 
66 2 3.99 F508del 
I 
II  0 
67 2 3.35 F508del I
I 
II  1 
68 1 4.16 L475P 
I 
  0 
69 1 3.45 F316fs 
I 
I  0 
70 2 4.25 * I
I 
  0 
71 1 4.17 F508del I
I 
II  1 
72 1 4.04 F508del 
I 
II 17 1 
73 2 2.78 F508del 
I 
II 0 0 
74 2 3.25 K684fs I
I 
I  0 
75 1 3.14 R117H 
I 
IV  1 
76 2 4.09 c.2657+3insA 
I 
  0 
77 2 4.40 F508del I
I 
II  1 
78 2 3.23 F508del 
I 
II  0 
79 2 3.69 R1162X 
I 
I  0 
80 2 4.12 W1282X I
I 
I  1 
81 2 4.31 F508del I
I 
II 0 0 
82 1 4.44 P67L 
I 
IV 23 0 
83 1 3.84 c.441delA 
I 
I 46 0 
84 2 3.30 F508del I
I 
II 0 1 
85 1 2.93 F508del 
I 
II 0 1 
86 2 2.25 F508del 
I 
II 0 1 
87 1 3.16 F508del I
I 
II  1 
88 2 3.16 * I
I 
 16 1 
89 2 3.58 S341SfsX29 
I 
I 0 0 
90 2 2.5 G551D 
I 
III 56 1 
91 2 3.41 F508del I
I 
II  1 
 
* Unknown, # H – Hospital Days, ^ Aug – Augmentin ~ G – Gender (1 – Male, 2 – Female) 











Appendix Table 2; Summary of Shannon index values and bile acid concentrations in the cross 
sectional cohort. 
Sample Bile acids Shannon Index Reads Sample Bile acids Shannon Index Reads 
1 0.0841 2.623736 14905 56 0.0257 2.123768 24809 
2 0.0562 2.690581 18227 57 0.0222 2.120983 9372 
3 0.0657 2.54197 9813 58 0.0148 2.281479 15682 
4 0.0549 2.466574 5719 61 0.0212 2.749276 32042 
5 0.0707 1.893592 33983 62 0.0134 2.511719 17134 
6 0.0749 2.669317 23420 63 0.0185 2.379834 24658 
7 0.0548 2.536743 32484 64 0.0208 2.135887 19088 
8 0.062 2.5502 34347 65 0.0184 2.24259 29916 
9 0.0396 2.579203 18191 66 0.0113 2.192011 17492 
10 0.048 3.063137 44222 67 0.0139 2.216605 13230 
11 0.1071 1.989198 33787 68 0.0063 2.333679 5094 
12 0.0599 1.958435 28376 69 0.0105 2.735136 23815 
14 0.0438 1.648071 26791 70 0.0125 3.014657 14318 
15 0.0196 2.789375 30466 71 0.027 2.164757 13720 
16 0.0435 1.658508 37536 72 0.0601 2.084145 26359 
17 0.0196 2.862336 63354 73 0.0229 2.275316 10014 
20 0.0237 2.045524 11366 74 0.0038 2.254727 9261 
21 0.0644 1.983253 13610 75 0.0112 3.172943 36965 
22 0.0202 2.930159 38301 76 0.0159 2.588906 11294 
23 0.0116 2.067256 31750 77 0.046 0.207159 13975 
24 0.0128 2.097885 6523 78 0.0326 2.112447 8781 
25 0.0098 2.484482 26335 79 0.0318 1.781911 12691 
26 0.0146 2.040025 18196 80 0.0044 2.363968 49242 
27 0.017 1.772314 30343 81 0.0389 1.691005 28280 
28 0.0421 2.302747 19449 82 0.0124 2.486593 28464 
29 0.0192 2.104598 44622 83 0.0413 2.915503 13726 
30 0.0294 2.039099 17278 84 0.0227 2.024782 7268 
31 0.0037 2.175337 32023 85 0.032 2.215801 24689 
32 0.0032 2.218581 31839 86 0.0344 2.21365 22775 
33 0.0035 2.128452 13359 87 0.0184 0.112218 103426 
35 0.0076 1.911904 38646 88 0.0421 2.522394 44816 
36 0.0046 1.997317 40075 89 0.0513 0.895432 15589 
37 0.0229 2.102168 11943 90 0.1528 0.629684 11482 
38 0 1.87854 7937 91 0.0401 2.212557 20140 
39 0.0248 2.123431 34390 
40 0.018 1.524188 32592 
41 0.011 2.104476 7281 
42 0.0231 1.939326 7748 
43 0.0152 1.957913 38184 
44 0.016 2.109537 32331 
45 0.007 2.274865 8180 
46 0.0996 2.328738 22260 
48 0.0099 2.178856 7552 
49 0.0114 2.393698 11890 
50 0.0206 2.086208 7694 
51 0.0374 1.331204 19667 
52 0.0181 1.959752 13926 
53 0.0644 2.690778 22992 





Appendix Table 3; Clinical Dataset for AREST CF Longitudinal Paediatric Cohort BALF 
samples. 
CS ID  L ID  G Age   Allele 2 Mut2  Symptoms H Augmentin 
BA+ (>0.015µM)       
90 1 C 2 16 Gly551Asp III Yes 140 1 
  D  30   Yes 56 1 
  F  52   Moist cough 4 1 
  G  63   Moist cough 19 1 
77 3 B 2 14 Phe508del II Frequent cough & 
occassional sputum 
0 1 
  C  27   Yes 13  
  E  43      
36 8 C 2 31 Ile336SerfsX28 I Cough  1 
  D  43   Cough  1 
  E  55   No  0 
  F  66     1 
Transitioning       
89 4 A 2 19 Ser341SerfsX29 I No 31 0 
  D  54   Yes 0 0 
  E  66   No 0 0 
51 5 B 1 14 Phe508del II No  0 
  C  28   No  0 
  D  40   No  0 
  F  64      
  G  76   No  0 
40 6 B 2 17 Leu259LeufsX1 I No  1 
  D  41   No  0 
  E  53   Occasional moist cough 1 
  F  62   No   
  G  65      
  H  75   Cough due for admission 1 
  I  88      
5 7 B 2 12 Phe508del II   1 
  D  36      
76 12 B 2 13 c.2657+3insA No 0 1 
  C  20   No 0 1 
  D  37   No 2 1 
  E  49   Frequent cough 0 
  F  60   No  0 
  G  72   No  0 
10 14 D 2 35 Unknown     
  E  47      




  E  47      
41 16 C 1 33 Asp1152His IV Nonproductive mild cough 0 
  D  45   No  1 
  F  56   No  1 
  G  67   No  1 
BA- (>0.015µM)        
87 2 B 1 13        Phe508del II No  0 
  C  26   No  1 
  G  73   No  1 
16 9 D 1 35 Unknown  No  1 
  E  47   Slight moist cough  0 
  F  58    
14 10 B 2 12 Phe508del II No   
  C  24   No  1 
  D  38   No  1 
  E  51     0 
15 11 A 2 16 c.3367G?Cp.gly1
123?arg 
 No  0 
  C  30     
50 13 C 2 14 Lys447ArgfsX2 I No   
  E  39   No  1 
  F  51   No  0 
  G  62     0 
  H  74   No  1 
75 17 B 1 15 Arg117His IV No 0 0 
  C  25   No  0 
  D  37   No  1 
  E  49   Cough and runny 
nose 
1 1 
  F  65   Slight cough 1 
9 18 C 1 34 Phe508del II No  
  D  49     0 
70 19 D 2 51 Unknown  No  1 
  E  62   No  0 
  F  74   Cough for few days 1 1 
 
CS; Cross sectional, L; Longitudinal, # H – Hospital Days, ^ Aug – Augmentin ~ G – Gender (1 – 
Male, 2 – Female) 
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The ability of Pseudomonas aeruginosa to colonise and persist in the Cystic Fibrosis (CF) 
lung has hindered the successful clinical management of CF. Chronic colonisation by this 
nosocomial pathogen is a leading cause of morbidity and mortality in the CF population. 
Therefore, understanding the environmental and host factors which contribute to the 
pathogens ability to persist are of utmost importance. Gastro-oesophageal reflux (GOR) and 
subsequent pulmonary aspiration has emerged as a major comorbidity in CF and a range of 
other respiratory conditions. The finding that bile acids are present in the lungs of paediatric 
patients, a potential consequence of GOR derived aspiration, and can cause P. aeruginosa to 
adopt a chronic lifestyle, was intriguing. In order to uncover the molecular mechanism 
through which bile modulates the behaviour of this pathogen, a combination of global 
transcriptomic and phenotypic analyses was undertaken. Bile responsive pathways responsible 
for virulence, adaptive metabolism, and redox control were identified, with macrolide and 
polymyxin antibiotic resistance increased significantly in the presence of bile. P. aeruginosa 
could utilise bile as a sole carbon source, with metabolic rewiring of the cell thought to 
contribute to the pathogens response to bile. Bile acids, and chenodeoxycholic acid (CDCA) 
in particular, elicited chronic biofilm behaviour in P. aeruginosa. Together, these data suggest 
that the capacity of P. aeruginosa to respond to bile may underpin its emergence as a 








The opportunistic gram negative pathogen Pseudomonas aeruginosa is the leading cause of 
morbidity and mortality in the Cystic Fibrosis (CF) cohort, with the airways of up to 70% of 
adult CF patients being colonised by this organism (1). Recent evidence has implicated a role for 
bile and bile acids in the progression of CF associated lung disease with reports that bile can 
modulate the behaviour of P. aeruginosa and other clinical pathogens (2-7). Reen and colleagues 
conducted a panel of phenotypic assays in order to elucidate the impact of physiological 
concentrations of bile (ranging from 0.003% to 0.3% (w/v) complex bovine bile) in two of the 
most widely utilised model strains of P. aeruginosa; PA14 and PAO1. PAO1, initially isolated 
from a wound, is moderately virulent in contrast to the PA14 burn wound isolate (8-10). 
However, the response to bile was found to be conserved in both isolates (7). Reen and 
colleagues found that P. aeruginosa exhibits an increase in biofilm formation and type six 
secretion in the presence of bile, consistent with the pathogens switch to a chronic lifestyle. 
Conversely, the repression of acute virulence associated systems such as type three secretion and 
swarming motility was also observed (7). The ability of P. aeruginosa to transition towards this 
chronic lifestyle is associated with a reduction in the effectiveness of antimicrobial treatment 
plans. Furthermore, a reduction in the quality of life of affected patients due to progressive loss 
of lung function also occurs following chronic colonisation, a consequence of increased lung 
inflammation and lung damage (11, 12).  Therefore, the mechanistic understanding of how this 
key respiratory pathogen emerges as a dominant member of the lung microbial community and 
adopts a chronic mode of growth in the presence of bile is crucial in facilitating the design of 




Bile and bile salts have been shown to have antimicrobial properties through its impact on 
bacterial cell membranes, proteins, DNA integrity and through its iron and calcium chelation 
properties (13-19). The in vitro tolerance of micro-organisms to bile is routinely tested with 
animal derived bile. Porcine bile is reported to most closely resemble human bile with respect to 
the relative proportions of bile salts, phospholipids, cholesterol and the ratios of glycine to 
taurine bile salts. However, its relatively high toxicity has precluded it from being widely used 
experimentally. Therefore, bovine bile which is known to be less toxic than porcine bile is more 
routinely used (20-22).  
Whilst not much is known regarding the bile tolerance capabilities of respiratory tract organisms, 
there is a wealth of knowledge regarding the ability of gastrointestinal tract microbes to survive 
and persist in the presence of bile (Results Table 4).  The gram negative bacteria Salmonella 
enterica, Escherichia coli and Vibrio spp have been shown to display a higher intrinsic resistance 
to bile when compared to gram positive bacteria (23-26). The lipopolysaccharide (LPS) moiety 
located in the outer membrane has been shown to be important in this increased resistance to bile 
with the tolQRA operon proposed to aid in the maintenance of membrane integrity (15, 27-29). 
Multidrug efflux pumps such as the AcrAB (also known as CmeABC) and EmrAB (also known 
as VceAB) pumps also contribute to bile tolerance and are involved in the removal of bile that 
permeates the outer membrane (15, 24, 30-32).  In addition to the role of efflux pumps, porins 
present in the outer membrane of E. coli and Vibrio cholerae have been shown to play a 
determining role in bile tolerance, with modifications to porin structure influencing the ability of 
bile salts to penetrate the membrane (24, 33). Additionally, bile salt hydrolases required for the 
degradation of bile acids have been shown to play a vital role in the bile tolerance of Listeria, 




From a transcriptional perspective, bile acids have been demonstrated to induce both a 
generalised and oxidative stress response in a variety of organisms including E. coli and 
Enterococcus faecalis strains (41, 42).  
The mechanisms through which bacteria sense and respond to bile and/or bile acids in the 
environment is not fully understood. However, it has been proposed to involve classical signal 
transduction systems including two component systems such as PhoPQ (43) and transcriptional 
activators such as RpoS and SigB (44, 45). Though P. aeruginosa has been shown to contain the 
PhoPQ two component system, the structural differences present in the sensor kinase domain 
infer that it may not have the same function in bile signal transduction as in enteric organisms 
(46). Alternatively, bacterial cells may indirectly transduce the bile response through detection of 
alterations in the cell membrane. Bile and/or bile acids have been shown to induce a wide range 
of responses in target organisms. In Salmonella, bile and/or bile acids are utilised as an integral 
environmental signal resulting in the repression of motility, induction of biofilm formation and 
invasion in to epithelial cells until conditions become more favourable (47-49). Bile salts have 
also been shown to increase the invasiveness of Campylobacter jejuni through an activation of  
Cia protein activity (50). In Vibrio parahaemolyticus, bile acids have been shown to increase 
virulence factor production and adherence to epithelial cells. Modulation of intracellular calcium 
concentrations is thought to mediate this response (51, 52). In contrast, bile acids have been 
shown to decrease virulence factor production in V. cholerae whilst inducing biofilm formation, 
which has been shown to be linked to increased levels of intracellular cyclic-di-GMP (53-55).  
This chapter aimed at deciphering the molecular mechanisms controlling the response of P. 
aeruginosa to bile, ultimately resulting in the switch to chronicity. This involved conducting a 




cyclic di GMP levels and redox status in the cell. In order to gain an insight into the gene 
systems underpinning the phenotypic response to bile a combination of transcriptome profiling 
and transposon mutant library screening was conducted. This screening process was of particular 
importance in identifying genetic elements mediating the bile response with this crucial lifestyle 
switch known to involve the action of several inter-connected, signal-mediated, regulatory 
systems. Bile is a complex mixture therefore the organism’s response to bile may represent a 
combinatorial response to the individual components of bile with bile acids central to the 
induction of biofilm formation. It is hoped that these findings may translate into enhanced 















Materials and Methods 
Bacterial strains and plasmids 
Strains and plasmids used in this study are outlined in Table 1 with primers outlined in Table 2. 
All cultures of P. aeruginosa were routinely grown in Tryptic Soy Broth (TSB) media or Luria-
Bertani broth (LB) with shaking at 180 rpm at 37˚C. Strains were maintained on Tryptic Soy 
Agar (TSA) or Luria-Bertani agar (LBA). For the purpose of antibiotic resistance assays 
Mueller-Hinton (MH) agar or broth was used. The following antibiotics were added to the 
growth media where appropriate; 50 µg/mL tetracycline.  Bovine bile was selected due to its 
non-toxic nature with concentrations of 0.3% or 0.03% (w/v) added to media prior to autoclaving 
at 105˚C for 30 min.  Complex bile salts and individual bile salts were prepared in either water or 
methanol and were added to sterile media after filter sterilising with a 0.2 µ filter to a final 
concentration of 50 µM or 200 µM. 
Table 1; An outline of strains and plasmids utilised in this study. 
Strain/plasmid Description Reference/source  
PAO1 Wild type Holloway 
collection 
PA14 Wild type (56) 
PA14::siaD PA14 harboring mariner Tn7 transposon insertion in PA14_02110 
(siaD);GmR 
(56) 
PA14::mexA PA14 harboring mariner Tn7 transposon insertion in PA14_05530 
(mexA);GmR 
(56) 
PA14::mexB PA14 harboring mariner Tn7 transposon insertion in PA14_05540 
(mexB);GmR 
(56) 
PA14::68110 PA14 harboring mariner Tn7 transposon insertion in 
PA14_68110;GmR 
(56) 
PA14::68120 PA14 harboring mariner Tn7 transposon insertion in 
PA14_68120;GmR 
(56) 
PA14::68130 PA14 harboring mariner Tn7 transposon insertion in 
PA14_68130;GmR 
(56) 






PA14::21210 PA14 harboring mariner Tn7 transposon insertion in 
PA14_21210;GmR 
(56) 
PA14::dctB PA14 harboring mariner Tn7 transposon insertion in PA14_68230 
(dctB);GmR 
(56) 
PA14::dctD PA14 harboring mariner Tn7 transposon insertion in PA14_68250 
(dctD);GmR 
(56) 
PA14::dctA PA14 harboring mariner Tn7 transposon insertion in PA14_49130 
(dctA);GmR 
(56) 
PA14::dctP PA14 harboring mariner Tn7 transposon insertion in PA14_68260 
(dctP);GmR 
(56) 
PA14::dctQ PA14 harboring mariner Tn7 transposon insertion in PA14_68280 
(dctQ);GmR 
(56) 
PA14::dctM PA14 harboring mariner Tn7 transposon insertion in PA14_68290 
(dctM);GmR 
(56) 
PA14::30840 PA14 harboring mariner Tn7 transposon insertion in 
PA14_30840;GmR 
(56) 
PA14::gtrS PA14 harboring mariner Tn7 transposon insertion in PA14_22960 
(gtrS);GmR 
(56) 
PA14::gltR PA14 harboring mariner Tn7 transposon insertion in PA14_22940 
(gltR);GmR 
(56) 
PA14::glcB PA14 harboring mariner Tn7 transposon insertion in PA14_06290 
(glcB);GmR 
(56) 
PA14::aceA PA14 harboring mariner Tn7 transposon insertion in PA14_30050 
(aceA);GmR 
(56) 





PA14 WT containing the empty pbbr1MCS4 plasmid;CbR This study 
PA14::glcB 
pbbr1MCS4 
PA14::glcB containing the empty pbbr1MCS4 plasmid;CbR This study 
PA14::glcB 
complemented 
PA14::glcB containing the glcB-pbbr1MCS4 plasmid;CbR This study 
pbbr1MCS4 Empty cloning vector; ApR, CbR (58) 
pbbr1MCS4-
glcB 
Cloning vector ligated to the glcB gene; ApR, Cbr This study 
PA14 pMP220 PA14 WT containing the empty pMP220 plamid; TcR This study 
PA14 pMP220-
cdrA 
PA14 WT containing the pMP220-cdrA reporter fusion This study 
pMP220 Transcriptional reporter; TcR (59) 
pMP220-cdrA cdrA-lacZ fusion in pMP220; TcR This study 
pMP220-
mexAB 
MexAB-lacZ fusion in Pmp220;Tcr BRC 
prk2013 Helper plasmid; KmR BRC 
CH3-blue 
competent cells 






Table 2; Primers utilised in this study. 
Primer Name Sequence 5’-3’ Reference 
Kpn1-glcB F GGggtaccCCGTCCAGAGCTGGTCTAGAGC This study 
BamH1-glcB R CGggatccCGGCAGAACGGTTGGGACAGCA This study 
Kpn1-cdrA F CGGggtaccCCGGATCGGCGCCTTGTTGCTGA This study 
Xba1-cdrA R TGCtctagaGCATGGCTATCCGGACGGACCAT This study 
Taq-proC F CTTCGAAGCACTGGGTGGAG            This study 
Taq-proC R TTATTGGCCAAGCTGTTCG                                This study 
Taq-hmgA F CCAACATCGACTTCGTGATCT                  This study 
Taq-hmgA R GGACGGAAGGTGTTCTCG                  This study 
Taq-fahA F AACGTCGGCAAGCTGTTC                     This study 
Taq-fahA R GATGGGCACGTGCTTGTA                                     This study 
Taq-maiA F GACATCCACCCGTTGCAC                This study 
Taq-maiA R ACTGCCGGACCTGCTCTT                       This study 
Taq-psrA F CGTCTGATCACCAGCAAGG              This study 
Taq-psrA R CCTTCTTCGAACCGAAGTGA           This study 
Taq-lasI F CCGCACATCTGGGAACTC This study 
Taq-lasI R CCAGCGTACAGTCGGAAAAG This study 
Taq-pqsA F CCTCGATTGGAGTGCCTTC        This study 
Taq-pqsA R GAACCCGAGGTGTATTGCAG                    This study 
Taq-phzS F CTGGGCTGGTTCGACATC                   This study 
Taq-phzS R CGGGTACTGCAGGATCAACT           This study 
Taq-dctA F GTTCTTCTCCGTGCTCTTCG           This study 
Taq-dctA R AACTCGAACACCGGCTTG                   This study 
Taq-dnr F GGTGCGCTACCTGCTGAC               This study 
Taq-dnr R ATTTCCACCCGGCAGTTC                    This study 
Taq-pslB F TACTTCCGATGCGCTGCT             This study 
Taq-pslB R GTCCTTCAACCGCTGCAC           This study 
 
RNA isolation and transcriptional analysis 
Three independent replicates of P. aeruginosa strain PAO1 were cultured in TSB in the presence 
and absence of 0.3% (w/v) bovine bile. Samples were inoculated at an O.D.600 nm 0.025 with 
shaking at 180 rpm at 37˚C. Cells were harvested for RNA extraction at O.D. 0.8 at which point 
500 µL culture was treated with 1 mL of RNA protect Bacteria Reagent (QIAGEN). Total RNA 
was extracted according to manufacturer’s instructions of the RNAeasy kit (QIAGEN) and 




(Germany) for Affymetrix 3’ Expression service analysis. The quality and quantity of the RNA 
was measured by Nanodrop and Agilent Bioanalyser 2100. ATLAS Biolabs undertook biotin-
labelling of cRNA, hybridisation, washing and scanning of the Affymetrix GeneChip 
(Pseudomonas aeruginosa Genome Array). The software GeneSpring GX was used for raw data 
analysis in order to identify changes in gene expression in the presence of bile. A student’s 
paired ttest (p ≤0.05) on robust multiarray average normalised data from the GeneSpring 
software provided a list of altered gene expression >1.5.  
Validation of the microarray was conducted on cDNA derived from extracted RNA. A mix of 
AMV reverse transcriptase, RNasin (100 U/µL), random primers (0.5 µg/µL) and 10 mM dNTPs 
(all obtained from Promega) were used to generate cDNA. Real time primers to gene targets of 
interest were designed using the Universal Probe Library Assay Design Center (Roche). 
RealTime PCR was conducted on a Chromo4 Continuous Fluorescence Detector (MJ Research) 
using FastStart TaqMAN Probe Master and universal probes. The housekeeper gene proC was 
used in all instances for measurements of relative gene expression levels.  
In order to move from transcriptional changes resulting from secondary affects arising from long 
term cellular metabolism, RNA was extracted from cells grown to early log phase. Three 
independent replicates of P. aeruginosa strain PA14 were cultured in the presence and absence 
of 0.3% (w/v) bovine bile. Samples were inoculated at an O.D.600 nm 0.025 with shaking at 180 
rpm at 37˚C. Cells were harvested for RNA extraction at O.D. 0.3 with the protocol for RNA 






Bile transcriptome comparison analysis 
A database consisting of all available transcriptomes from P. aeruginosa comprising a total of 
250 datasets was available in BRC. XLSTAT software was used to generate a Pearson 
Correlation matrix. (www.xlstat.com). The pheatmap software package (R 3.21) was used to 
generate an association tree of the relationship of the bile transcriptome to the other 
transcriptomes in the database, based on the Pearson correlation matrix.   
Elastolysis assay 
A standard Elastin Congo Red (ECR) assay with modifications was used to measure elastolytic 
activity. Cells were harvested from mid-log phase PTSB (5% (w/v) peptone, 0.25% (w/v) TSB) 
cultures were washed and re-suspended in PTSB at an O.D.600nm 0.05 in the presence and absence 
of 0.3% (w/v) bile. Cultures were incubated for 21 h at 37˚C with shaking at which point the 
supernatant was filtered with a 0.45 µM filter. A 50 µL sample of the filtered supernatant was 
added to tubes containing 20 mg of ECR and 1 mL of (0.1M Tris [pH 7.2], 1Mm CaCl2] buffer. 
Tubes were incubated for a further 18 h at 37˚C with rotation and subsequently placed on ice 
after the addition of 100 µL of 0.12 M EDTA. Centrifugation at 13,000 rpm for 5 min removed 
insoluble ECR, with the supernatant collected and measurement of the O.D495nm conducted. 
Absorption due to P. aeruginosa pigment production was corrected for by subtracting the 
O.D.495nm of each sample incubated in the absence of ECR.  
Pyocyanin assay 
Overnight cultures of PA14 WT were adjusted to an OD600nm 0.05 in LB with and without 0.3% 
(w/v) bovine bile and incubated at 37˚C with shaking at 180 rpm. After 8 h and 16 h, to obtain a 




chloroform was added to the cell free supernatant, vortexed and centrifuged for 5 min at 5000 
rpm. The bottom blue phase was transferred to a tube containing 0.2 M hydrochloric acid, 
vortexed and centrifuged at 5000 rpm for 5 min. The absorbance of the top pink phase was read 
at an OD520nm.  
Congo red binding assay  
Polysaccharide production of P. aeruginosa was measured by culturing at an O.D. 600nm 0.05 in 2 
mL of PI medium (20 g peptone, 10 g K2SO4, 1.4 G MgCl2-6H2O, 25 mg triclosan, glycerol 20 
mL /L) in the presence and absence of 0.3% (w/v) bile for 48 h at 37˚C without shaking. 
Polysaccharides were collected by centrifugation and resuspended in 1 mL of 20 mg/mL Congo 
red suspended in PI media and. Tubes were incubated for 90 min with shaking. Polysaccharides 
and bound congo red were removed by centrifugation at 13,000 rpm for 5 min where the 
supernatant was collected and the O.D.490nm measured. The total congo red percentage left in the 
supernatant was measured relative to the un-inoculated media control.  
Promoter fusion construction 
The region of the PA14 gene cdrA beginning at -500 to +20 relative to the translational start site 
was amplified by PCR with the addition of KpnI and XbaI restriction sites. This gene of interest 
and pMP220 plasmid were double digested with restriction enzymes KpnI and XbaI, ligated 
together and transformed into CH3-blue chemically competent E. coli cells (BIOLINE). The 
successful promoter fusion was transformed into PA14 WT. 
Promoter fusion analysis 
P. aeruginosa cultures containing the mexAB-pMP220 promoter fusion plasmid were grown in 




the presence and absence of 0.3% and 0.03% (w/v) bile and incubated at 37˚C with shaking at 
150 rpm. A time course assay was conducted with sampling at the logarithmic and stationary 
phase of growth. At each sampling timepoint, a 1 mL aliquot was taken where the O.D.600nm was 
recorded and 80 µL of permeabilisation buffer was added to 20 µL of culture. A β-galactosidase 
assay from the lacZ promoter fusions was performed according to a modified protocol first 
described by Miller (Miller JH, 1972). Samples and substrate solution were incubated at 30˚C for 
30 min prior to commencement of the assay. 600 µL of substrate solution was added to the 
samples noting the time it takes for a yellow colour to develop at which point 700 µL of stop 
solution was added. After centrifugation for 13,000 rpm for 5 min, the O.D420nm is recorded. A 
cdrA-pMP220 promoter fusion was constructed to indirectly assay the levels of cyclic di-GMP in 
the cell. P. aeruginosa cultures containing the cdrA-pMP220 promoter fusion were grown either 
in TSB supplemented with tetracycline. Cells were adjusted to an O.D600nm 0.02 in the presence 
and absence of bile with a time course assay was conducted for the WT  
Miller units calculation: (O.D420nm X 1000)/(O.D600nm X 0.02 X Time) 
Permeabilisation buffer was made up using 100 mM dibasic sodium phosphate, 20 mM 
potassium chloride, 2 mM magnesium sulphate, 0.8 mg/mL CTAB, 0.4 mg/mL sodium 
deoxycholate and 5.4 μL/mL beta-mercaptoethanol. Substrate solution consists of 60 mM dibasic 
sodium phosphate, 40 mM monobasic sodium phosphate, 1 mg/mL ONPG and 2.7 μL/mL β-
mercaptoethanol. Stop solution is solution a 1M sodium carbonate. 
Biofilm assays 
Overnight cultures were adjusted to an O.D600nm 0.05 in LB/TSB in the presence and absence of 




plates respectively and incubated at 37˚C overnight. Biofilm formation was measured by 
removing culture by pipetting. Wells were washed with water by pipetting to remove any 
unattached biofilm. Attached biofilm was measured by staining for 30 min with 1 mL/ 200 µL of 
0.1 % (w/v) crystal violet. 100% (v/v) ethanol was used to solubilize the crystal violet followed 
by a measurement of the absorbance at a wavelength of 595nm.  
Antibiotic resistance assay 
Overnight cultures of P. aeruginosa were adjusted to 0.5 MacFarland units in MH broth. MH 
agar plates supplemented with or without 0.3% or 0.03% (w/v) bile were uniformly swabbed 
with culture. Antibiotic discs or E-strips (Thermo Scientific) were placed on to the surface of the 
agar manually or using a disc dispenser. Plates were left to incubate at 37 ˚C overnight after 
which the zone of inhibition was measured. The following antibiotics were tested by disc assay; 
amikacin, tetracycline, azithromycin, chloramphenicol, ciprofloxacin, erythromycin, piperacillin-
tazobactam and gentamicin with the following were tested by e-strip; polymyxin B, colistin and 
erythromycin. Time-course growth kinetic assays were performed on a BioScreenC plate reader 
at 37˚C. Overnight cultures of P. aeruginosa were adjusted to O.D.600nm 0.05 in MH 
supplemented with increasing concentrations of polymyxin B or erythromycin in the presence 
and absence of bile.  
Bioinformatic analysis 
The KEGG (Kyoto Encyclopaedia of Genes and Genomes) pathway database was used for 
further analysis of the bile transcriptome. The KEGG database (freely available from 
http://www.genome.ad.jp/kegg/) is a repository of annotated genomic information used for the 




representations of key cellular processes including central metabolism and signal transduction.  
Genes altered in the presence of bile were mapped using the KEGG pathway database to identify 
global changes and pathways of interest. 
Redox and cellular respiration analysis 
Overnight cultures of P. aeruginosa were adjusted to O.D600nm 2.0 with 200 µL of adjusted 
cultured added to 25 mL of TSB supplemented with 0.01 mg/mL of tetrazolium violet (Sigma 
Aldrich). Cultures were incubated at 37˚C shaking at 180 rpm for 24 h. Formazan production 
was measured by centrifuging 5 mL of culture at 5,000 g for 5 min. The supernatant was 
discarded with the pelleted cells re-suspended in 1.2 mL of dimethyl sulfoxide and centrifuging 
again at 5,000 g for 5 min. The O.D510nm was recorded of the cell free supernatant. 
Growth screen of the PA14 NR transposon mutant library on complex 
The complete PA14 non redundant transposon mutant library was screened for the ability to grow 
on 1X M9 minimal media (10X M9 minimal media; 1L H2O, 72g Na2HPO4, 30g KH2PO4, 5g NaCl 
and 10g NH4Cl) supplemented with 1.5% (w/v) bile as a sole carbon source with MgSO4 and FeCl 
provided as cofactors. The QPix2-XT colony picker was used to transfer the library for the growth 
screen into 96 well plates with plates left to incubate overnight at 37˚C. Following incubation, the 
O.D600nm of the 96 well plates was recorded. Candidates from the global screen were selected by 
reading the O.D600nm where anything less than 0.2 was considered to have abolished or a reduction 
in growth on bile when compared to the WT which reached O.D600nm 0.5. The global screen yielded 
638 candidates which were subsequently further tested where a reading less than 0.1 was selected 
as a candidate. This yielded 390 candidates which were included in one final round of screening 




Complementation of mutants  
Transposon mutants from the Harvard collection were complemented in trans by cloning of the 
coding sequence of the respective genes into the pBBR1MCS-4 plasmid system. Primers used for 
amplification of each loci are described in Table 2. Following amplification by PCR, samples were 
loaded on an agarose gel and the appropriate fragment was excised and purified using the QIAGEN 
Gel Extraction kit (QIAGEN). Restriction sites engineered into the primers facilitated direct 
cloning in to similarly digested pBBR1MCS-4 plasmid. Ligations were performed overnight and 
transformation into E. coli was subsequently achieved using chemically competent CH3 Blue cells 
(Bioline). Conjugation into the mutant strains was performed by tri-parental mating using the 
pRK2013 helper plasmid with selection on M9 media supplemented with citrate for exclusion of 
donor E. coli. As controls, plasmid alone was also transformed into each strain. 
Motility assays 
Swarming motility was measured on 0.6% (w/v) Eiken agar in the presence and absence of 
bile/bile salts. Sterile toothpicks were used to inoculate to gently inoculate a single colony onto 
the surface of the Eiken agar with minimal pressure. Plates were incubated overnight for 1-2 
days with degree of motility visualized and recorded. 
Alkyl-quinolone extraction 
Overnight cultures of P. aeruginosa were adjusted to an OD600nm 0.02 in 20 mL TSB with or 
without 0.3% (w/v) bovine bile and incubated at 37˚C with shaking at 180 rpm for 8 h. Culture 
was centrifuged at 5000 rpm for 15 min to obtain a cell free supernatant. Alkyl quinolones were 
extracted by addition of 10 mL of acidified ethyl acetate followed by vortexing and 




stored at -20˚C overnight. Rotary evaporation was completed to remove the solvent with extracts 
re-suspended in 1 mL of methanol for analysis by thin layer chromatography. 
Biofilm screen of the PA14 NR transposon mutant library 
The complete PA14 non redundant transposon mutant library encompassing 6000 mutants was 
screened for biofilm formation in LB supplemented with 0.3% (w/v) bile. The original library 
consisted of 5800 mutants representing mutations in 4600 genes. During replication of the library 
empty wells were included as controls to monitor library contamination and a selection of 
mutants were re-picked due to poor growth. The PA14 non redundant library was created using 
the Mar2XT7 transposon with a subset of mutants created using the Tn5 based transposon. The 
QPix2-XT colony picker was used to transfer the library for the biofilm screen.  The biofilm 
assay was processed as described above. Candidates were selected from the initial screen based 
on an O.D595nm readout of the neat plate between 1 and 2.5 yielding 508 candidates of interest. 
These 508 candidates underwent three further independent rounds of testing in LB supplemented 
with 0.3% (w/v) bile where 246 isolates were selected for a final round of screening if the 
O.D595nm value was between 1 and 2.5 on the neat plate or between 0.2-0.8 in a 1 in 10 dilution. 
These 246 genes of interest were tested for biofilm formation in both the presence and absence of 
bile with the final list of targets consisting of strains that exhibited less than a 1.5-fold increase in 
biofilm formation in the presence of bile. A separate biofilm screen of the PA14 NR library of a 
subset of 150 sensory and response regulator mutants was conducted to identify potential signal 






Growth on bile salts 
Growth of P. aeruginosa PA14 WT on 1X M9 minimal media (10X M9 minimal media; 1L H2O, 
72g Na2HPO4, 30g KH2PO4, 5g NaCl and 10g NH4Cl) supplemented with a range of complex bile 
salts concentrations (ranging from 1 µM-5 mM) as a sole carbon source with MgSO4 and FeCl 
provided as cofactors was tested as follows. An overnight culture was centrifuged at 3000 rpm for 
10 min, the supernatant was removed, and cells were re-suspended in 1 mL of PBS. To ensure all 
spent media was removed, cells were re-centrifuged at 3000 rpm for 10 min with the supernatant 
removed and cells re-suspended in 1 mL of PBS. A starting O.D. of 0.025 was added to 20 mL of 
M9 minimal media with a range of bile salt concentrations added. A visual inspection of conical 
flasks was carried out after 24 h of growth. 
Statistical Analysis 
Data presented is the average of at least three independent biological replicates. Statistical analysis 













Transcriptional and phenotypic analysis of P. aeruginosa response to bile 
Determining the global transcriptional response of Pseudomonas aeruginosa to physiological 
concentrations of bile 
 
In order to elucidate the molecular mechanism underpinning the phenotypic response of P. 
aeruginosa to bile, transcriptome profiling was conducted in the presence and absence of 0.3% 
(w/v) bile. This revealed a bile responsive gene expression signature in which 367 genes were 
altered, 120 of which exhibited increased gene expression and 247 of which displayed decreased 
gene expression when compared to the untreated control (fold changes ranged from 41.0 to -
59.4-fold). Genes which were greater than 5-fold up/down regulated are outlined in Table 4 with 
the complete list of altered gene expression outlined in Appendix Table 1.  
Table 3; Most highly expressed and repressed genes in the presence of bile categorised by gene 
function according to COG analysis. 
Upregulated genes in the presence of bile 
Gene Name Fold Change Gene Description 
Energy production and conversion 
PA0195 pntA 5.698029 putative NAD(P) transhydrogenase, subunit alpha part 1 
PA0196 pntB 6.072907 pyridine nucleotide transhydrogenase, beta subunit 
PA0521  5.02969 probable cytochrome c oxidase subunit 
PA1183 dctA 5.316506 C4-dicarboxylate transport protein 
PA2634 aceA 8.60934 isocitrate lyase  
PA2953  5.112918 electron transport flavoprotein-ubiquinone oxidoreductase 
PA3092 fadH1 10.94138 2,4-dienoyl-coA reductase  
PA4770 lldP 6.846915 L-lactate permease 
PA4771 lldD 6.366787 L-lactate dehydrogenase 
Lipid transport and metabolism 
PA0506  12.92649 probable acyl-CoA dehydrogenase 
PA0508  41.03524 probable acyl-CoA dehydrogenase 
PA1748  5.433264 probable enoyl-CoA hydratase/isomerase  




PA3014 faoA 8.045702 fatty-acid oxidation complex alpha subunit 
PA3925  6.362694 probable acyl-coA thiolase 
Inorganic ion transport and metabolism 
PA0524 norB 11.78624 nitric-oxide reductase subunit B 
PA1051  6.853995 probable transporter 
PA2662  6.388695 conserved hypothetical protein 
Post translational modification, protein turnover and chaperones 
PA1596 htpG 5.018658 heat shock protein 
Unknown   
PA2663 ppyR 8.42526 psl and pyoverdine operon regulator 
 
Downregulated genes in the presence of bile 
Gene Name Fold Change Gene Description 
Energy production and conversion 
PA1984 exaC 59.43127 NAD+ dependent aldehyde dehydrogenase  
PA2247 bkdA1 11.76501 2-oxoisovalerate dehydrogenase alpha subunit 
PA2248 bkdA2 8.665485 2-oxoisovalerate dehydrogenase beta subunit 
PA2249 bkdB 8.010507 branched chain alpha keto acid dehydrogenase lipoamide 
PA2250 lpdV 10.54123 lipoamide dehydrogenase-Val 
Lipid transport and metabolism 
PA0493  12.16488 probable biotin-requiring enzyme 
PA0494  12.53772 probable acyl-CoA carboxylase subunit 
PA0887 acsA 8.322072 acteyl-coenzyme A synthetase  
PA1999 dhcA 31.30977 dehydrocarnitine coA transferase subunit A 
PA2013 liuC 12.64843 putative 3-methylglutaconyl-CoA hydratase  
PA2014 liuB 14.03458 methylcrotonyl-CoA carboxylase, beta subunit 
PA2015 liuA 10.92419 putative isovaleryl-CoAdehydrogenase  
PA2552  10.12445 probable acyl-CoA dehydrogenase  
PA2553  17.72097 probable acyl-CoA thiolase  
PA2555  14.54166 probable AMP-binding enzyme 
PA5174  10.50413 probable beta-ketoacyl synthase  
Carbohydrate transport and metabolism 
PA2114  12.58743 probable major facilitator superfamily transporter 
PA3187  37.64074 probable ATP binding component of ABC transporter  
PA3190  37.49556 probable binding protein component of ABC transporter  
PA3195 gapA 11.15306 glyceraldehyde 3-phosphate dehydrogenase  
Amino acid transport and metabolism 
PA0129 bauD 7.690926 amino acid permease 
PA0495  14.14879 hypothetical protein 
PA0865 hpd 9.271919 4-hydroxyphenylpyruvate dioxygenase  




PA2110  9.982603 hypothetical protein 
PA2111  11.69932 hypothetical protein 
PA4024 eutB 9.765597 ethanolamine ammonia-lyase large subunit 
PA4502  5.121125 probable binding protein component of ABC transporter  
Secondary metabolites biosynthesis, transport and catabolism 
PA2008 fahA 34.14261 fumarylacetoacetase 
PA2009 hmgA 54.90419 homogentisate 1,2-dioxygenase  
Cell wall/membrane/envelope biogenesis 
PA2113 opdO 15.40829 pyroglutamate porin 
PA3186 oprB 5.547807 glucose/carbohydrate outer membrane protein precursor 
Coenzyme transport and metabolism 
PA1905 phzG2 5.702814 probable pyridoxamine 5'-phosphate oxidase  
PA2112  10.56511 conserved hypothetical protein 
PA4217 phzS 5.672542 flavin-containing monooxygenase  
Transcription   
PA2016 liuR 7.376461 regulator of liu genes 
PA5380 gbdR 9.957009 putative amidotransferase 
Nucleotide transport and metabolism 
PA3516  8.26889 probable lyase  
Post translational modification, protein turnover and chaperones 
PA2069  5.337103 probable carbamoyl transferase 
Unknown   
PA0099  5.363333 hypothetical protein 
PA0131 bauB 5.099461 beta-alanine biosynthetic protein 
PA0132 bauA 9.548833 beta-alanine:pyruvate transaminase  
PA0492  9.769155 conserved hypothetical protein 
PA0730  20.26402 probable transferase 
PA0852 cbpD 5.277362 chitin-binding protein  
PA2109  13.239 hypothetical protein 
PA2358  7.733476 hypothetical protein 
PA2554  7.59388 probable short chain dehydrogenase  
PA3234  5.911297 probable sodium:solute symporter 
PA4211 phzB1 8.585621 probable phenazine biosynthesis protein 
 
In order to further investigate the significance of this bile gene expression profile, genes were 
characterized based on functionality according to gene ontology and KEGG pathway analysis (Fig. 
1). This highlighted an induction of genes involved in energy production and conversion (PA0195, 




trafficking and secretion associated genes were repressed in the presence of bile (PA0078-
PA0096). Consistent with a switch towards a chronic lifestyle transcriptional changes were evident 
in genes associated with virulence traits, biofilm production and antibiotic resistance. 
 
Figure 1. Categorization of the bile transcriptome according to the functionality of genes with altered expression in 
the presence of bile according to gene ontology. Genes associated with energy production and conversion are induced 







A unique bile specific transcriptional signature exists 
In order to assess whether the bile transcriptome displays a unique gene expression response and 
to more comprehensively elucidate the transcriptional mechanism through which bile elicits its 
response, the bile transcriptome was compared to a database consisting of 250 publicly available 
P. aeruginosa transcriptomes available in the BIOMERIT Research Centre. Analysis of the 
database using a Pearson correlation matrix heatmap facilitated the measurement of relatedness 
of the bile transcriptome to these other transcriptomes (Fig. 2A). The bile transcriptome was 
found to be most similar to a PA14 vs phhR mutant (Pearson score; 0.282). The phenylalanine 
(PhhR) catabolic regulon including phhC, hpd, hmgA, maiA and fahA were found to be repressed 
in the presence of bile and validated by RT-PCR (Fig. 2B). The bile transcriptome was also 
found to be similar a gtrS mutant vs PAO1 (0.143). The GtrS-GltR two component system is 
involved in the regulation of glucose metabolism and the type three secretion system, both of 
which are altered in the bile transcriptome. The bile transcriptome was inversely related to 
aromatic amino acids vs serine in synthetic CF sputum media (-0.203) and the pycR mutant vs 
PAO1 (-0.135). PycR is a LysR transcriptional regulator which has been demonstrated to be 





Figure 2. (A) Pearson correlation heatmap matrix demonstrating a unique bile specific response distinct to that of the 
most closely clustered transcriptomes. (B) RT-PCR validation of selected genes from the PhhR catabolic regulon; 
hmgA, fahA, maiA confirm the findings of the global bile transcriptome.  
 
Importantly, comparison of the bile transcriptome to the transcriptomes it clustered closely with 
revealed that the gene expression profile displayed in the presence of bile was distinct to that of 
similar transcriptomes, confirming that the response to bile is not simply due to a generalized 
stress response. Though there is crossover in the global gene expression profiles of these 
transcriptomes, the bile specific signature encompasses changes in quorum sensing, secretion 
systems, biofilm formation, antibiotic resistance, and redox control. Within the transcriptomes 




(T3SS, hcn, phz) and the chronic lifestyle (psl, mexAB-oprM and siaA-D) which were altered in 
the bile transcriptome were not affected in the same manner in any of the clustered 
transcriptome. The global gene expression profile elicited by exposure to bile is consistent with 
the phenotypic switch to a chronic lifestyle previously reported (7).  
Quorum Sensing 
Quorum sensing is a complex, hierarchical, cell density regulated cell-cell signalling network 
controlling virulence and biofilm formation in P. aeruginosa. In addition to the classical 
regulation of QS by increased population cell density, recent evidence has shown environmental 
signals contribute to QS control. Upon reaching a threshold cell density there is a release of 
chemical signals resulting in the induction of an array of genes. Three QS systems are well 
described in P. aeruginosa; the AHL based systems Las and Rhl and the P. aeruginosa AQ 
system PQS, whilst an emerging role for IQS has been described. It has been demonstrated by 
promoter fusion (lasR, rhlR and pqsA) that bile increases the expression of these three QS 
systems. The transcriptional changes observed in the presence of bile are consistent with these 
findings indicating an earlier activation of QS with a 1.82 fold induction of lasI and a 1.61 fold 
induction of pqsA (Fig. 3A). LasI and PqsA are involved in synthesis of the autoinducer proteins 
required for activation of their respective QS systems with the latter being the first gene of a five 
gene alkylquinolone biosynthetic operon pqsA-E. Interestingly, elevated levels of the LasI signal 





Figure 3. (A) Impact of bile on the QS circuitry in P. aeruginosa in the presence of bile. Upregulated genes are 
highlighted in green, downregulated genes are highlighted in red and unaltered genes are highlighted in black. (B) 
Increased elastolytic activity in bile treated samples as evidenced by increased levels of Congo red present in bile 
treated culture supernatant (C) Downregulation of pyocyanin production in LB supplemented with bile in early 
stationary phase with no significant difference in late stationary phase.  
However, in silico transcriptome analysis of downstream QS target genes revealed that in some 
cases rather than the classical activation of genes, expression was unaltered or repressed. This 
could be explained by the involvement of genes in multiple pathways which are often under the 
control of multiple regulatory networks. The impact of bile on the expression of these QS systems 
and downstream effectors may be more pronounced in later stationary phase. An elastolysis assay 
was conducted and revealed a significant increase in elastase activity in the presence of bile (Fig. 




supports the hypothesis of induction of downstream effectors as the cell enters stationary phase. 
Pyocyanin production was reduced in early stationary phase with no significant difference in late 
stationary phase in the presence of bile which is consistent with the repression in expression of the 
phzS gene, the final enzyme of the pyocyanin biosynthetic pathway (Fig. 3C). 
Type Three and Type Six Secretion Systems 
The Type three secretion system (TS33) and the type six secretion system (T6SS) are a complex, 
highly regulated apparatus utilized by P. aeruginosa to inject effector proteins into both host 
cells and neighbouring bacteria. Using a needle-like machinery similar to bacteriophage 
Pseudomonas can manipulate cells with which it interacts with. The T3SS is encoded by 36 
genes located on 5 operons with at least 6 additional genes encoding effectors and chaperone 
proteins (61). There is transcriptional repression of both the translocation apparatus, effectors 
and regulatory proteins in the presence of bile (Fig. 4). This is in line with chronic isolates of P. 
aeruginosa from CF patients who gradually lose the ability to secrete type three effector 
proteins. Hence whilst this system is important for acute infection, it is less so in the persistence 
of P. aeruginosa throughout infection. However, there has been a growing appreciation for the 
role that T3SS may play in infection as it has been reported that T3SS is induced under 
microaerobic conditions. These conditions would be more reflective of the CF lung environment. 
In contrast, the T6SS which is responsible for the delivery of toxins to other competing 
organisms is found to remain functional in chronic isolates. T6SS are encoded by three distinct 
gene clusters; Hcp1 secretion island (HSI)-I, HSI-II and HSI-III. Whilst transcript levels of HSI-I 
and HSI-II were found to be down regulated in the presence of bile, a previous study reported 
up-regulation of the tssA1 promoter (HSI-I system) (Fig. 4). The difference between these 




the promoter fusion assay was conducted using stationary phase cells which are potentially more 
reflective of P. aeruginosa chronic infection.  
Figure 4. Transcriptome analysis of T3SS highlighting a significant transcriptional down-regulation of genes within 
the operon. Transcriptional analysis of the T6SS operons shows bile causes a significant transcriptional down-
regulation of the HSI-I and HSI-II operons with no impact observed on the HIS-III operon. 
 
Biofilm Formation 
P. aeruginosa is known to exist in a biofilm; a multicellular community protected by a matrix of 
extracellular polymeric substances, in the lungs of CF patients. In P. aeruginosa there are three 
primary polysaccharides contributing to the formation of a biofilm; alginate, Pel and Psl. In 
addition to these polysaccharides, extracellular DNA, flagella, type IV pili and fimbriae have also 
been shown to be important components of the biofilm matrix. The primary polysaccharide utilized 
by PAO1 is Psl. However, PA14 has been shown to lack a complete psl locus and hence primarily 
utilizes Pel (62). The induction of biofilm formation in P. aeruginosa in the presence of bile was 




pel and alginate genes were unaltered, the psl operon (A,B,E,G) was upregulated. Psl has been 
shown to be a major contributor to biofilm formation with a crucial role in the initiation of biofilm 
development and the maturation into a mature biofilm. Hence, the up-regulation of this system in 
PAO1 in the presence of bile is significant. The increased expression of Psl was supported by an 
increase in polysaccharide production in the presence of bile as measured by a Congo red binding 
assay. The Congo red binding assay is an inverse assay hence the lower the Congo red 
measurement indicates increased polysaccharide production (Fig. 5A). Furthermore, the 
transcriptional regulator PsrA which is linked to the positive regulation of expression of the psl 
operon and repression of T3SS was also found to be upregulated. This was confirmed by RT-PCR 
analysis (Fig. 5B).  
Figure 5. (A) Increased polysaccharide production in the presence of bile as measured by the inverse Congo red 
binding assay hence polysaccharide production is increased in the presence of bile. (B) Confirmation of induction of 
the psrA gene by RT-PCR analysis. 
The intracellular accumulation of the second messenger c-di-GMP has been associated with the 
switch towards a biofilm lifestyle. The levels of c-di-GMP in the cell is determined by the activity 




molecule. In P. aeruginosa 41 proteins involved in c-di-GMP synthesis/degradation have been 
identified, with the GGDEF domain containing diguanylate cyclase siaD (PA0169) found to be 
upregulated in the presence of bile. The localised pools of c-di-GMP in the cell control the 
reciprocal regulation of bacterial motility and biofilm formation (63). This led to investigations of 
the impact of bile on c-di-GMP levels in the cell. A cdrA-pMP220 promoter fusion was constructed 
and conjugated into PA14 WT allowing for the indirect measurement of cyclic di-GMP levels in 
the cell. This revealed increased levels of cyclic di GMP in the presence of bile at all time-points 
tested (Fig. 6A). This increase is consistent with the findings that bile induces biofilm production. 
Furthermore, this increase in biofilm formation is abolished in the transposon mutant diguanlyate 
cyclase siaD indicating the importance of cyclic di-GMP in the biofilm response to bile (Fig. 6B) 
Figure 6. (A) Increased cyclic di GMP levels in the presence of bile as measured by cdrA-pMP220 promoter fusion 
at three timepoints; log, early stationary and late stationary (B) Crystal violet attachment assay showing loss of the 








The ability of organisms to produce a biofilm is associated with an increase in both tolerance and 
resistance to antibiotics further impeding the clinical management of bacterial infections. In 
addition to bile induced biofilm formation, there was a transcriptional induction of several multi-
drug resistance systems in the presence of bile. This included increased expression of the 
mexAB-oprM system as well as mexR the transcriptional repressor of this system. However, 
repression by mexR may be overcome through oxidation. MexAB-oprM has been shown to 
confer resistance to a range of antibiotics including quinolones, macrolides, tetracycline, 
chloramphenicol, novobiocin and the majority of β-lactams. Increased expression of PA3310, a 
gene recently proposed to play a role in polymyxin resistance and PA5157-5159 encoding 
components homologous to the EmrAB efflux system in E. coli were also observed with the 
latter shown to confer resistance to nalidixic acid. Therefore, the impact of bile on antibiotic 
resistance of P. aeruginosa to a panel of clinically relevant antibiotics was investigated. 
Antibiotic susceptibility was measured using a combination of antibiotic discs and E-strips. Disc 
assay analysis revealed increased resistance to chloramphenicol and the macrolides azithromycin 
and erythromycin in the presence of bile (Fig. 7). Erythromycin and azithromycin are members 
of the macrolide class of antibiotics which target bacterial translation. Azithromycin in particular 
is routinely used in the treatment of CF as in addition to its antimicrobial properties, it has also 
been found to exhibit anti-inflammatory properties. The increased resistance observed was found 
to be independent of the PA5157-5160 systems (Fig. 7). However, in the clinical isolate TY5021 
overexpressing the MexAB pump, no further increase in macrolide resistance (azithromycin and 
erythromycin) was observed in the presence of bile. The TY5021 strain was resistance to the 




erythromycin. This suggests that activation of MexAB may potentially contribute to bile induced 
macrolide resistance. Upon testing chloramphenicol the mutants derived from the PA14 NR 
library were found to be completely resistant irrespective of bile treatment and so this antibiotic 
was not investigated any further.  
 
Figure 7. Antibiotic susceptibility disc assay in (A) PA14 WT and (B) PA01 WT for the following antibiotics 
amikacin 30 (AK), tetracycline 30 (TE), azithromycin 15 (AZM), chloramphenicol 30 (C), ciprofloxacin 5 (CIP), 
erythromycin 15 (E), piperacillin/tazobactam 110 (TZP) and gentamicin 10 (CN). Increased azithromycin resistance 
(C) and erythromycin resistance (D) occur independently of the MexAB and PA5157-5160 efflux pumps. 
E-strip analysis confirmed increased resistance to erythromycin, as well as an increase in resistance 
to the polymyxin antibiotics colistin (also known as polymyxin E) and polymyxin B (Fig. 8). The 
antibiotics vancomycin and oxacillin were also tested but PA14 was found to be completely 




The polymyxin class of antibiotics target the permeability of cell membranes and are considered a 
last resort antibiotic for the therapeutic control of P. aeruginosa due to the high level of toxicity. 
Resistance to polymyxins has been shown to derive from modification of the lipid A group of LPS 
with a potential role for PA3310 (PA14_21210) in this process. Bile induced resistance, however, 
was shown to be independent of this gene (Fig. 8C).  
Figure 8. (A) E-strip antibiotic resistance assay highlighting increased resistance to polymyxin B, colistin and 
erythromycin in the presence of bile. P. aeruginosa was completely resistant to the antibiotics vancomycin and 
oxacillin in both the presence and absence of bile. (B) Representative plates of the polymyxin B e-strip assay (i) 
untreated and (ii) bile treated. (C) Growth kinetic assays in (i) PA14 WT in MH broth (ii) PA14 WT in MH broth 
supplemented with 0.3% (w/v) bile and (iii) A PA14 Tm 3310 all in concentrations of polymyxin ranging from 0.3 







There is an ever-growing appreciation of the link between central metabolism to virulence in 
pathogens (64). With this in mind and to gain a further understanding of the molecular mechanism 
potentially underpinning the phenotypic response to bile, detailed KEGG pathway analysis of 
central metabolism and pathways feeding into central metabolism was undertaken (Fig. 9). This 
highlighted a transcriptional induction of the early stages of the citric acid cycle also known as the 
tricarboxylic acid cycle (TCA) and a branch point within the TCA known as the glyoxylate shunt 
(acnB, aceA and glcB) which is known to facilitate utilization of fatty acids and acetate. Further 
supporting a role for the glyoxylate shunt in the bile response was the repression of genes in the 
later stage of the TCA cycle (idh) and though fumC2 expression was not altered the subsequent 
gene in the operon was down regulated.  Additional repression at the C4-dicarboxylate branch 
points of the TCA cycle including succinate, fumarate and malate were also observed. This finding 
is consistent with recent reports from in situ transcriptomics and metabolic flux analysis of P. 





Figure 9. KEGG pathway analysis of the TCA cycle with genes found to be upregulated in bile denoted in green and 
genes found to be downregulated in bile denoted in red. Mapping identified a transcriptional upregulation of the 
glyoxylate pathway with a transcriptional repression of the later stages of the TCA responsible for the generation of 
the electron carrier NADH.  
Upon establishing the role of the TCA cycle, the role of three other central carbon pathways (the 
Emden-Meyerhof pathway also known as glycolysis, the pentose phosphate pathway and the 
Entner-Doudoroff pathway) were investigated by mapping to KEGG (Fig. 10). This analysis 
showed repression of genes involved in glucose metabolism of the Entner-doudoroff pathway (glk, 
zwf, pgl, edd) and an upregulation of genes involved in the pentose phosphate pathway (rpe, tktA). 
An integrated, global figure of the impact of bile on all the pathways relating to central carbon 




Figure 10. KEGG pathway analysis of the central carbon pathways; Embden-meyerhof/glycolysis pathway, pentose 
phosphate pathway and the Entner-Doudoroff pathway reveals altered carbon flux away from the Entner-Doudoroff 
pathway and through the pentose phosphate pathway.  
The observed transcriptional changes indicating a rewiring/reorganisation of central metabolism 
could be expected to manifest and have consequences on the redox potential within the cell. In 
order to test this hypothesis a tetrazolium violet reduction assay was conducted. This assay 
measures the reduction of tetrazolium violet to a colored formazan and hence is an indirect 
measurement of the NAD+/NADH redox modulating couple in the cell. Redox carriers including 
NAD+/NADH form the basis of cellular metabolism with redox homeostasis essential to the 
survival of the cell. A significant suppression of cellular respiration was observed in the presence 
of both 0.3% and 0.03% (w/v) bile suggesting an increased amount of NAD+ in the cell in the 
presence of bile (Fig. 11A). These redox changes were further supported by the morphological 
changes observed in P. aeruginosa colonies grown on TSA supplemented with bile (Fig. 11B). 




not evident on untreated plates highlighting that bile may elicit its effect on P. aeruginosa through 
redox. The alteration of numerous systems relating to cellular metabolism, as well as changes in 
redox potential in the cell suggests that the response of P. aeruginosa to bile may potentially 
involve a form of adaptive metabolism. 
      
Figure 11. (A) Redox suppression in the presence of bile as shown by tetrazolium violet reduction assay. (B) Colony 
morphology assay on TSA with wrinkling phenotype in the presence of bile indicating redox changes within the cell 
in the presence of bile. 
 
Investigating the direct response of P. aeruginosa to bile  
The transcriptome implicated a metabolic signature potentially mediating the response to bile. In 
order to determine the immediate transcriptional response to bile and decipher direct responses 
from possible secondary effects, an earlier transcriptional profile conducted at an O.D.600nm 0.3 
was conducted. The following down-regulated genes were selected for analysis; hmgA, dnr and 




12). The significant transcriptional changes observed in the transcriptome and validated by RT-
PCR were not evident at this early log timepoint. The only gene significantly altered at this 
earlier timepoint was psrA, a transcriptional regulator known to respond to long chain fatty acid 
signals. Therefore, the up-regulation of this gene could be in response to the presence of fatty 
acids in complex bile.  Though pqsA was also upregulated in the presence of bile, this was not 
statistically significant (p=0.055). Though this trend towards increased expression indicates that 
quorum sensing may play a fundamental role in the direct response to bile as a signal.  
 
Figure 12. RT-PCR analysis of RNA extracted from P. aeruginosa cells grown to early log phase (O.D 0.3). A 
selection of genes found to be altered in the presence of bile at O.D. 0.8 were selected for analysis. However, the only 
gene from the panel of genes that was tested found to be significantly altered was the transcriptional regulator psrA, 
which is known to respond to fatty acids present in complex bile. Therefore, there does not appear to be a direct 
transcriptional response to bile. Data presented is the mean of three independent biological replicates. Statistical 




Global screen of the PA14 NR library for loci involved in the growth on bile 
As mentioned previously, the signal transduction system(s) mediating the response of P. 
aeruginosa and other respiratory tract organisms to bile had not yet been identified. However, 
the bile tolerance capabilities of enteric organisms has been well characterised in recent years, 
perhaps a reflection of its importance in the carriage of these organisms in the gastrointestinal 
tract (Table 4).  The bile tolerance responsiveness of these enteric organisms involves a 
combination of efflux pumps, porins, outer membrane modifications, bile salt hydrolases and 
















Table 4; Mechanisms of bile and bile acids tolerance strategies in a range of enteric bacteria. 






Signal transduction/Two component system 
Efflux pump 
Transcritpional regulator/DNA binding protein 
Enterobactrial common antigen biosynthesis 


























Signal transduction/Two component system 
Porin 


































Campylobater jejuni Efflux cmeABC (32, 78) 
Enterococcus 
faecalis 





General stress response 
Bile salt hydrolases 
Transcritpional regulator 
Transport protein 
DNA repair protein 
groESL 
bsh, pva, btlB 
sigB 










Bile salt hydrolases 
























Heat shock protein 
Metabolic changes 
Energy production 






























The distribution of some of these key bile tolerance systems present in a selection of 
gastrointestinal tract organisms and P. aeruginosa are outlined below. The presence of these 
systems in respiratory tract organisms may point to a unified response to bile. However, these 
systems may display structural and hence functional differences. 
 
Figure 13. Distribution of bile tolerance systems, the efflux pumps AcrAB and EmrAB, membrane associated systems 
TolQRAB and GalUE and the two component system PhoPQ in a range of Proteobacterial organisms based on 
sequence homology.  
In order to investigate the systems underpinning the response of P. aeruginosa to bile, screening 
of the PA14 NR transposon mutant library was undertaken.  Two screens of the PA14 mutant 
library were conducted; one screening for the inability to grow on minimal media with bile as a 
sole carbon source and the second for mutants that no longer displayed enhanced biofilm in the 
presence of bile (Fig. 14). The transcriptomic analysis revealed a programmed metabolic shift in 
the presence of bile. P. aeruginosa was found to be able to utilise bile as a sole carbon source when 
supplemented into M9 minimal media, however it was unable to grow on bile acids as a sole carbon 




utilisation of bile as a carbon source may be connected to the signal transduction pathways 
mediating the response to bile with a growing body of research implicating adaptive metabolism 
to virulence control in a range of species.  We therefore first wanted to identify the genetic elements 
underpinning the growth of P. aeruginosa on bile as a sole carbon source.  
  
 
Figure 14. Outline of the processing of two functional screens of the PA14 NR library (A) Growth screen on M9 
minimal media supplemented with 1.5% (w/v) bile with growth being recorded spectrophotometrically (B) Biofilm 
screen in LB supplemented with 0.3% (w/v) bile processed by a crystal violet assay.  
Screening of the PA14 transposon mutant library for mutants defective for growth on bile as a sole 
carbon source led to the identification of a single mutant auxotrophic for growth on bile; glcB. The 
growth defect on bile in this mutant was confirmed not to be due to a generalised growth defect on 
all carbon sources. Complementation of this mutant in trans restored the ability of this mutant to 





Figure 15. Complementation of the glcB mutant in trans restores growth on complex bile with the growth kinetics of 
the WT strain, the glcB mutant and the complemented glcB mutant illustrated.  
glcB encodes the enzyme malate synthase G, the second enzyme of the glyoxylate shunt, a 
metabolic pathway that bypasses the later stages of the citric acid cycle allowing for the conversion 
of isocitrate to malate. The expression of the glyoxylate shunt enzymes has been found to be 
upregulated in chronic P. aeruginosa isolates (105-107) with the glcB gene 2.31 fold upregulated 
in the bile transcriptome. The glyoxylate shunt has been shown to be essential for the utilisation 
of acetate and fatty acids as carbon sources, with a potential role for this system in the oxidative 
stress response.  
The functional significance for the lack of the glyoxylate shunt system in the presence of bile was 
investigated with a range if phenotypic assays. The first gene of the glyoxylate pathway was also 
included in this analysis as it was tested and found to be incapable of utilizing bile as a sole carbon 
source; aceA encoding for the enzyme isocitrate lyase (Appendix Figure 2).  This revealed that the 
phenotypic response to bile is retained in glyoxylate pathway mutants (aceA and glcB).  The 
induction of biofilm formation and alkyl quinolone signals HHQ and PQS as well as the repression 




transposon mutants (Fig. 16). Pyocyanin production was also found to be unaltered in these 
mutants as in the WT.  
Figure 16. (A) Biofilm formation and (B) swarming motility (C) TLC analysis of AQ production and (D) 
measurement of pyocyanin production in the WT, glcB and aceA mutants in the presence and absence of bile. The bile 
response in the glcB and aceA mutants are comparable to that of the WT. Data presented is the average of at least three 
independent biological replicates. 
The perturbations of redox potential in the presence of bile was the primary phenotype connecting 
adaptive metabolism to bile. It was previously hypothesised based on the findings of the bile 
transcriptome that the reduction of intracellular redox potential was due to the induction of the 
glyoxylate shunt and the bypassing of the later stages of the citric acid cycle. The TCA is a primary 
source for the generation of reduced electron carriers such as NADH (Fig. 9). Therefore, the 




bypassing the later stages of the TCA may underpin this bile altered redox potential. The shift 
towards reduced redox potential in the presence of bile was not evident in the glcB mutant and was 
found to be restored upon complementation (Fig. 17). The maintenance of the phenotypic response 
of glyoxylate shunt mutants would suggest that the pathways governing these key transitions occur 
upstream of flux through the glyoxylate shunt and upstream of the shift in redox potential. These 
data also indicate that these key phenotypic responses of P. aeruginosa to bile are independent of 
growth on bile as a carbon source though metabolic flux may still play a role.  
 
Figure 17. Redox potential is unaffected by bile in a glcB mutant, but the repression of redox in the presence of bile 
is restored in the complemented isogenic strain. 
Global screen of the PA14 NR library for loci involved in the biofilm response to bile  
As the growth screen identified a single gene which was found to be unaltered in terms of its bile 
responsive capabilities a global biofilm screen of the PA14 NR mutant library was undertaken to 
identify other signal transduction components mediating the bile response (Fig. 14). The 




this mode of growth. Therefore, the screen aimed at identifying mutants for which there was loss 
or a reduction in the biofilm response to bile. After a global screen 5800 mutants and a subscreen 
consisting of 150 sensory and response regulator mutants of in LB treated with 0.3% (w/v) bile, 
508 candidates were selected for further testing. These 508 candidates underwent three further 
independent rounds of testing in LB supplemented with 0.3% (w/v) bile where 246 isolates were 
selected for a final round of testing. These 246 genes of interest were validated for the bile 
responsive biofilm phenotype by testing biofilm in both the presence and absence of bile. The 
final list of gene targets consisted of 30 mutants that exhibited less than a 1.5-fold increase in 
biofilm formation compared to >3 fold increase in the WT control in the presence of bile (Table 
5).  
Table 5; Candidates of interest potentially mediating the biofilm response of P. aeruginosa to 
bile. 
PA14 PAO1 Gene Name Gene Function 
PA14_05570 PA4292  Phosphate transporter 
PA14_07620 PA0584 cca tRNA nucleotidyl transferase 
PA14_09470 PA4211 phzB1 Phenazine biosynthesis protein 
PA14_12260 PA3986  Hypothetical protein 
PA14_16430 PA3708 wspA Chemotaxis transducer 
PA14_21110 PA3319 plcN Non-hemolytic phospholipase C  
PA14_21320 PA3301  Lysophospholipase 
PA14_22940 PA3192 gltR Two-component response regulator  
PA14_22960 PA3191 gtrS Two-component sensor 
PA14_24020 PA3101 xcpT General secretion pathway protein G 
PA14_27470 PA2831  Zinc carboxypeptidase 
PA14_30840 PA2571  Signal transduction histidine kinase 
PA14_32940 PA2449 gcsR Transcriptional regulator 
PA14_33220 PA2430  Hypothetical protein 
PA14_33430 PA2418  Pirin-related protein 
PA14_36100 PA2212 pdxA 4-hydroxythreonine-4-phosphate dehydrogenase 
PA14_36180 PA2206  LysR type transcriptional regulator 




PA14_42120 PA1734  Hypothetical protein 
PA14_48830 PA1196 ddaR Transcriptional regulator 
PA14_49130 PA1183 dctA C4-dicarboxylate transporter 
PA14_56700 PA4360  Hypothetical protein 
PA14_59990   Hypothetical protein 
PA14_61840 PA4674  Antitoxin HigA 
PA14_68230 PA5165 dctB Two-component sensor 
PA14_68250 PA5166 dctD Two-component response regulator 
PA14_70430 PA5335  Hypothetical protein 
PA14_72210 PA5471  Hypothetical protein 
PA14_72960 PA5530  MFS dicarboxylate transporter 
 
In silico analysis of the finalised list of genes of interest further supported the transcriptome 
findings that a rewiring of central metabolism plays a role in the P. aeruginosa response to bile. 
The two component system DctB-DctD regulating C4-dicarboxylate transport and the two 
component system GtrS-GltR regulating glucose transport were identified as bile non-responders 
with no significant increase in biofilm formation in the presence of bile as in the WT strain (Fig. 
18). Interestingly, while gtrS and PA2571 exhibited comparable biofilm levels to the untreated 
WT, dctB trended towards, and dctD had, significantly higher levels of biofilm.  In addition to 
the sensory system controlling C4-dicarboxylate transport, the transporter protein DctA itself 
was also identified as a candidate which was found to be upregulated in the presence of bile in 
the transcriptome. As well as regulating the DctA transporter, DctB-DctD is also involved in the 
regulation of the DctPQM transporters with DctA responsible for transport at higher C4-
dicarboxylate concentrations and DctPQM required for transport at lower C4-dicarboxylate 
concentrations. In order to test whether the biofilm response to bile was underpinned by these 
transport systems, these mutants were tested for biofilm formation in the presence of bile. 
However, while the biofilm response to bile was abolished in dctA, the dctPQM mutants retained 




gene is responsible for signal transduction of the bile response and rather a combination of 
redundant systems is responsible. 
Figure 18. Independent validation of the biofilm screen of the library confirms the results obtained from the global 
screen of the library, however the gltR mutant was found to display a significant increase in biofilm production in the 
presence of bile. Data presented is the average of at least three independent biological replicates.             
Active Component of bile 
Bile is a complex mixture consisting primarily of bile salts, fatty acids and cholesterol. With the 
phenotypic response of P. aeruginosa established in the presence of complex bile, investigations 
into the specific component of bile eliciting these responses was undertaken. This revealed that a 
complex mixture of bile salts, at clinically significant concentrations of 50 µM and 200 µM, were 
capable of eliciting an increase in biofilm formation, repression of swarming motility and 
repression of redox as previously established in complex bile (Fig. 19). However, the increased 
resistance to the antibiotic polymyxin as measured by growth kinetic analysis was not evident in 
the presence of bile salts. Additionally, whilst the long chain fatty acid myristic acid was also 
observed to increase biofilm formation, there was no significant effect on swarming motility and 




on key chronic associated phenotypes and are an active component in the bacteria’s response to 
bile.  
Figure 19. Phenotypic response of P. aeruginosa to bile salts; (A) Biofilm formation, (B) Swarming motility, (C) 
Redox potential and (D) Antibiotic resistance. As observed in the presence of complex bile, bile salts were capable of 
modulating these key chronic associated phenotypes.  
There are twelve abundant bile acids in humans, with evidence that bile acids elicit differential 
responses within the host depending on their structure. In order to establish whether the different 
bile acids elicit differential responses in P. aeruginosa, twelve individual bile acids were profiled 
for their impact upon biofilm production and swarming motility. This revealed that though all bile 
acids tested could reduce swarming motility, only the bile acids CDCA and TLCA significantly 




Figure 20. Impact of individual bile acids on two key phenotypes; biofilm formation and swarming motility. The bile 
acids CDCA and TLCA were capable of increasing biofilm production and repressing swarming motility confirming 
that not all bile acids display the same biological effects.  
 
Having previously identified key signal transduction components mediating the response to 
complex bile, it was necessary to establish whether these systems were involved in the bile acids 
response to bile. This highlighted a loss of the bile acid induced biofilm response to bile in these 
mutants. This is interesting as P. aeruginosa is incapable of utilising bile acids as a sole carbon 
source and therefore delineating the connection between bile acid signalling and metabolic 






Figure 21. Biofilm formation in response to bile salts in signal transduction mutants highlighting these mutants do 
















The emergence of P. aeruginosa as the dominant organism within the CF lung microbiota is a 
hallmark in the pathophysiology of the progression of chronic respiratory disease and the decline 
in lung function. The transition of this organism towards a biofilm lifestyle presents a major 
challenge to the clinical management respiratory disease, whereby the organism becomes 
refractive to antibiotic interventions. Though early intervention strategies have significantly 
improved patient welfare in patients with CF, P. aeruginosa continues to hinder the effective 
clinical control of this chronic respiratory disease. Furthermore, with the WHO classifying P. 
aeruginosa as a critical pathogen for the identification of novel antimicrobials (108), there is an 
urgent need for knowledge of the mechanisms through which P. aeruginosa exerts its 
competitive advantage within polymicrobial communities. Deciphering P. aeruginosa’ 
emergence and adaptation within the lung environment facilitates the identification of novel drug 
targets improving early intervention strategies and patient prognosis.  
The aspiration of bile into the lungs of respiratory patients has emerged as a major host factor 
modulating the progression of chronic respiratory disease (5-7, 109), particularly through its 
impact on the key CF pathogen P. aeruginosa. Though investigations into the impact of bile on 
some of the primary phenotypes present in bile had been conducted, little was known regarding 
the molecular mechanism mediating these phenotypic responses. In order to gain a deeper insight 
into the gene expression response potentially governing the phenotypic response, transcriptomics 
in the presence and absence of bile was undertaken. The bile transcriptome signature was found 
to be distinct to many P. aeruginosa stress response transcriptomes suggesting the transcriptional 
response to bile was not simply a generalised stress response. The transcriptional response was 




there was a repression of acute virulence genes such as those involved in type three secretion and 
pyocyanin production and an up regulation of chronic associated genes such as those associated 
with antibiotic resistance (mexAB) and biofilm formation (psl). Furthermore, the increased 
expression of the diguanylate cyclase siaD which is associated with increased levels of cyclic di 
GMP in the cell is also consistent with an increase in biofilm formation in the presence of bile. 
A potential shift in central metabolic flux was evident in the bile transcriptome with a 
transcriptional induction of the glyoxylate shunt and repression of the later stages of the citric 
acid cycle. This shift in central metabolism appeared to manifest in an altered redox status in the 
presence of bile. Furthermore, the identification of glcB in the growth screen on bile as a carbon 
source further reinforces the relative importance of the glyoxylate shunt in P. aeruginosa, though 
the mechanism of uptake of bile into the cell remains unknown. The glyoxylate shunt has been 
shown to be essential for the utilisation of fatty acids and acetate as carbon sources and allows 
organisms to bypass the later stages of the TCA in order to conserve carbon for gluconeogenesis 
(110-114). The regulation of virulence through adaptive metabolism and particularly through the 
induction of the glyoxylate shunt has been implicated in the pathogenesis of a range of microbes 
including Candida albicans, Saccharomyces cerevisiae, Mycobacterium tuberculosis, P. 
aeruginosa and will continue to be discerned in the years to come.  
In the yeasts C. albicans and S. cerevisiae, induction of the glyoxylate shunt is observed upon 
phagocytosis by macrophages (115). In C. albicans the glyoxylate enzymes are essential to 
survival within the phagosome and required for full fungal virulence in a mouse model (115-
117). The importance of this system in vivo was highlighted in clinical isolates where high 
activity was observed for the glyoxylate enzymes (118).  In the bacterial pathogen M. 




glyoxylate genes with mouse models of infection demonstrating increased levels of isocitrate 
lyase mRNA (119-121). The differential expression in various host cells supports a role for this 
system in survival and persistence (122, 123). In Salmonella enterica serovar Typhimurium, the 
glyoxylate shunt has been shown to be necessary for persistence in chronic infection (124, 125).  
In P. aeruginosa the link between alterations to central metabolism and virulence is supported by 
the requirement of the glyoxylate shunt for activation of the T3SS (126, 127). Additionally, the 
upregulation of glyoxylate enzymes in end stage clinical isolates indicates a role for this system 
in persistence within the host (106). The glyoxylate shunt has recently been shown to play a role 
in the mediation of an oxidative stress response in P. aeruginosa, and in several other organisms 
the glyoxylate shunt is induced in response to oxidative stress (128-132).Within the bile 
transcriptome, there are elements of an oxidative stress response hence the functional 
significance of the upregulation of the glyoxylate shunt in the presence of bile and the observed 
enhancement in antibiotic resistance may be in part connected to potential bile induced oxidative 
stress (133). Although P. aeruginosa is capable of utilising bile as a sole carbon source, the 
ability of glyoxylate shunt mutants to respond to bile for the tested phenotypes; biofilm, 
swarming motility and AQ production, suggests that the bile response is not solely due to the 
metabolism of bile as a carbon source. However, metabolic flux and a shift in redox potential 
appear to be involved in part in the molecular mechanism of the bile response.  
Further evidence implicating adaptive metabolism to the bile response came from the biofilm 
screen of the PA14 mutant library. The production of a biofilm is central to persistence within 
the host, with bile significantly increasing this key chronicity phenotype. The functional screen 
identified two two-component systems (TCS), DctBD and GtrS-GltR, and an orphan sensor 




involved in the regulation of C4-dicarboxylate uptake including succinate, fumarate and malate 
through control of the C4-dicarboxylate transporters DctA and DctPQM (134). The orphan 
sensor kinase PA2571 was previously bioinformatically characterised as a C4-dicarboxylate 
regulator so it is possible there is a connection between these two systems. The finding that the 
later stages of the TCA are transcriptionally repressed, which if reflected at the protein level 
would result in lower cellular levels of C4-dicarboxylates, supports the hypothesis of adaptive 
metabolism mediating the bile response. The GtrS-GltR two component system is involved in the 
regulation of glucose transport and metabolism (135). This metabolism associated TCS has been 
linked to the regulation of T3SS and virulence in a mouse model of infection (136). The 
requirement of two metabolism associated TCSs for bile induced biofilm formation, highlights 
the complexity of the response. Rather than the classical ligand-receptor systems, the role of 
these TCSs may be to sense the rewiring of central metabolism and modulate the behaviour of 
the bacteria accordingly. However, the hyperbiofilm phenotype of some of these mutations may 
confound the interpretation of the non-responsiveness of these mutants to bile as they already 





Figure 22. Model of the potential signal transduction systems mediating the response to bile and/or bile acids. 
Complex bile is a mixture of a range of components including bile acids, phospholipids, 
cholesterol and fatty acids. Bile acids are the major constituent of bile constituting roughly 60% 
of the substance (137). Biofilm, redox and swarming motility were all modulated in response to 
bile acids in line with the previously observed effects in the presence of bile. P. aeruginosa could 
not use bile acids as a sole carbon source, and yet redox potential was still repressed in the 
presence of bile acids. This serves to reinforce the view that reprogramming of central 
metabolism occurs independent of the utilisation of bile as a substrate for growth. Of the 12 bile 
acids tested, the primary bile acid CDCA was capable of inducing biofilm formation whilst 
repressing swarming motility. The conjugation of CDCA with either glycine or taurine resulted 
in the abolishment of these phenotypes. This confirmed previous findings that different bile acids 
exhibit differential biological effects (138-140). The bile acid conjugation process has been 




composition of the gut microbiota and their contribution to the bile acid profiles present within 
an individual must be further investigated for their influence on the progression of lung disease 
(Fig. 23). 
 
Figure 23. Bile acid synthesis in humans, with three categories of bile acids evident. The formation of primary bile 
acids (CA, CDCA, GCA, GCDCA, TCA and TCDCA), secondary bile acids (DCA, LCA, GDCA, TLCA, TUDCA 
and TDCA) and tertiary bile acid (UDCA) is impacted by gut bacteria.  
The findings of this research support the previous hypothesis that bile and bile acids are 
capable of triggering the key respiratory pathogen P. aeruginosa to adopt a chronic, antibiotic 
refractive lifestyle. This behavioural switch appears to be mediated by a combination of 
adaptive metabolism and altered redox though further investigations will be required to 
further unravel the complexities of the bile response. The presence of bile acids in the lungs 
of CF patients is therefore worrying, with this evidence indicating it has a role in the 




prevention of bile acid transmission into the lungs may be an attractive drug target. The goal 
of such strategies being the prevention of the onset of chronic bacterial infection ultimately 
improving patient’s quality of life. Surgical intervention in the form of laparoscop ic Nissen 
Fundoplication provides a physical barrier to reflux and is currently the gold standard for the 
clinical control of reflux and reflux derived bile aspiration (143-145). However, as acquisition 
and onset of infection can begin early in life, surgery is not always a viable option and can be 
risky in paediatric patients. Therefore, alternative strategies targeted at clinical control of 
GOR such as macrolides which display pro-kinetic activity may be of use (146). This option 
has the added benefit of targeting colonising pathogens. Alternatively, neutralising the 
biological effects of bile acids through administration of nebulized bile acid sequestrants 
should also be considered. Clinical interventions may also be based on the prevention of the 
pathogen’s response to bile. The targeting of primary metabolism by narrow spectrum 
antibiotics may be one such avenue to be explored (147).  As we further our understanding of 
the impact of bile on the pathophysiology of respiratory disease, bile acids may become 
biological markers for at risk patients. The design of point of care devices that can rapidly 
detect the presence of bile acids may further improve the effective clinical management of 
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Appendix Figure 1. Overview of the impact of bile on central metabolic pathways in P. aeruginosa; tricarboxylic 
acid cycle, Embden-Meyerhof pathway and the Entner-Doudoroff pathway. 
 
Appendix Figure 2.  Mutation of the glyoxylate shunt gene aceA results in an inability of P. aeruginosa to utilise bile 




Appendix Table 1; Transcriptome profiling ≥ 1.5 fold change in bile treated vs untreated. 
Gene  Name Fold Change Gene Description 
Upregulated genes 
PA0009 glyQ 1.5691702 glycyl-tRNA synthetase alpha chain 
PA0013  1.9993705 conserved hypothetical protein 
PA0024 hemF 1.5071424 coproporphyrinogen III oxidase, aerobic 
PA0025 aroE 1.6457433 shikimate dehydrogenase 
PA0061  1.7197822 hypothetical protein 
PA0158 triC 1.527921 RND triclosan efflux transporter 
PA0165  2.3387754 hypothetical protein 
PA0169 siaD 2.6718676 diguanylate cyclase (GGDEF) domain 
PA0170  2.435536 hypothetical protein 
PA0171  2.2755358 hypothetical protein 
PA0172 siaA 1.9316213 signal transduction protein 
PA0195 pntA 5.698029 putative NAD(P) transhydrogenase, subunit alpha part 1 
PA0196 pntB 6.0729065 pyridine nucleotide transhydrogenase, beta subunit 
PA0200  1.6779655 hypothetical protein 
PA0276  4.9222007 hypothetical protein 
PA0293 aguB 1.6108009 N-carbamoylputrescine amidohydrolase 
PA0305  1.7579664 acylhomoserine lactone acylase B 
PA0316 serA 1.6069735 D-3-phosphoglycerate dehydrogenase 
PA0352  1.7676547 probable transporter 
PA0424 mexR 2.4193532 multidrug resistance operon repressor 
PA0425 mexA 1.9427047 RND multidrug efflux membrane fusion precursor 
PA0426 mexB 1.6745746 RND multidrug efflux transporter 
PA0427 oprM 1.5616528 multidrug efflux outer membrane protein OprM precursor 
PA0438 codB 1.7552981 cytosine permease 
PA0482 glcB 2.3145316 malate synthase G 
PA0506  12.926492 probable acyl-CoA dehydrogenase 
PA0507  2.1321254 probable acyl-CoA dehydrogenase 
PA0508  41.035236 probable acyl-CoA dehydrogenase 
PA0520 nirQ 2.6049857 regulatory protein 
PA0521  5.02969 probable cytochrome c oxidase subunit 
PA0522  2.437193 hypothetical protein 
PA0524 norB 11.786244 nitric-oxide reductase subunit B 
PA0547  1.6460618 probable transcriptional regulator 
PA0548 tktA 1.877121 transketolase 
PA0559  1.875097 conserved hypothetical protein 
PA0580 gcp 1.6231686 O-sialoglycoprotein endopeptidase 
PA0607 rpe 1.627546 ribulose-phosphate 3-epimerase 
PA0609 trpE 1.5326068 anthranilate synthetase component I 
PA0642  1.5662348 hypothetical protein 
PA0654 speD 2.553722 S-adenosylmethionine decarboxylase proenzyme 
PA0665  1.741449 conserved hypothetical protein 
PA0667  1.9470879 conserved hypothetical protein 
PA0715  1.820787 hypothetical protein 
PA0729  1.5332638 hypothetical protein 
PA0750 ung 1.8501233 uracil-DNA glycosylase 
PA0775  1.7557627 conserved hypothetical protein 




PA0839  2.3640356 probable transcriptional regulator 
PA0840  2.290152 probable oxidoreductase 
PA0905 rsmA 2.0960267 global regulator protein 
PA0916  1.5262712 conserved hypothetical protein 
PA0917 kup 1.5049281 potassium uptake protein Kup 
PA0945 purM 1.7995995 phosphoribosylaminoimidazole synthetase 
PA0960  1.5693022 hypothetical protein 
PA0975  2.0938315 probable radical activating enzyme 
PA0976  2.3919008 conserved hypothetical protein 
PA0996 pqsA 1.610995 AMP-dependent synthetase/ligase 
PA1051  6.853995 probable transporter 
PA1137  4.652861 probable oxidoreductase 
PA1151 imm2 1.5625875 pyocin S2 immunity protein 
PA1183 dctA 5.316506 C4-dicarboxylate transport protein 
PA1198  2.0251155 conserved hypothetical protein 
PA1228  1.8131458 hypothetical protein 
PA1244  1.5826671 hypothetical protein 
PA1296  1.5636294 probable 2-hydroxyacid dehydrogenase 
PA1299  1.7093493 conserved hypothetical protein 
PA1317 cyoA 2.316115 cytochrome o ubiquinol oxidase subunit II 
PA1318 cyoB 2.6973588 cytochrome o ubiquinol oxidase subunit I 
PA1319 cyoC 2.7420776 cytochrome o ubiquinol oxidase subunit III 
PA1320 cyoD 3.0416453 cytochrome o ubiquinol oxidase subunit IV 
PA1321 cyoE 2.38073 cytochrome o ubiquinol oxidase protein 
PA1432 lasI 1.8146873 autoinducer synthesis protein  
PA1554  1.518187 cytochrome c oxidase, cbb3-type, CcoN subunit 
PA1596 htpG 5.018658 heat shock protein 
PA1649  3.7435198 probable short-chain dehydrogenase 
PA1687 speE 2.2749867 spermidine synthase 
PA1736  1.934638 probable acyl-CoA thiolase 
PA1748  5.4332643 probable enoyl-CoA hydratase/isomerase  
PA1757 thrH 1.7832674 homoserine kinase 
PA1772  1.8780539 probable methyltransferase 
PA1787 acnB 1.7395196 aconitate hydratase 2 
PA1828  2.5765126 probable short chain dehydrogenase 
PA1829  2.7639565 hypothetical protein 
PA1830  4.272302 hypothetical protein 
PA1831  3.9432259 hypothetical protein 
PA1834  1.5483704 hypothetical protein 
PA1847 nfuA 2.1300695 Fe/S biogenesis protein 
PA1959 bacA 1.6784254 bacitracin resistance protein 
PA1970  2.1638315 hypothetical protein 
PA1971 braZ 1.7112839 branched chain amino acid transporter protein 
PA2063  1.778673 hypothetical protein 
PA2120  2.5226676 hypothetical protein 
PA2231 pslA 1.6181463 Psl exopolysaccharide biosynthesis 
PA2232 pslB 1.7325034 Psl exopolysaccharide biosynthesis 
PA2235 pslE 1.666137 Psl exopolysaccharide biosynthesis 
PA2237 pslG 1.5830181 Psl exopolysaccharide biosynthesis 
PA2251  1.5470891 hypothetical protein 




PA2272 pbpC 1.9574057 penicillin binding protein 3A 
PA2282  1.712276 hypothetical protein 
PA2285  3.5870645 hypothetical protein 
PA2404  1.6703215 hypothetical protein 
PA2453  1.524613 hypothetical protein 
PA2524 czcS 1.5139198 signal transduction histidine kinase 
PA2550  3.6004841 probable acyl-CoA dehydrogenase 
PA2619 infA 1.5810775 initiation factor 
PA2629 purB 2.0843713 adenylosuccinate lyase 
PA2634 aceA 8.60934 isocitrate lyase  
PA2653  2.838192 probable transporter 
PA2662  6.3886952 conserved hypothetical protein 
PA2663 ppyR 8.42526 psl and pyoverdine operon regulator 
PA2705  3.5481186 hypothetical protein 
PA2706  2.975919 hypothetical protein 
PA2707  2.770848 hypothetical protein 
PA2730  1.540463 hypothetical protein 
PA2734  1.7171118 hypothetical protein 
PA2735  1.8188722 probable restriction modification system protein 
PA2740 pheS 1.5846324 phenylalanyl-tRNA synthetase alpha-subunit 
PA2828  1.9770868 probable amino transferase 
PA2849 ohrR 2.1531365 Mar-type transcriptional regulator 
PA2854  1.6191936 conserved hypothetical protein 
PA2876 pyrF 1.6983404 orotidine 5'-phosphate decarboxylase 
PA2890 atuE 1.6387995 putative isohexenylglutaconyl-coA hydratase 
PA2901  1.6329596 hypothetical protein 
PA2951 etfA 2.38636 electron transport flavoprotein alpha subunit 
PA2952 etfB 2.771388 electron transport flavoprotein beta subunit 
PA2953  5.1129184 electron transport flavoprotein-ubiquinone oxidoreductase 
PA2956  2.0893328 conserved hypothetical protein 
PA2957  2.7422466 probable transcriptional regulator 
PA2975 rluC 1.5661113 riobosomal large subunit pseudouridine synthase C 
PA3001  1.5636102 probable glyceraldehyde-3-phosphate dehydrogenase 
PA3006 psrA 3.473089 transcriptional regulator 
PA3011 topA 1.5169479 DNA topoisomerase I 
PA3012  3.0956378 hypothetical protein 
PA3013 foaB 8.261979 fatty-acid oxidation complex beta subunit 
PA3014 faoA 8.045702 fatty-acid oxidation complex alpha subunit 
PA3039  1.6068201 probable transporter 
PA3046  1.7461492 conserved hypothetical protein 
PA3079  1.5431921 hypothetical protein 
PA3080  2.2197092 hypothetical protein 
PA3092 fadH1 10.941382 2,4-dienoyl-coA reductase  
PA3136  4.564559 probable secretion protein 
PA3142  1.5115281 integrase 
PA3179  2.6249208 conserved hypothetical protein 
PA3277  1.5552263 probable short chain dehydrogenase 
PA3299 fadD1 2.3626924 long-chain-fatty-acid coA ligase 
PA3310  1.5319793 conserved hypothetical protein 
PA3312  1.6154325 probable 3-hydroxybutyrate dehydrogenase 




PA3397 fprA 1.5781447 oxidation-reduction process 
PA3430  2.112962 probable aldolase 
PA3436  3.7672973 hypothetical protein 
PA3441  2.885145 probable molybdopterin-binding protein 
PA3454  2.2919114 probable acyl-coA thiolase  
PA3530 bfd 2.1058738 bacterioferretin-associated ferredoxin 
PA3533 grxD 1.6208036 cell redox homeostasis 
PA3564  1.5504247 conserved hypothetical protein 
PA3604 erdR 1.8984143 response regulator 
PA3608 potB 2.6690738 polyamine transport protein 
PA3610 potD 3.1713614 polyamine transport protein 
PA3636 kdsA 1.6291608 2-dehydro-3-deoxyphosphooctonate aldolase 
PA3648 opr86 1.8314524 outer membrane protein 
PA3673 plsB 1.5458521 glycerol-3-phosphate acyltransferase 
PA3713 spdH 2.438359 spermidine dehydrogenase 
PA3742 rplS 1.6403929 50S ribosomal protein L19 
PA3810 hscA 1.9194839 heat shock protein 
PA3815 iscR 1.97773 iron-sulfur cluster assembly transcription factor 
PA3817  1.9172465 probable methyltransferase 
PA3818 suhB 2.426292 extragenic suppressor protein 
PA3832 holC 1.6676788 DNA polymerase III, chi subunit 
PA3860  2.786317 probable AMP-binding enzyme 
PA3876 narK2 2.4774816 nitrite extrusion protein 2 
PA3915 moaB1 2.683761 molybdopterin biosynthetic protein B1 
PA3925  6.362694 probable acyl-coA thiolase 
PA3979  2.2068381 hypothetical protein 
PA3980  1.5200603 conserved hypothetical protein 
PA4053 ribE 1.5947592 6,7-dimethyl-8-ribityllumazine synthase 
PA4055 ribC 2.0001235 rioboflavin synthase alpha chain 
PA4139  2.0021958 hypothetical protein 
PA4280 birA 1.6605364 cellular protein modification process 
PA4291  1.5189809 hypothetical protein 
PA4292  1.5532227 probable phosphate transporter 
PA4385 groEL 2.1746135 60 kDa chaperonin 
PA4386 groES 1.6020151 10 kDa chaperonin 
PA4389  2.9126391 probable short chain dehydrogenase 
PA4390  2.3305416 hypothetical protein 
PA4404  1.5881593 hypothetical protein 
PA4432 rpsI 2.0233817 30S ribosomal protein S9 
PA4435  3.31337 probable acyl-CoA dehydrogenase 
PA4519 speC 2.5638704 ornithine decarboxylase 
PA4524 nadC 1.5230906 nicotinate-nucleotide pyrophosphorylase 
PA4574  1.8216043 conserved hypothetical protein 
PA4588 gdhA 4.843752 glutamate dehydrogenase 
PA4602 glyA3 1.5978534 serine hydroxymethyltransferase 
PA4615 fprB 1.7907255 ferredoxin reductase-type FAD binding protein 
PA4621  1.950093 probable oxidoreductase 
PA4625 cdrA 2.0494714 cyclic diguanylate-regulated TPS partner A 
PA4637  1.6872619 hypothetical protein 
PA4640 mqoB 1.8581218 malate:quinone oxidoreductase 




PA4646 upp 1.5125525 uracil phosphoribosyltransferase 
PA4676  1.7414601 probable carbonic anhydrase 
PA4729 panB 1.6376442 3-methyl-2-oxobutanoate hydroxymethyltransferase 
PA4730 panC 1.6072731 pantoate-beta-alanine ligase 
PA4731 panD 2.025211 aspartate 1-decarboxylase precursor 
PA4739  1.6100599 conserved hypothetical protein 
PA4744 infB 1.610814 translation initiation factor IF-2 
PA4747 secG 2.002634 secretion protein 
PA4755 greA 1.554067 transcription elongation factor 
PA4757  1.7081891 conserved hypothetical protein 
PA4758 carA 2.2199163 carbamoyl-phosphate synthase small chain 
PA4759 dapB 4.5988173 dihydrodipicolinate reductase  
PA4768 smpB 1.660908 ssrA-binding protein 
PA4770 lldP 6.846915 L-lactate permease 
PA4771 lldD 6.3667874 L-lactate dehydrogenase 
PA4817  1.8832077 hypothetical protein 
PA4840  2.423288 conserved hypothetical protein 
PA4855 purD 1.5000381 phosphoribosylamine -glycine ligase 
PA4873  1.8353506 probable heat shock protein 
PA4928  2.0750062 conserved hypothetical protein 
PA5019  1.8728709 conserved hypothetical protein 
PA5020  3.9215884 probable acyl-CoA dehydrogenase 
PA5023  2.9872162 conserved hypothetical protein 
PA5035 gltD 2.323267 glutamate synthase small chain 
PA5048  1.5303047 probable nuclease 
PA5072  1.859174 probable chemotaxis transducer 
PA5076  1.7966675 probable binding protein component of ABC transporter 
PA5118 thiI 1.7867571 thiazole biosynthesis protein  
PA5119 glnA 2.0239024 glutamine synthetase 
PA5125 ntrC 1.7712349 two component response regulator 
PA5138  1.514509 hypothetical protein 
PA5157  2.4622345 probable transcriptonal regulator 
PA5158  2.5326378 probable outer membrane protein precursor 
PA5159  3.614299 multdrug resistance protein 
PA5192 pckA 2.1203341 phosphoenoylpyruvate carboxykinase 
PA5215 gcvT1 1.6615047 glycine-cleavage system protein T1 
PA5275  2.443186 conserved hypothetical protein 
PA5296 rep 1.955691 ATP-dependent DNA helicase  
PA5315 rpmG 1.5917709 50S ribosomal protein L33 
PA5347  2.2524781 hypothetical protein 
PA5407  2.249299 hypothetical protein 
PA5430  1.5518764 hypothetical protein 
PA5435  2.3119483 probable transcarboxylase subunit 
PA5482  2.1968896 hypothetical protein 
PA5503  1.51603 probable ATP-binding component of ABC transporter 
PA5526  1.5122871 hypothetical protein 
PA5530  2.2498746 C5-dicarboxylate transporter 
PA5561 atpI 1.9720086 ATP-synthase protein I 
Pae_tRNA_Ala  2.1793957  
Pae_tRNA_Gln  1.674767  




Pae_tRNA_His  1.8042011  
Pae_tRNA_Ile  1.868528  
Pae_tRNA_Leu  1.9550334  
Pae_tRNA_Lys  1.9264927  
Pae_tRNA_Thr  3.0495825  
Pae_tRNA_Val  1.7678549  
    
Downregulated genes 
PA0028  1.5948375 hypothetical protein 
PA0039  2.143605 hypothetical protein 
PA0048  2.94961 probable transcriptional regulator 
PA0050  1.984994 hypothetical protein 
PA0078 tssL1 2.1075292 Hcp secretion island I (HSI-I) type VI secretion system 
PA0079 tssK1 1.6049535 Hcp secretion island I (HSI-I) type VI secretion system 
PA0081 fhA1 1.7814412 Hcp secretion island I (HSI-I) type VI secretion system 
PA0082 tssA1 2.4476979 Hcp secretion island I (HSI-I) type VI secretion system 
PA0083 tssB1 2.0212882 Hcp secretion island I (HSI-I) type VI secretion system 
PA0084 tssC1 2.1767128 Hcp secretion island I (HSI-I) type VI secretion system 
PA0085 hcp1 1.9435418 Hcp secretion island I (HSI-I) type VI secretion system 
PA0086 tagJ1 2.6898286 Hcp secretion island I (HSI-I) type VI secretion system 
PA0087 tssE1 2.6551623 Hcp secretion island I (HSI-I) type VI secretion system 
PA0088 tssF1 1.9184635 Hcp secretion island I (HSI-I) type VI secretion system 
PA0089 tssG1 2.39119 Hcp secretion island I (HSI-I) type VI secretion system 
PA0093 tse6 1.7975425 Hcp secretion island I (HSI-I) type VI secretion system 
PA0094  1.6072897 hypothetical protein 
PA0095  1.8542596 conserved hypothetical protein 
PA0096  2.1944344 hypothetical protein 
PA0099  5.3633327 hypothetical protein 
PA0100  1.680287 hypothetical protein 
PA0112  1.6479193 hypothetical protein 
PA0122 rahU 3.615853 Hemolysin, aegerolysin type 
PA0129 bauD 7.6909256 amino acid permease 
PA0130 bauC 4.95721 oxopropanonate dehydrogenase 
PA0131 bauB 5.0994606 beta-alanine biosynthetic protein 
PA0132 bauA 9.548833 beta-alanine:pyruvate transaminase  
PA0176 aer2 2.1970596 aerotaxis transducer 
PA0178  1.7684873 probable two component sensor 
PA0179  2.57306 probable two component response regulator 
PA0250  1.566561 conserved hypothetical protein 
PA0261  1.7094259 hypothetical protein 
PA0262 vgrG2b 1.8797104 type VI secretion system Vgr family protein 
PA0263 hcpC 4.5870194 secreted protein 
PA0265 gabD 1.9571402 succinate-semialdehyde dehydrogenase 
PA0266 gabT 2.0194545 4-aminobutyrate aminotransferase 
PA0296 spuI 1.7034112 glutamylpolyamine synthetase  
PA0297 spuA 2.749863 probable glutamine amidotransferase 
PA0298 spuB 1.9352928 glutamylpolyamine synthetase  
PA0299 spuC 1.9077505 Polyamine:pyruvate transaminase  
PA0328 aaaA 1.7097926 arginine-specific autotransporter 
PA0345  1.5220128 hypothetical protein 




PA0459  1.9906839 probable ClpA/B protease ATP binding subunit 
PA0492  9.769155 conserved hypothetical protein 
PA0493  12.164877 probable biotin-requiring enzyme 
PA0494  12.537723 probable acyl-CoA carboxylase subunit 
PA0495  14.1487875 hypothetical protein 
PA0504 bioD 2.1558855 dethiobiotin synthase 
PA0527 dnr 1.785652 transcriptional regulator 
PA0563  2.0404708 conserved hypothetical protein 
PA0602  2.9482942 probable binding component of ABC transporter 
PA0730  20.264019 probable transferase 
PA0744  2.6036005 probable enoyl-coA hydratase/isomerase 
PA0745  2.601556 probable enoyl-coA hydratase/isomerase 
PA0782 putA 2.399258 proline dehydrogenase  
PA0783 putP 2.7099984 sodium/proline symporter 
PA0789  2.135822 probable amino acid permease 
PA0796 prpB 1.6505334 carboxyphosphonoenolpyruvate phosphonomutase  
PA0798 pmtA 1.7103677 phospholipid methyltransferase 
PA0818  1.538232 hypothetical protein 
PA0852 cbpD 5.2773623 chitin-binding protein  
PA0853  1.5048496 probable oxidoreductase  
PA0855  2.013548 hypothetical protein 
PA0865 hpd 9.271919 4-hydroxyphenylpyruvate dioxygenase  
PA0870 phhC 3.1358166 aromatic amino acid aminotransferase 
PA0871 phhB 2.0197833 pterin-4-alpha-carbinolamine dehydratase  
PA0872 phhA 1.843872 phenylalaine-4-hydroxylase 
PA0887 acsA 8.322072 acteyl-coenzyme A synthetase  
PA1015  1.5982444 probable transcriptional regulator 
PA1069  1.9617678 hypothetical protein 
PA1073 braD 1.8554968 branched chain amino acid transport protein 
PA1130 rhlC 2.571125 rhamnosyltransferase 2 
PA1131  2.6840458 probable major facilitator superfamily transporter 
PA1170  3.169312 conserved hypothetical protein 
PA1173 napB 1.9207349 cytochrome c-type protein precursor 
PA1175 napD 1.769999 protein of periplasmic nitrate reductase 
PA1176 napF 2.807975 ferredoxin protein  
PA1177 napE 2.4080005 periplasmic nitrate reductase protein 
PA1293  3.1160045 hypothetical protein 
PA1336 aauS 1.5600288 signal transduction histidine kinase 
PA1338 ggt 3.2098217 gamma-glutamyltranspeptidase precursor 
PA1377  2.1422617 conserved hypothetical protein 
PA1378  2.501052 hypothetical protein 
PA1396  2.6544714 probable two component sensor 
PA1415  1.5845275 hypothetical protein 
PA1418  2.5522227 probable sodium:solute symport protein 
PA1469  1.776468 hypothetical protein 
PA1494  1.6269441 mucoidy inhibitor gene A 
PA1511 vgrG2a 2.014915 type VI secretion system Vgr family protein 
PA1538  1.5359794 probable flavin-containing monooxygenase 
PA1565 pauB2 8.70774 FAD-dependent oxidoreductase  
PA1591  2.0886438 hypothetical protein 




PA1609 fabB 2.2841575 beta-ketoacyl-ACP synthase I 
PA1610 fabA 2.9927423 beta-hydroxydeacnoyl-ACP dehydrase 
PA1611  1.7661884 hybrid sensor kinase 
PA1612  1.7176058 hypothetical protein 
PA1639  2.3704023 hypothetical protein 
PA1647  1.8923525 probable sulfate transporter 
PA1656 hsiA2 2.6254783 Hcp secretion island I (HSI-II) type VI secretion system 
PA1657 hsiB2 3.1352513 Hcp secretion island I (HSI-II) type VI secretion system 
PA1658 hsiC2 3.1408982 Hcp secretion island I (HSI-II) type VI secretion system 
PA1659 hsiF2 3.9727623 Hcp secretion island I (HSI-II) type VI secretion system 
PA1663 sfa2 4.714584 Hcp secretion island I (HSI-II) type VI secretion system 
PA1664 orfX 4.7656765 Hcp secretion island I (HSI-II) type VI secretion system 
PA1665 fha2 4.4706626 Hcp secretion island I (HSI-II) type VI secretion system 
PA1666 lip2 2.7888627 Hcp secretion island I (HSI-II) type VI secretion system 
PA1667 hsij2 3.4455078 Hcp secretion island I (HSI-II) type VI secretion system 
PA1668 dotU2 3.3361132 Hcp secretion island I (HSI-II) type VI secretion system 
PA1669 icmF2 3.4615045 Hcp secretion island I (HSI-II) type VI secretion system 
PA1670 stp1 2.32084 Hcp secretion island I (HSI-II) type VI secretion system 
PA1691 pscT 1.7019385 translocation protein in type three secretion 
PA1692  1.9261502 probable translocation protein in type three secretion 
PA1693 pscR 1.9027892 translocation protein in type three secretion 
PA1694 pscQ 2.4248476 translocation protein in type three secretion 
PA1698 popN 1.8647052 type three secretion outer membrane protein precursor 
PA1699 pcr1 2.2103293 negative regulator of protein secretion 
PA1700 pcr2 2.8731177 type three secretion protein 
PA1701 pcr3 2.8128605 type three secretion protein 
PA1703 pcrD 2.2703972 type three secretory apparatus protein 
PA1705 pcrG 2.268675 type three secretion regulator 
PA1706 pcrV 2.441468 type three secretion protein 
PA1707 pcrH 2.5031915 regulatory protein 
PA1708 popB 3.310198 translocator protein 
PA1709 popD 3.3381078 translocator outer membrane protein precursor 
PA1710 exsC 3.9618962 exoenzyme S synthesis protein C precursor 
PA1711 exsE 3.2902606 type three secretion protein 
PA1712 exsB 3.4639027 exoenzyme S synthesis protein B 
PA1713 exsA 2.269879 transcriptional regulator 
PA1714 exsD 2.0926607 negative regulator of protein secretion 
PA1715 pscB 2.127073 type three export apparatus protein 
PA1716 pscC 2.4568872 type three secretion outer membrane protein precursor 
PA1718 pscE 1.9889266 type three secretion export protein 
PA1719 pscF 2.4587705 type three secretion export protein 
PA1720 pscG 2.1631007 type three secretion export protein 
PA1721 pscH 2.7372322 type three secretion export protein 
PA1722 pscI 2.2609296 type three secretion export protein 
PA1725 pscL 2.0760052 type three secretion export protein 
PA1732  1.9571875 conserved hypothetical protein 
PA1759  1.9743236 probable transcriptional regulator 
PA1760  3.1952362 probable transcriptional regulator 
PA1761  2.0183575 hypothetical protein 
PA1762  1.8740104 hypothetical protein 




PA1775 cmpX 1.6878084 conserved cytoplasmic membrane protein 
PA1797  4.6390796 hypothetical protein 
PA1818 LdcA 3.1492357 lysine-specific PLP-dependent carboxylase  
PA1819  1.9307975 probable amino acid permease 
PA1844 tse1 2.373152 Hcp secretion island I (HSI-I) type VI secretion system 
PA1852  3.399476 hypothetical protein 
PA1869  2.6705492 probable acyl-carrier protein 
PA1894  2.0885706 hypothetical protein 
PA1895  1.9763824 hypothetical protein 
PA1897  2.7002308 hypothetical protein 
PA1903 phzE2 3.8006172 phenazine biosynthesis protein 
PA1904 phzF2 4.305888 probable phenazine biosynthesis protein 
PA1905 phzG2 5.7028136 probable pyridoxamine 5'-phosphate oxidase  
PA1950 rbsK 1.501952 ribokinase 
PA1963  2.0812864 hypothetical protein 
PA1984 exaC 59.43127 NAD+ dependent aldehyde dehydrogenase  
PA1986 pqqB 2.1094584 pyrroloquinolone quinone biosynthesis protein B 
PA1999 dhcA 31.309772 dehydrocarnitine coA transferase subunit A 
PA2003 bdhA 2.8883147 3-hydroxybutyrate dehydrogenase  
PA2008 fahA 34.142612 fumarylacetoacetase 
PA2009 hmgA 54.90419 homogentisate 1,2-dioxygenase  
PA2010  2.1838396 probable transcriptional regulator 
PA2011 liuE 3.4714077 3-hydroxy-3-methylglutaryl-CoA lyase  
PA2013 liuC 12.648429 putative 3-methylglutaconyl-CoA hydratase  
PA2014 liuB 14.03458 methylcrotonyl-CoA carboxylase, beta subunit 
PA2015 liuA 10.924191 putative isovaleryl-CoAdehydrogenase  
PA2016 liuR 7.376461 regulator of liu genes 
PA2019 mexX 1.5939317 RND multi drug efflux membrane fusion protein precursor 
PA2041  2.957639 amino acid permease 
PA2044  1.6550866 hypothetical protein 
PA2066  3.08255 hypothetical protein 
PA2069  5.337103 probable carbamoyl transferase 
PA2080 kynU 1.9059906 kynureninase  
PA2109  13.239002 hypothetical protein 
PA2110  9.982603 hypothetical protein 
PA2111  11.699324 hypothetical protein 
PA2112  10.565109 conserved hypothetical protein 
PA2113 opdO 15.40829 pyroglutamate porin 
PA2114  12.587432 probable major facilitator superfamily transporter 
PA2123  1.5930154 probable transcriptional regulator 
PA2193 hcnA 2.0849488 hydrogen cyanide synthase  
PA2194 hcnB 2.4813926 hydrogen cyanide synthase  
PA2195 hcnC 2.7307336 hydrogen cyanide synthase  
PA2196  1.603319 tetR family transcriptional regulator 
PA2247 bkdA1 11.765008 2-oxoisovalerate dehydrogenase alpha subunit 
PA2248 bkdA2 8.665485 2-oxoisovalerate dehydrogenase beta subunit 
PA2249 bkdB 8.010507 branched chain alpha keto acid dehydrogenase lipoamide 
PA2250 lpdV 10.541232 lipoamide dehydrogenase-Val 
PA2304 ambC 1.5349882 AMB biosynthetic protein 
PA2305 ambB 1.8090299 AMB biosynthetic protein 




PA2378  1.5142914 probable aldehyde dehydrogenase  
PA2423  1.9415448 hypothetical protein 
PA2464  2.2603655 hypothetical protein 
PA2503  1.558646 hypothetical protein 
PA2537  1.8237628 probable acyltransferase 
PA2538  1.863953 hypothetical protein 
PA2539  2.16321 conserved hypothetical protein 
PA2540  2.290972 conserved hypothetical protein 
PA2541  2.353624 probable CDP-alcohol phosphatidyltransferase 
PA2552  10.1244545 probable acyl-CoA dehydrogenase  
PA2553  17.720968 probable acyl-CoA thiolase  
PA2554  7.5938797 probable short chain dehydrogenase  
PA2555  14.5416565 probable AMP-binding enzyme 
PA2573  1.7526189 probable chemotaxis transducer 
PA2624 idh 1.5125592 isocitrate dehydrogenase  
PA2637 nuoA 1.7138935 NADH dehydrogenase I chain A 
PA2682  1.5942562 conserved hypothetical protein 
PA2684 tse5 2.1057823 protein secretion by the type VI secretion system 
PA2685 vgrG4 1.5318247 Hcp secretion island I (HSI-I) type VI secretion system 
PA2702 tse2 1.8557568 protein secretion by the type VI secretion system 
PA2703 tsi2 2.2335365 Hcp secretion island I (HSI-I) type VI secretion system 
PA2725  1.7536601 probable chaperone  
PA2726  2.0102458 probable radical activating enzyme  
PA2727  1.776595 hypothetical protein 
PA2728  1.5782139 hypothetical protein 
PA2752  1.720396 conserved hypothetical protein 
PA2759  1.9633168 hypothetical protein 
PA2761  2.1907022 hypothetical protein 
PA2776 pauB3 2.2253318 FAD-dependent oxidoreductase  
PA2780  2.649256 hypothetical protein 
PA2781  1.8431194 hypothetical protein 
PA2788  1.7293639 probable chemotaxis transducer 
PA2790  1.6003789 hypothetical protein 
PA2792  1.6244026 hypothetical protein 
PA2867  1.7818938 probable chemotaxis transducer 
PA2868  2.5292265 hypothetical protein 
PA2883  1.7968694 hypothetical protein 
PA2950 pfm 2.7392774 proton motive force protein 
PA2967 fabG 1.761908 3-oxoacyl-(acyl-carrier-protein)reductase  
PA2968 fabD 2.5239315 malonyl-CoA-(acyl-carrier protein)transacylase  
PA3038  4.6687083 probable porin 
PA3054  1.6859233 hypothetical protein 
PA3068 gdhB 3.46976 NAD-dependent glutamate dehydrogenase  
PA3089  1.915602 hypothetical protein 
PA3111 folC 1.9460045 folylpolygultamate synthetase  
PA3181  2.4894865 2-keto-3-deoxy-6-phosphogluconate aldolase  
PA3182 pgl 2.4615443 6-phosphogluconolactonase  
PA3183 zwf 1.8612951 glucose-6-phosphate 1-dehydrogenase  
PA3186 oprB 5.547807 glucose/carbohydrate outer membrane protein precursor 
PA3187  37.640736 probable ATP binding component of ABC transporter  




PA3191 gtrS 2.3700728 glucose transporter sensor  
PA3192 gltR 2.8294287 two component response regulator  
PA3193 glk 2.5788982 glucokinase  
PA3194 edd 2.3691285 phospholgluconate dehydratase  
PA3195 gapA 11.153055 glyceraldehyde 3-phosphate dehydrogenase  
PA3222  1.8008807 hypothetical protein 
PA3232  1.7556814 probable nuclease 
PA3234  5.911297 probable sodium:solute symporter 
PA3266 capB 2.062545 cold acclimation protein B 
PA3267  2.013526 hypothetical protein 
PA3271  2.1071553 probable two component sensor 
PA3289  2.1252868 hypothetical protein 
PA3294 vgrG4a 2.0742862 type VI protein secretion system complex 
PA3326 clpP2 2.1203053 ATP-dependent Clp protease proteolytic subunit 
PA3327  2.6560686 probable non ribosomal peptide synthetase  
PA3330  2.478699 probable short chain dehydrogenase  
PA3331  2.440465 cytochrome P450 
PA3332  2.590828 conserved hypothetical protein 
PA3333 fabH2 2.5470762 3-oxoacyl-(acyl-carrier-protein)synthase III 
PA3335  3.2118356 hypothetical protein 
PA3355  2.0893073 hypothetical protein 
PA3356 pauA5 3.517199 glutamylpolyamine synthetase  
PA3361 lecB 4.9500566 fucose-binding lectin PA-IIL 
PA3362  1.601258 hypothetical protein 
PA3363 amiR 2.094657 aliphatic amidase regulator 
PA3365  2.497356 probable chaperone  
PA3366 amiE 1.7536775 aliphatic amidase 
PA3403  1.6708249 hypothetical protein 
PA3471  2.838807 probable malic enzyme  
PA3478 rhlB 1.5629418 rhamnosyltransferase chain B 
PA3483  1.7651366 hypothetical protein 
PA3484 tse3 2.1280935 Hcp secretion island I (HSI-I) type VI secretion system 
PA3485 tsi3 2.2205892 Hcp secretion island I (HSI-I) type VI secretion system 
PA3487 tle5 2.6968684 phospholipase D active protein 
PA3488 tli5 2.0857  Hcp secretion island I (HSI-I) type VI secretion system 
PA3511  1.7608668 probable short chain dehydrogenase  
PA3516  8.26889 probable lyase  
PA3519  3.9683826 hypothetical protein 
PA3535  2.5359788 probable serine protease 
PA3560 fruA 2.0949857 phosphotransferase system transporter fructose specific IIBC 
PA3561 fruK 1.8346641 1-phosphofructokinase  
PA3562 fruI 1.6994203 phosphotransferase system transporter enzyme I 
PA3570 mmsA 1.8595018 methylmalonate-semialdehyde dehydrogenase  
PA3581 glpF 3.1833086 glycerol uptake facilitator protein 
PA3582 glpK 3.2480462 glycerol kinase 
PA3583 glpR 1.5413748 glycerol-3-phosphate regulon repressor  
PA3622 rpoS 1.8654066 sigma factor 
PA3661  3.144587 hypothetical protein 
PA3711  1.5237778 probable transcriptional regulator 
PA3716  1.9169841 hypothetical protein 




PA3779  1.6678269 hypothetical protein 
PA3786  1.5774021 hypothetical protein 
PA3791  2.0427399 hypothetical protein 
PA3841 exoS 2.0348053 exoenzyme S  
PA3842 spcS 3.8800082 specific Pseudomonas chaperone for ExoS 
PA3843  2.883644 hypothetical protein 
PA3850  1.5037203 hypothetical protein 
PA3858  1.5532614 probable amino acid binding protein 
PA3859  1.5182569 carboxylesterase 
PA3906  1.6909509 hypothetical protein 
PA3924  2.2293808 probable medium chain acyl-CoA ligase  
PA3960  1.9433469 hypothetical protein 
PA4024 eutB 9.765597 ethanolamine ammonia-lyase large subunit 
PA4025  3.6506097 ethanolamine ammonia-lyase light chain 
PA4040  1.6383013 hypothetical protein 
PA4124 hpcB 1.984254 homoprotocatechuate 2,3-dioxygenase  
PA4126  2.3422012 probable major facilitator superfamily transporter 
PA4127 hpcG 1.919759 2-oxo-hept-3-ene- 1,7 dioate hydratase  
PA4129  2.7885988 hypothetical protein 
PA4130  2.168181 probable sulfite or nitrite reductase  
PA4131  2.43465 probable iron-sulfur protein 
PA4132  2.3007894 conserved hypothetical protein 
PA4134  3.8384316 hypothetical protein 
PA4198  2.1332781 probable AMP-binding enzyme 
PA4211 phzB1 8.585621 probable phenazine biosynthesis protein 
PA4217 phzS 5.672542 flavin-containing monooxygenase  
PA4290  3.2010045 probable chemotaxis transducer 
PA4296 pprB 1.8907439 two component response regulator  
PA4312  1.676818 conserved hypothetical protein 
PA4316 sbcB 1.8292457 exodeoxyribonuclease I 
PA4318  1.994757 hypothetical protein 
PA4320  1.7371818 hypothetical protein 
PA4321  1.8312458 hypothetical protein 
PA4348  1.9334596 conserved hypothetical protein 
PA4397 panE 1.6094146 ketopantoate reductase  
PA4441  1.5054107 hypothetical protein 
PA4464 ptsN 1.5437149 nitrogen regulatory IIA protein 
PA4489 magD 1.5218936 endopeptidase inhibitor protein 
PA4490 magC 1.7564965 hypothetical protein 
PA4495  1.8454317 hypothetical protein 
PA4496  3.494979 probable binding protein component of ABC transporter  
PA4497  3.9295037 probable binding protein component of ABC transporter  
PA4498 mdpA 2.8390453 metallo-dipeptidase aeruginosa 
PA4500  3.5027168 probable binding protein component of ABC transporter  
PA4502  5.121125 probable binding protein component of ABC transporter  
PA4503  3.6120512 probable permease of ABC transporter 
PA4504  3.6977658 probable permease of ABC transporter 
PA4505  2.5218732 probable ATP binding component of ABC transporter  
PA4506  2.7894301 probable ATP binding component of ABC transporter  
PA4521 ampE 1.6189638 antibiotic response protein 




PA4551 pilV 1.9267063 type 4 fimbrial biogenesis protein 
PA4583  1.598647 conserved hypothetical protein 
PA4591  1.6394689 hypothetical protein 
PA4592  1.6008954 probable outer membrane protein precursor  
PA4603  1.5413858 hypothetical protein 
PA4604  1.9048488 conserved hypothetical protein 
PA4605  1.9862462 conserved hypothetical protein 
PA4607  1.6575047 hypothetical protein 
PA4660 phr 1.5931557 deoxyribodipyrimidine photolyase  
PA4736  1.645675 hypothetical protein 
PA4737  1.5593427 hypothetical protein 
PA4846 aroQ1 3.026733 3-dehydroquinate dehydratase  
PA4847 accB 2.2632728 biotin carboxyl carrier protein 
PA4848 accC 2.665176 biotin carboxylase  
PA4890 desT 2.196814 negative regulator of fatty acid metabolic process 
PA4917  1.6167381 hypothetical protein 
PA4978  2.09403 hypothetical protein 
PA5015 aceE 2.4748633 pyruvate dehydrogenase  
PA5016 aceF 1.9336244 dihydrolipoamide acetyltransferase  
PA5033  1.9714878 hypothetical protein 
PA5058 phaC2 2.070579 poly(3-hydroxyalkanoic acid) synthase 2 
PA5062  1.645185 conserved hypothetical protein 
PA5089 pldB 1.8433772  phospholipase D active protein 
PA5112 estA 2.2522578 esterase 
PA5113  1.7548673 hypothetical protein 
PA5114  1.5116537 hypothetical protein 
PA5152  1.6229354 probable ATP binding component of ABC transporter  
PA5154  3.0212357 probable permease of ABC transporter 
PA5155  1.8666053 amino acid ABC transporter membrane protein 
PA5167 dctP 2.2897437 C4 dicarboxylate transport 
PA5168 dctQ 2.9596171 C4 dicarboxylate transport 
PA5169 dctM 3.794928 C4 dicarboxylate transport 
PA5174  10.5041275 probable beta-ketoacyl synthase  
PA5184  1.951973 hypothetical protein 
PA5208  2.355181 conserved hypothetical protein 
PA5212  3.2855444 hypothetical protein 
PA5219  1.9625584 hypothetical protein 
PA5220  3.035381 hypothetical protein 
PA5230  1.5580871 probable permease of ABC transporter 
PA5235 glpT 1.5808283 glycerol-3-phosphate transporter 
PA5266 vgrG6 2.6062305 type VI protein secretion system complex 
PA5271  1.510594 hypothetical protein 
PA5290  1.6901497 conserved hypothetical protein 
PA5302 dadX 2.7517176 catabolic alanine racemase 
PA5303  3.682151 conserved hypothetical protein 
PA5304 dadA 3.0453987 D-amino acid dehydrogenase,small subunit 
PA5312 pauC 2.6244156 aldehyde dehydrogenase  
PA5313 gabT2 1.7187879 transaminase  
PA5329  1.5208641 conserved hypothetical protein 
PA5348  3.6003451 probable DNA binding protein 




PA5367 pstA 1.555267 membrane protein component of ABC phosphate transporter 
PA5374 betI 2.1576834 transcriptional regulator 
PA5380 gbdR 9.957009 putative amidotransferase 
PA5396  1.9843612 hypothetical protein 
PA5410 gbcA 3.55013 putative ring hydroxylating dioxygenase 
PA5421 fdhA 1.9251707 glutathione-independent formaldhyde dehydrogenase  
PA5428  1.5123227 probable transcriptional regulator 
PA5429 aspA 4.8744445 aspartate ammonia-lyase  
PA5458  1.5078423 hypothetical protein 
PA5461  1.7103561 hypothetical protein 
PA5510  1.8075719 probable transporter 
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Pseudomonas aeruginosa is the key respiratory pathogen found to dominate the Cystic Fibrosis 
lung microbiome. This versatile and opportunistic pathogen has been shown to undergo 
extensive genomic adaptation in order to chronically colonise and persist within the CF lung 
environment. Rapid evolutionary adaptations of P. aeruginosa allows it to both evade the host 
immune response and outcompete co-colonising residents of the lung microbiota. These 
adaptations include increased antibiotic resistance, loss of quorum sensing, a switch to a mucoid 
phenotype and an altered metabolism. However, whilst several studies describe the mutations 
that frequently arise in clinical isolates of P. aeruginosa, it remains unclear as to what the 
environmental factors governing the emergence of these genetic variants are. Bile aspiration, a 
consequence of gastro-oesophageal reflux, has recently emerged as a major co-morbidity in CF. 
This key host factor has been shown to shape the CF microbiota and promote the emergence of 
dominant proteobacterial pathogens including P. aeruginosa. In order to investigate whether bile 
may act as a selective pressure for genetic adaptation within the CF lung, populations of P. 
aeruginosa were experimentally evolved in Artificial Sputum Medium, a media known to 
resemble conditions present in the CF lung, in the presence and absence of bile. Pigmented 
variants of P. aeruginosa emerged exclusively in the presence of bile. Whole genome 
sequencing analysis identified single nucleotide polymorphisms (SNPs) in the pyocyanin (phzS) 
and pyomelanin (hmgA) pathways, as well as mutations in a key quorum sensing regulator 
(lasR). Phenotypic characterisation of colonies taken from ASM supplemented with bile, 
compared with those from untreated ASM, revealed elevated biofilm formation and a selection 
for the retention of swarming motility. Phenotypic analysis of the pigmented derivatives 




pigmented derivatives exhibited a loss of the biofilm response and redox response to bile with a 
loss of Pseudomonas Quinolone Signal (PQS) production also observed. The loss of redox 
repression in the presence of bile could be explained by this defective Alkyl-Quinolone (AQ) 
production. Together, these findings suggest that the adaptation of P. aeruginosa to long term 
bile exposure is underpinned by the selection of sub-populations of alternative pigment 



















Chronic respiratory disease poses a major societal challenge, with the rapid onset of the post-
antibiotic era representing a serious threat to the clinical management of infections associated 
with these conditions (1, 2). As is often the case, the development of chronic microbial infections 
results in a shift in clinical regimens wherein these infections are no longer treatable using 
conventional antibiotics. Therefore, understanding the factors that contribute to respiratory 
pathogen’s ability to shift from acute to chronic infections is of paramount importance in order to 
identify alternative interventions and reduce the global reliance on antibiotics.  
Though the prognosis for this life-limiting autosomal recessive disorder Cystic Fibrosis has 
considerably improved in recent years, challenges remain in the successful implementation of 
these innovative therapies (3-6). Principal among these is the maintenance of health and lung 
function in paediatric patients. Lower respiratory infections are reported from as early as the first 
weeks of life and are strongly associated with the development of pulmonary inflammation and 
bronchiectasis (7, 8). Early acquisition of respiratory pathogens particularly P. aeruginosa is 
associated with clinical decline and increased mortality with P. aeruginosa positive cultures 
detected in patients as young as 3 months of age (9, 10). Successful early eradication has been 
associated with reduced prevalence of chronic P. aeruginosa infections in later life and hence is 
of paramount importance in the provision of optimal CF care (11-13).  
The pathogen-centric focus to the management of respiratory infections has been challenged 
somewhat in recent years with the advent of next generation sequencing technologies. Genomics 
based studies have uncovered richly diverse microbial communities in the lungs of both healthy 




disease conditions (9, 14). Micro-evolution, the extent of which has been shown to differ 
between mild and severe cases of disease, of pathogens within these diverse communities has 
also received considerable attention with a growing appreciation for the extent of phenotypic 
heterogeneity present within these populations (15-21). The acquisition of highly transmissible 
strains also contributes to the genetic diversity present in P. aeruginosa infection (22)The ability 
of pathogens such as P. aeruginosa to adapt to novel environments, with the presence of multiple 
phenotypic and genotypic variants reported in vivo, facilitates persistence and colonisation in 
challenging niches such as the lungs of patients with respiratory disease (23-27).  
The most common CF pathogen P. aeruginosa encounters and must tolerate numerous stressors 
within the CF lung environment if it is to survive and thrive in the host. These include but are not 
limited to the toleration of fluctuations in pH and oxygen, nutrient availability, and resisting 
elimination by residential host immune cells and by-products of inflammation. The emergence of 
hyper-mutator strains with enhanced rates of spontaneous mutations often due to defective DNA 
mismatch repair systems (mutS, mutL, uvrD) is proposed to be beneficial to the long-term 
survival of P. aeruginosa (28-30). A variety of pathoadaptive mutations have been described in 
key virulence, regulatory, antibiotic resistance and metabolism genes with the most common 
mutations identified in P. aeruginosa clinical isolates recently outlined in a review by 






Figure 1. An overview of the most common pathoadaptive mutations by functional category reported to be present in 
clinical isolates of P. aeruginosa. Taken from Winstanley et al., 2016. 
Mutations in key signalling pathways e.g. LasR are particularly prevalent among P. aeruginosa 
clinical isolates (32, 33), with pigmented variants also reported in several studies (15, 34). 
Furthermore, re-wiring of regulatory networks in these clinical isolates has been uncovered, 
suggesting a complex adaptive response to environmental challenges (33, 35). These changes can 
lead to growth phase dependent alterations in virulence (36). Though, there are reports of 
multiple evolutionary trajectories it would appear there is convergent evolution, with mutations 
in multiple pathways leading to the same beneficial end goal (37, 38). One example of such a 




wsp operon, associated with the regulation of biofilm formation, were capable of yielding the 
beneficial adaptive phenotype i.e. through multiple different pathways (37). To enhance early 
treatment strategies of lung disease in CF, improvements in our understanding of the host and 
environmental factors that contribute to both pathogen acquisition and dysbiosis of the lower 
respiratory microbiota is essential. 
Bile acids, one of the major components of bile, have been detected in the lungs of patients with 
respiratory disease, and have been shown to correlate directly with increased morbidity and 
colonisation by P. aeruginosa (39, 40). This is further supported by several independent studies 
that show a correlation between bile reflux and pathogen colonisation in patients with CF (41-
43), with evidence of increased inflammation and lung impairment also reported (44). 
Furthermore, both bile and bile acids have been shown to modulate the behavioural lifestyle of 
P. aeruginosa causing it to adopt a chronic lifestyle (39, 45). This would appear to occur through 
transcriptional rewiring of the cell, with changes in virulence systems, signalling molecules, and 
key metabolic pathways including the glyoxylate shunt observed (39). While we have uncovered 
key insights into the mechanisms through which bile influences the behaviour of P. aeruginosa, 
little is known about how the pathogen responds to long term bile exposure. This would be of 
particular interest considering the temporal nature of aspiration and its emerging role in shaping 
the microbiology of the lungs (46). 
This study was designed to investigate the response of P. aeruginosa to bile in Artificial Sputum 
Media (ASM) cycled over an extended period. Increased production of pyocyanin (PYO) upon 
culturing in ASM supplemented with bile was initially observed and confirmed by transcriptional 
analysis. Over time, pigmented morphologies were observed to emerge exclusively in bile 




production, perhaps a consequence of elevated community levels produced in response to bile. 
Whole genome sequencing and single nucleotide polymorphism analysis revealed key genetic 
changes in the pigmented variants, including point mutations in the quorum sensing regulator 
lasR. The pigmented mutants were found to be unresponsive to bile with respect to biofilm 
formation and redox potential suppression. Furthermore, production of the Alkyl-Quinolone PQS 
was found to be abolished in the red and brown pigmented variants.  Defective AQ production 
was found to underpin the abolished redox repression in the presence of bile. These findings 
implicate a role for AQs in the bile induced shift in redox potential with additional unidentified 
















Materials and Methods 
Bacterial culture 
Strains and plasmids utilised in this study are outlined in Table 1 below. All cultures of P. 
aeruginosa were routinely grown in Tryptic Soy Broth (TSB) media or Luria-Bertani broth (LB) 
with shaking at 180 rpm at 37˚C. Strains were maintained on Tryptic Soy Agar (TSA) or Luria-
Bertani agar (LBA). For the purpose of the antibiotic resistance assays Mueller-Hinton (MH) 
agar or broth was used. Bovine bile at a concentration of 0.3% (w/v) was added to media either 
prior to autoclaving at 105˚C for 30 min or after autoclaving by filter sterilisation with a 0.2 µM 
filter.   
Table 1; Description of strains and plasmids utilised in the study. 
Strain/plasmid Description Source  
PA14 Wild type (47) 
PA14::mutS PA14 harboring mariner Tn7 transposon insertion in PA14_17500 (mutS);GmR (47) 
PA14::phzM PA14 harboring mariner Tn7 transposon insertion in PA14_09490 (phzM);GmR (47) 
PA14::phzS PA14 harboring mariner Tn7 transposon insertion in PA14_09400 (phzS);GmR (47) 
PA14::hmgA PA14 harboring mariner Tn7 transposon insertion in PA14_38510 (hmgA);GmR (47) 
PA14::pqsA PA14 harboring mariner Tn7 transposon insertion in PA14_51430 (pqsA);GmR (47) 
PA14::pqsC PA14 harboring mariner Tn7 transposon insertion in PA14_51410 (pqsC);GmR (47) 
PA14::pqsE PA14 harboring mariner Tn7 transposon insertion in PA14_51380 (pqsE);GmR (47) 










Table 2; Primers utilised in this study. 
Primer Name Sequence 5’-3’ Reference 
PA14_46660 F AGCCAGCGAAGACCTGTTCG This study 
PA14_46660 R GGCGAACATGGTCGACCAGT This study 
aer F CGCTGATCGCGCAGATGTAC This study 
aer R TCGGCGATGCCCTTGATCAC This study 
sppR F AACCAGCGCCTGCAACTGGT This study 
sppR R AAGTCCGGCGAGGTGAAGGA This study 
fha1 F TTCGCCGAACTGCTCGGCAA This study 
fha1 R CGGGTTGTTCTGCACAGGCT This study 
cupB5 F ATGTTCGGCCACGTCTCCGA This study 
cupB5 R CGCTGGCATCCACGTTGAAC This study 
PA14_15200 F CACGACCTGGCGTTCCTCAA This study 
PA14_15200 R GCCAGCATTACTGCGCCGAT This study 
PA14_70580 F TCAAGGTCGCCGACCTGATG This study 
PA14_70580 R AGGTCCAGCAACTGGCTCTG This study 
PA14_25030 F TCGAGTACCGCATCACGCTG This study 
PA14_25030 R CATCAGGTACAGCGGCACCA This study 
gnd F CGGCGAAGCTGGTGATCATC This study 
gnd R GGTCGAGGTCGAGGTAGTTG This study 
PA14_00970 F CGAAGCGCAGATGGAAGCCA This study 
PA14_00970 R TCAGGAACGCCGTAGTCGAG This study 
PA14_57610 F CCGAGAACCCTGTTCAGCTC This study 
PA14_57610 R CGTACTCGTCGCCATCCAGT This study 
pchF F ACGCCACGGTGATCCACGAT This study 
pchF R GTGGAGCCGGAGGTGTAGAT This study 
PA14_32015 F TCGACCAGAGCTTCATCGCC This study 
PA14_32015 R AGGCTACGTCGGATGCGCTT This study 
hmgA F GGAAGCAGGTCTCGTTGAGC This study 
hmgA R AGTCGAGGTTCATCTGAGGC This study 
phzM F TTCCGCAACGAGATCCAG This study 
phzM R CGTTCGTCAACGTCATCG This study 
phzS F CGGTGGATAACCGAATGCGG This study 
phzS R TGGCGTCTTCGTTCCTGGTC This study 
lasR F GATATCGGGTGCCGAATC This study 
lasR R TAGAAGGGCAAATTACCG This study 
Taq-proC F CTTCGAAGCACTGGGTGGAG This study 
Taq-proC R TTATTGGCCAAGCTGTTCG This study 
Taq-phzS F CTGGGCTGGTTCGACATC This study 
Taq-phzS R CGGGTACTGCAGGATCAACT This study 
Taq-phzM F ACCTGCTGAGGGATGTCG This study 
Taq-phzM R GAACTCCTCGCCGTAGAACA This study 
Taq-phzH F GGTGTTCGGCATCGTTTC This study 






Pyocyanin assay in ASM 
Overnight cultures of P. aeruginosa were adjusted to an OD600nm 0.05 in ASM with and without 
3%, 0.3% and 0.03% bovine bile (w/v) and incubated at 37˚C with shaking at 180 rpm. After 24 
h and 96 h, test cultures (10 mL) were centrifuged at 5000 rpm for 15 min to obtain a cell free 
supernatant. Chloroform (3 mL) was added to the cell free supernatant, vortexed and centrifuged 
for 5 min at 5000 rpm. The bottom blue phase was transferred to a tube containing 2 ml of 0.2 M 
hydrochloric acid, vortexed and centrifuged at 5000 rpm for 5 min. The absorbance of the top 
pink phase was read at OD520nm.  
Pyocyanin and Alkyl quinolone extraction 
Overnight cultures of P. aeruginosa were adjusted to an OD600nm 0.02 in 20 mL TSB with or 
without 0.3% (w/v) bovine bile and incubated at 37˚C with shaking at 180 rpm for 8 h. Culture 
was centrifuged at 5000 rpm for 15 min to obtain a cell free supernatant with resulting 
supernatant split into two 10 mL tubes. Pyocyanin was extracted as described in the pyocyanin 
assay conducted for ASM. Alkyl quinolones were extracted by addition of 10 mL of acidified 
ethyl acetate followed by vortexing and centrifugation for 5 min at 5000 rpm. The top clear 
phase was transferred to a fresh tube and stored at -20˚C overnight. Rotary evaporation was 
completed to remove the solvent with extracts re-suspended in 1 mL of methanol for analysis by 
thin layer chromatography. 
Thin layer chromatography 
A normal phase silica TLC plate was prepared by immersing in a solution of potassium 
phosphate monobasic for half an hour. The TLC plate was activated in a hybridisation oven for 1 




loaded as controls. The plate was developed in 95:5 dichloromethane:methanol and visualised 
under UV light.  
Cycled culture of P. aeruginosa in ASM 
ASM cultures were initiated by inoculation of 2 x 106 cells from an overnight culture of a PA14 
mutS transposon mutant into 20 mL ASM in the presence and absence of 3% (w/v) bovine bile. 
The mutS transposon mutant was selected due to the mutation in its DNA repair system resulting 
in enhanced mutation frequency therefore speeding up the rate of mutation and experimental 
outcome (48). Cultures were incubated at 37˚C static for 96 h with transfer (1:100) into fresh 
ASM media after mechanical homogenisation. Transfers were repeated for 180 days 
(encompassing 45 transfers and approximately 315 bacterial generations).  
Colony morphology assay 
3 µL of overnight TSB cultures were spotted on to TSA with or without 0.3% (w/v) bovine bile. 
The spot was allowed to dry at room temperature before incubation at 37˚C overnight. Plates 
were transferred back to room temperature, with colony morphology monitored and recorded 
over a period of 7 days.  
Pigment extraction 
Strains of interest were inoculated at an O.D of 0.05 in 50 mL of MH in a 250 ml conical flask 
for 48 hrs with visual indication of pigment production. Pigments were successfully extracted by 
centrifugation of 40 mL of culture at 5000 rpm for 10 min. 10 mL of ethanol was added to 2 mL 
of the cell free culture supernatant. The supernatant/ethanol mixture was centrifuged at max 
speed for a further 10 min. The resulting supernatant was rotary evaporated with compounds 





Overnight cultures were adjusted to an O.D600nm 0.05 in TSB in the presence and absence of bile. 
1 mL was transferred in to 24-well plates and incubated static at 37˚C overnight. Biofilm 
formation was measured by removing spent culture by pipetting. Wells were washed with water 
by gentle pipetting to remove any unattached biofilm. Attached biofilm was measured by 
staining for 30 min with 1 mL of 0.1% (w/v) crystal violet. 100% (v/v) ethanol was used to 
solubilise the crystal violet followed by a measurement of the absorbance at a wavelength of 
595nm.  
Antibiotic resistance assay 
Overnight cultures of P. aeruginosa were adjusted to 0.5 MacFarland units in MH broth. MH 
agar plates supplemented with or without 0.3% (w/v) bile were uniformly swabbed with culture. 
E-strips (Thermo Scientific) were placed on to the surface of the agar manually. Plates were left 
to incubate at 37˚C overnight after which the diameter of the zone of inhibition was recorded. 
Swarming motility assay 
Swarming motility was measured on LB 0.8% (w/v) agar or 0.6% (w/v) Eiken Agar in the 
presence and absence of 0.3% (w/v) bile. Sterile toothpicks were used to gently inoculate a 
single colony onto the surface of the Eiken Agar with minimal pressure. Plates were incubated 
overnight for 1-2 days with degree of motility visualised and recorded. 
Redox assay 
Overnight cultures of P. aeruginosa were adjusted to O.D600nm 2.0 with 200 µL of adjusted 




Aldrich). Cultures were incubated at 37˚C shaking at 180 rpm for 24 h. Formazan production 
was measured by centrifuging 5 mL of culture at 5,000 g for 5 min. The supernatant was 
discarded with the pelleted cells re-suspended in 1.2 mL of dimethyl sulfoxide and centrifuging 
again at 5,000 g for 5 min. The O.D510nm was recorded of the cell free supernatant. 
Whole genome sequencing 
Genomic DNA was extracted from bacterial strains of interest using a Gentra PureGene DNA 
Extraction Kit (QIAGEN) with isolated DNA re-suspended in sterile water. Paired end 
sequencing was conducted by Eurofins Genomics using Illumina MiSeq V3 with 2x300bp reads. 
Reads were mapped to the P. aeruginosa UCBPP-PA14 NC_008463.1 reference genome and 
delivered as BAM and BAI files. Further sequence analysis for SNP identification was 
conducted using the Integrative Genome Viewer software platform using the reference strain 
UCBPP-PA14 and the more recent PA14 Or genome sequence (NZ_LT608330.1). 
Statistical Analysis 
Data presented is the average of at least three independent biological replicates. Statistical analysis 










Pyocyanin production is elevated in ASM supplemented with bile 
Bile has emerged as a central host factor capable of modulating behavioural changes in the key 
opportunistic respiratory pathogen P. aeruginosa (39, 45). Transcriptomic analysis conducted in 
the presence of bile has previously revealed changes in the expression of an array of quorum 
sensing and PYO related genes (39). Furthermore, the shift in redox towards that of decreased 
reducing potential in the cell observed in that study was notable considering the inherent 
relationship between PYO (and other phenazine pigments) and the maintenance of redox 
homeostasis within the cell. Therefore, we investigated the impact of bile on PYO production in 
P. aeruginosa PA14 grown in ASM, which is known to mimic conditions found within the CF 
lung environment.  
Bile, at various sub-inhibitory concentrations was shown to significantly increase production of 
PYO in P. aeruginosa in ASM when compared to untreated ASM cultures (Fig. 2A). Induction 
was evident at 24 h incubation and was found to be most pronounced at 96 h in the presence of 
3% (w/v) bile. Gene expression analysis as measured by qRT-PCR (primers outlined in Table 2) 
analysis of three branch point PYO biosynthetic genes (phzH, phzM, phzS) revealed a significant 
increase in the expression of phzS in bile treated ASM cultures (Fig. 2B). A trend towards 
increased expression of phzH and phzM was also observed although it did not reach statistical 
significance. PhzS, encoding a flavin-containing monooxygenase, is the final gene of the PYO 
biosynthetic pathway and is responsible for the conversion of 5-methylphenazine-1-carboxylic 
acid betaine to PYO. The increased expression of this gene may therefore underpin the 




Growth curve analysis was undertaken to investigate the impact that the accumulation of PYO 
within the community may have on growth rate. An upper range concentration of 50 μg/ml, 
representative of the elevated levels observed in bile treated cultures, was selected. A recent 
study by Meirelles and co-workers has shown that elevated levels of PYO can have both 
beneficial and detrimental effects on P. aeruginosa populations (49). Consistent with these 
findings we found that a concentration of 50 µg/ml of PYO reduced the growth rate and resulting 
biomass accumulation of P. aeruginosa (Fig. 2C). To investigate the effects of longer-term bile 
exposure on PYO production, P. aeruginosa was serially transferred into fresh ASM at 96 h 
intervals. Subsequent PYO analysis following three rounds of 96 h growth confirmed that PYO 
levels remain elevated following the prolonged exposure to bile (Fig. 2D). Therefore, it was 
essential to understand the mechanism(s) by which P. aeruginosa might adapt to these elevated, 
toxic levels of PYO which would potentially represent a selective pressure for the evolution of P. 






Figure 2. (A) The phenazine PYO is elevated in ASM supplemented with a range of bile concentrations (B) Enhanced 
PYO production is underpinned by increased phzS expression, the final step of the PYO biosynthetic pathway, as 
measured by RT-PCR analysis. No significant change in gene expression was observed for phzH or phzM, the two 
other central genes in PYO biosynthesis. (C) PYO, at a concentration of 50 µg/ml reduces the growth rate and biomass 
of P. aeruginosa. (D) Serially cycling P. aeruginosa in ASM supplemented with bile confirms the consistent up-
regulation of PYO production over time. 
Pigmented variants of Pseudomonas aeruginosa emerge exclusively in the presence of bile 
Upon confirmation that PYO levels remained elevated upon sequential transfer of P. aeruginosa 
in ASM supplemented with bile, serial transfers were performed for a duration of 6 months 
encompassing approximately 45 transfers outlined in Figure 3 below (n=3). Regular sampling 
was undertaken in order to monitor the emergence of phenotypic variants and to assess whether 
these variants are stably retained in the population. As described in studies by Wassermann et al, 




protein is known to increase the spontaneous mutation frequency of the strain hence facilitating 
rapid in vitro evolution experimentation (48, 50-53). Furthermore, the high rate of mutS mutation 
observed in clinical isolates of P. aeruginosa isolated from the CF lung environment further 
supports the use of this mutant in vitro (54-56).  
 
 
Figure 3. Outline of experimental design assessing the impact of bile and subsequent enhanced pyocyanin production 
on the evolution of P. aeruginosa. Serial transfer of culture was conducted every 96 h for the duration of 6 months 
with sampling of cultures at regular intervals to monitor phenotypic diversification in the presence of bile. Phenotypic 
analysis was conducted on end time point isolates. 
Biofilm analysis of 9 randomly selected isolates from untreated ASM and 9 randomly selected 
isolates from bile treated ASM obtained from 3 independent biological replicates revealed that 
bile adapted ASM isolates displayed elevated biofilm levels relative to untreated ASM isolates 
(Fig. 4). Consistent with the findings of Winstanley and colleagues, swarming motility appeared 




of swarming motility in several of the bile treated ASM colonies. These findings were further 
confirmed by a global analysis of isolates taken from the final replicate of the adaptive 
experiment encompassing 48 colonies from ASM treated bile and 48 colonies from untreated 
ASM. The same pattern of enhanced biofilm and retention of swarming motility was observed 
(Appendix Figure 1 & 2). This suggests that the presence of bile in the environment selects for 
isolates adapted towards enhanced biofilm formation. This analysis was considered to be 









Figure 4. Biofilm formation and swarming motility in 9 colonies isolated from (A) untreated ASM and (B) bile treated 
ASM. Colonies recovered from untreated ASM display biofilm levels comparable to that of the ancestral progenitor 
strain with a loss of the swarming motility phenotype. In contrast, colonies recovered from bile treated ASM exhibit 
enhanced biofilm formation relative to the ancestral progenitor strain with a retention of swarming motility.  
The bile responsiveness of the strains from the global analysis was also investigated. We have 
previously established that P. aeruginosa exhibits increased biofilm formation in the presence of 
bile therefore it would be expected that UT isolates which have had no previous exposure to bile 
would behave in this way. The majority of the UT colonies (80%) displayed a significant 
increase in biofilm formation in the presence of bile (Fig. 5). Therefore, the biofilm response to 





Figure 5. Biofilm formation of untreated ASM isolates in the presence and absence of 0.3% (w/v) bile highlighting 
that the majority of colonies recovered from untreated ASM retain their responsiveness to bile. 
 
Regarding the BT isolates, as the screen showed that many of the isolates display a hyper-biofilm 
phenotype, it was important to establish whether biofilm formation could be further induced or 
has a bile adaptive mutation locked these isolates in to a hyper-biofilm active state. In contrast to 
UT isolates, the majority of BT colonies (71%) biofilm formation was not significantly increased 
in the presence of bile (Fig. 6). As mentioned above, this is possibly due to the already elevated 
biofilm in the untreated strains. Taken together this analysis highlights that the process of 







Figure 6. Biofilm formation of colonies recovered from bile treated ASM isolates in the presence and absence of 0.3% 
(w/v) bile. The majority of these colonies do not exhibit a statistically significant increase in biofilm formation in the 
presence of bile which may be attributed to the prior adaptation to bile.  
 
Swarming motility in the UT and BT isolates was also investigated, due to its relationship with 
biofilm formation. Global screen analysis was conducted on LB 0.8% (w/v) agar (Fig. 7) with 
validation carried out on Eiken agar which is the media more routinely used for the testing of 
swarming motility in P. aeruginosa. For the majority of UT colonies there is an apparent loss of 
swarming motility on LB 0.8% (w/v) agar i.e. strains appear to be non-motile (Fig. 7). 
Interestingly, even those isolates which appeared to be swarming on LB 0.8% (w/v) agar, upon 
validation on Eiken agar the resulting motility appeared to resemble a more swimming like 




formation of tendrils. Furthermore, unlike in the ancestral strain where bile represses swarming 
motility there is little to no repression of motility in the UT colonies which relates back to the 
apparent loss of swarming motility even in the absence of bile (Appendix Figure 2). The majority 
of BT colonies retained their ability to swarm on LB 0.8% (w/v) agar (Fig. 7) with a repression 
of this motility observed in the presence of bile (Appendix Figure 2). It is noteworthy that 
although the BT colonies exhibit increased biofilm production, there also appears to be a strong 
selection for the retention of swarming motility in ASM supplemented with bile. This differs 
from reports of the inverse nature of the relationship between biofilm formation and swarming 
motility and should be further investigated.  
 
 
Figure 7. Swarming Motility of 48 strains isolated from untreated ASM and 48 strains isolated from ASM 
supplemented with bile on LB 1% (w/v) agar with a representative validation of colonies on Eiken agar. Colonies 
isolated from ASM supplemented with bile retained their ability swarm while those isolated from untreated ASM 




 Colony morphology analysis revealed the emergence of uniquely pigmented variants of P. 
aeruginosa derived from ASM in the presence of bile, with yellow, red and brown pigmented 
derivatives observed (Fig. 8). The yellow pigmented variant was the first to emerge, followed by 
the brown and red pigmented variants, respectively. The yellow pigmented variant emerged after 
approximately 40 generations, the brown pigmented variant emerged after approximately 120 
generations, followed by the red pigmented variant which appeared after approximately 144 
generations.  
 
Figure 8. Colony morphology analysis on LB agar of (A) UT colonies top view (B) UT colonies bottom view (C) BT 
colonies top view and (D) BT colonies bottom view. By comparing both the top and bottom view images the colony 




The yellow pigmented variant became the most dominant member of the community 
representing approximately 60% of the population with the brown and the red variants 
comprising approximately 10% and 5% of the population respectively upon completion of the 
experiment. Interestingly, though the brown and red derivatives were maintained in the 
community, they did not significantly increase in abundance suggesting that though their 
presence is an advantage there may be some fitness cost preventing them from outcompeting 
within the population. The apparent overexpression of a green pigment potentially the phenazine 
pyocyanin in the presence of bile may contribute to the appearance of alternative pigmented 
variants of P. aeruginosa. 
Colony morphology analysis revealed the unique pigment production of BT colonies. In contrast 
to the bile treated ASM cultures, the majority of colonies obtained from untreated ASM appear 
to either retain green pigmentation, most likely a result of intact phenazine production, or lose 
pigmentation completely. Furthermore, colony morphologies of the untreated ASM cells 
appeared larger and more rugose than their bile treated counterparts, which were smaller and 
more smooth (Fig. 8). 
Genotypic profiling of the mutants to characterise the genetic changes underpinning the 
pigmented variants 
As the pigmented derivatives emerged exclusively in the presence of bile, red pigmented variants 
(n=3), brown pigmented variants (n=3) and yellow pigmented variants (n=3) were selected for 
further analysis in order to elucidate their functional importance in the presence of bile. Colony 
morphology analysis confirmed the stable production of the brown/red/yellow pigment which 
appears to be extruded from the colony (Fig. 9A). However, in the presence of bile there appears 




likely underpins the production of these alternative pigments, the regulatory pathway governing 
the regulation of pigment production appears to still be responsive to bile (Fig. 9B).  
 
Figure 9. (A) Representative colony morphology analysis of the brown, red and yellow pigmented variants on TSB 
agar and (B) TSB agar supplemented with 0.3% (w/v) bile highlighting pigment production with further induction in 
the presence of bile. (C) Whole genome sequence analysis with strain PA14 Or as the reference strain. 
Whole genome sequencing analysis was conducted on a representative red, brown and yellow 
pigmented isolate. Paired end sequencing was conducted by Eurofins Genomics using Illumina 
MiSeq V3 with 2x300bp reads. Reads were mapped to the P. aeruginosa UCBPP-PA14 




for SNP identification was conducted using the Integrative Genome Viewer software platform 
using the reference strain UCBPP-PA14 and the more recent PA14 Or genome sequence 
(NZ_LT608330.1). Sequence validation following PCR amplification using gene-specific 
primers outlined in Table 2 was carried out on selected target genes in the mutS ancestral strain. 
While all three isolates were found to have 294 SNP’s in common when using the UCBPP-PA14 
reference strain, this number was reduced down to 61 SNP’s when using PA14 Or as a reference 
strain (Fig. 9C). This finding is important when considering the use of these reference genomes 
for SNP analysis of P. aeruginosa clinical isolates and highlights the potential importance of 
using multiple reference genomes in clinical genome analysis. An overview of the genetic events 
within each of the individual isolates is described in Table 3 with further information available in 
Appendix Table 1-5. The presence of mutations in common between the brown and red isolate 
suggest they derived from the same strain before diverging.  
Table 3; Genetic events present in all three pigmented variants, the brown pigmented variant 
alone, the red pigmented variant alone, the yellow pigmented variant alone and in both the brown 
and red isolates. 








Common  11 8 32 2 8 
Brown 14 9 50 5 8 
Red  7 23 52 4 15 
Yellow 10 21 70 3 6 





Nucleotide substitutions outlined in Table 3 may be considered as synonymous or non-
synonymous. Synonymous mutations do not cause a change to the encoded amino acid due to the 
redundancy of the genetic code and therefore will not affect the functionality of the protein and 
hence are considered silent mutations. Non-synonymous mutations cause a change to the 
encoded amino acid which have the potential to alter protein functionality depending on the 
location of the amino acid within the protein. All of the SNP’s (mutation events) identified were 
mapped across the total PA14 genome (kb) to identify potential hot spots of mutation (Fig. 10). 
 
 
Figure 10. Mutation events across the PA14 genome in (A) All three pigmented derivatives (B) Brown  








Indels in coding regions represent the most important category as these will definitively alter the 
protein are outlined in Figure 11. 
 
Figure 11. Insertion/Deletions and premature stop codons (grey) in coding regions (A) All three pigmented derivatives 
(B) Brown pigmented derivative (C) Yellow pigmented derivative and (D) Red pigmented derivative. 
 
Within the genome of the brown pigmented variant a single base pair substitution at nucleotide 
984 of a T to a C was identified in the hmgA gene. This non-synonymous substitution results in a 
change of the amino acid phenylalanine (TTC) to leucine (CTC). This single base pair mutation 







Figure 12. hmgA sequence anaylsis in (A) mutS original strain (B) red pigmented variant (C) brown pigmented variant 
and (D) yellow pigmented variant depicting the SNP exclusively present in the brown pigmented derivative. 
 
Loss of function mutations in hmgA have previously been shown to result in production of the 
brown polymeric pigment pyomelanin by P. aeruginosa (Fig. 14) (57). Though there is no 
crystal structure available for hmgA in P. aeruginosa, a crystal structure has been described in 
Pseudomonas putida. Phenylalanine 328 is located in the binding pocket of the protein, with 
substitution of this amino acid to leucine likely to impact protein function.  However, both 
phenylalanine and leucine are non-polar hydrophobic amino acids therefore definitively 
attributing production of the brown pigment to the SNP identified in this study would require 
protein structure analysis to determine whether the change amino acid would have a significant 







Within the genome of the red pigmented variant sequence analysis revealed the insertion of a 
cytosine nucleotide at position 125 of the phzS encoded protein. The production of a red pigment 
in P. aeruginosa has previously been reported for phzS mutants, suggesting that this insertion 
underpins the pigmentation the red variant (58). The insertion of a cytosine at position 125 
resulted in a +1 frameshift mutation which was confirmed by PCR sequencing (Fig. 13) and 
extended to all other red variants tested (data not shown). The emergence of a phzS mutation 
which would prevent the production and accumulation of pyocyanin could therefore be in 
response to the overexpression of this phenazine (Fig. 14). 
 
Figure 13. phzS sequence anaylsis in (A) mutS original strain (B) red pigmented variant (C) brown pigmented variant 
and (D) yellow pigmented variant highlighting the insertion of a C nucleotide exclusively in the red pigmented 
derivative. 
Interestingly, subsequent plating of red pigmented variants consistently led to loss of 
pigmentation in a subset of colonies. Sequencing of these colonies revealed reversion back to the 
original ancestral sequence. This is consistent with previous studies describing a high frequency 
of reversion for +1 frameshift mutations in a mutS mutant (59). This finding validated that 




red pigment in these mutants. Additionally, pigment extraction and preparative TLC analysis 
from a phzS transposon mutant and the red derivative further reinforced these findings with an 
RF value of 0.92 obtained for both the phzS mutant and the red pigmented isolate. LC mass 
spectrometry analysis would ideally be applied for definitive confirmation that these are the 
same pigment. 
While the potential causative mutations could be identified for the red and brown pigmented 
variants, no likely mutation could be located that could underpin production of the yellow 
pigment, with phzM, which has previously been proposed to result in production of a yellow 
pigment, remaining unchanged in all strains.  
 
 
Figure 14. Genetic basis of the pyomelanin and pyocyanin biosynthetic pathway. All of the SNP’s (mutation events) 
identified were mapped across the total PA14 genome (kb) to identify potential hot spots of mutation (Fig. 10). 
Phenotypic analysis of the pigmented variants 
In order to further elucidate the importance of the emergence of the pigmented variants in the 
presence of bile red pigmented variants (n=3), brown pigmented variants (n=3) and yellow 




including, biofilm formation, swarming motility, antibiotic resistance, growth and redox was 
conducted in order to further understand the potential functionality of these isolates within the 
total community.  
Biofilm formation 
Biofilm formation was assessed in a crystal violet assay (Fig. 15). The brown pigmented variants 
displayed a significantly higher biofilm formation relative to the mutS mutant strain in untreated 
media. However, in contrast to mutS there was no significant increase in biofilm observed in the 
presence of bile. This finding was also evident in the red pigmented variant, however only one 
red isolate displayed enhanced biofilm formation relative to the original strain. The behaviour of 
the yellow pigmented strains more closely resembled that of the control strain with enhanced 
biofilm formation in the presence of bile observed for two of the three isolates tested. 
Interestingly, even in the absence of bile these mutants were found to be hyper-biofilm formers, 
exhibiting enhanced biofilm formation relative to the ancestral strain, as measured by the crystal 
violet assay. Hence, supporting a transition towards a biofilm lifestyle in these isolates. 
However, there is a degree of phenotypic heterogeneity present amongst these isolates consistent 
with reports from other evolutionary adaptation experiments as well as strains recovered from 







Figure 15. Biofilm formation in TSB in the presence and absence of bile in the pigmented derivatives. The red and 
bown pigmented derivatives displayed no significant increase to bile in the presence or bile while two of three yellow 
variants tested did.  
Swarming Motility 
The swarming motility of the respective pigmented variants was tested on Eiken agar and Eiken 
agar supplemented with bile (Fig. 16). The three brown mutants displayed a form of motility that 
would not be strictly characterised as true swarming motility as there wasn’t the formation of the 
classical swarming tendrils. Repression of motility in the presence of bile was also observed. 
Two out of three of the red pigmented variants were swarming mutants whilst one displayed 
reduced swarming capability. The yellow pigmented variants retained their capacity to swarm 
and displayed a marked reduction in swarming in the presence of bile as is observed in the mutS 






Figure 16. Swarming motility in the brown (B), red (R) and yellow (Y) mutants and the MutS transposon mutant. The 
brown pigmented derivatives did not display a classical swarming motility phenotype but there was a repression of 
this motility in the presence of bile. The red pigmented derivative was found to be a swarming mutants whilst the 
yellow pigmented derivative retained its ability to swarm with a repression of motility in the presence of bile.  
Antibiotic resistance 
P. aeruginosa isolates from the CF lung have been shown to display altered antibiotic 
susceptibility profiles. This is potentially mediated by exposure to antibiotics within the lung 
environment resulting in adaptation and increased resistance. We therefore wanted to investigate 
whether exposure to bile influenced antibiotic resistance profiles in our pigmented mutant 
derivatives. Three clinically relevant antibiotics, previously investigated in chapter 2 were 
examined; erythromycin, colistin and polymyxin B (Fig. 17). Resistance to erythromycin in the 
untreated experiment was comparable in all pigmented derivatives with the increase in resistance 
in the presence of bile retained in all strains except R2 and Y2. The brown pigmented isolates 
were shown to have an even greater increase in resistance to erythromycin in response to bile 




erythromycin antibiotic resistance. The brown and red pigmented variants retained the same 
antibiotic profile to the mutS mutant. The yellow mutants however displayed a reduction in their 
resistance to colistin and polymyxin in the presence of bile.  
 
 
Figure 17. Erythromycin, colistin and polymyxin B resistance in the presence and absence of bile. The bile responsive 
profile of the red and brown pigmented derivatives was retained whilst the yellow pigmented derivative appeared to 
have lost its increase in resistance to the antibiotics tested in the presence of bile. 
Redox 
In elucidating the molecular mechanism underpinning the response of P. aeruginosa to bile, 
alterations in redox status appear intricately connected to the organism’s ability to thrive in bile. 
Furthermore, the functional role of pigments in P. aeruginosa is linked to the maintenance of 
redox homeostasis within the cell. Therefore, it was imperative to investigate by a tetrazolium 
violet reduction assay whether the redox status of the cell was altered in comparison to the 
original ancestral strain. The perturbations of redox homeostasis appear intricately connected to 
the ability of P. aeruginosa to thrive in bile. Transcriptional profiling has previously shown 
changes in the expression of genes encoding metabolic pathways, while redox was shown to be 
repressed in the presence of bile (39). Furthermore, the functional role of pigments within P. 




the redox status of the pigmented variants was investigated and compared to the original 
ancestral isolate. The phzS transposon mutant exhibited a similar response to the WT and mutS 
mutant, with a repression of redox in the presence of bile (Fig. 18). However, while redox 
potential in the pigmented variants was comparable to wild-type, mutS, and phzS mutants in the 
absence of bile, no reduction in potential was evident upon challenge with bile. This indicates 
that redox potential is ‘locked in’ in these variants and the metabolic changes underpinning its 
repression are not manifesting in these strains. Furthermore, similar to the antibiotic resistance 
and biofilm phenotypes, the modulation of chronic associated phenotypes in the red pigmented 
variants therefore cannot solely be attributed to its pigment production capabilities (Fig. 18).  
 
 
Figure 18. Redox assay of the brown, red and yellow pigmented variants. The brown and red pigmented variants no 







Akyl quinolone signalling is central to an effective bile response in P. aeruginosa 
The observation that pigmented variants no longer exhibited increased biofilm formation or 
reduced redox potential in the presence of bile led us to further investigate the possible 
mechanisms underlying this. The finding that a phzS mutant still retained an intact biofilm 
response to bile suggested that neither pigment production alone, nor loss of PYO production 
through mutation of phzS, were solely responsible. This raised the intriguing possibility that 
another signalling system was involved, potentially upstream of PYO, with the AHL-PQS axis 
considered a likely target. Evidence supporting this hypothesis was provided through the SNP 
analysis whereby LasR was found to exhibit a single amino acid change in both the red and 
brown mutants from independent replicates of the serial cycling experiment (Appendix Table 1-
5). Loss of LasR functionality has been previously shown to result in decreased levels of PQS 
within the cell, with lasR mutations described in clinical isolates of P. aeruginosa isolated from 
the lungs of CF patients (32). Interestingly, the yellow pigmented mutants in which redox is still 
suppressed in the presence of bile, did not show any change in lasR sequence. 
Analysis of PYO production revealed PYO production was abolished in the red and brown 
pigmented variants (Fig. 19A). This is unsurprising in the red pigmented mutant given the loss of 
phzS activity. Analysis of AQ production by Thin Layer Chromatography of the red pigmented 
variant for which the underlying mutation has been identified revealed altered AQ profiles, 
consistent with their genotypic profile as putative lasR mutants. PQS production was abolished 
in these strains, while its biological precursor HHQ was retained, comparable to the profile of a 
pqsH mutant (Fig. 19B). Interestingly, increased HHQ production was observed in the presence 




response. It was also notable that both PQS and HHQ production was retained in the phzS 
mutant. (Fig. 19B). 
From the community perspective, loss of PQS signalling might be expected to result in a less 
competitive sub-population of P. aeruginosa, considering its central role in virulence regulation 
and its emerging role as an inter-kingdom effector (62, 63). Though loss of PQS would result in 
reduced PYO levels within the cell, thus potentially addressing any toxicity issues arising from 
the induction of this pigment in ASM supplemented with bile, this would already be achieved by 
mutation of the phzS gene. Therefore, the role of PQS in response to bile may be more central to 
adaptation of the population, within what would appear to be an enhanced biofilm community. 
To investigate this, several mutants affected for AQ signalling were tested for their biofilm and 
redox response to bile. Loss of the PQS biosynthetic genes did not result in the loss of bile 
induced biofilm formation. This suggested that HHQ and other AQs produced by the pqsA-E 
operon were not required for a functional bile-induced biofilm response (Fig. 19C). 
Interestingly, the loss of the PQS biosynthetic genes resulted in a loss of redox repression in the 
presence of bile with redox potential considerably higher than the WT counterpart in these 
mutants (Fig. 19D). This finding would strongly implicate a role for alkyl-quinolones in the 
perturbations of redox potential observed in the presence of bile with the red and brown 







Figure 19. (A) Loss of PYO production in the red and brown pigmented variants and phzS mutant. (B) TLC analysis 
indicates loss of PQS production in the red pigmented derivative, consistent with the possible loss of lasR identified 
in the SNP comparisons. A phzS mutant retains PQS production, indicating loss of PQS occurs independent of pigment 
production. (C) Mutations of the PQS biosynthetic genes did not significantly affect the ability of P. aeruginosa to 
increase biofilm formation in response to bile. (D) Mutations of the PQS biosynthetic genes resulted in a loss of redox 













The clinical treatment of respiratory disease is faced with several challenges, not least the rapid 
decline in novel antibiotic discovery (64). Innovative approaches to pathogen control have been 
the focus of intensive research efforts, yet resistance continues to increase globally in spite of 
improved stewardship and hygiene control (65). Studies into host factors capable of modulating 
bacterial behaviour are important in facilitating the development of these innovative intervention 
strategies and will be key to their successful implementation. There is increasing evidence 
implicating a role for gastro-oesophageal reflux and subsequent pulmonary aspiration in the 
progression of CF and other chronic respiratory diseases (39, 40, 42-44, 46). To date, 
experimental analysis investigating bile/bacterial interactions has focused on phenotypic 
responses linked to the acute-chronic switch in P. aeruginosa and pathogenesis in general in 
gastrointestinal pathogens. However, little is known about the consequences for longer term 
exposure to bile in these organisms and the nature of the adaptation that might occur. Therefore, 
in this study we performed a cycling experiment with P. aeruginosa cultured in ASM, a 
synthetic media designed to more closely mimic conditions encountered within the sputum rich 
CF lung. Adaptation through enhanced biofilm formation, lasR mutation and pigmentation was 
observed in bile treated samples. The emergence of non-synonymous mutation in the brown 
pigmented variant in the hmgA gene, a member of the tyrosine catabolic operon, encoding the 
enzyme homogentisate-1,2-dioxygenase is interesting in light of the 55 fold downregulation of 
this gene in the bile transcriptome. Mutation of this gene results in the overproduction of the 
red/brown pigment pyomelanin. Pyomelanogenic P. aeruginosa clinical isolates are frequently 
recovered from the lungs of CF patients with 5% of P. aeruginosa strains isolated from the lungs 




investigated and revealed that inactivation of hmgA confers enhanced resistance to oxidative 
stress, reduced bacterial clearance and increased persistence in a chronic infection model, 
phenotypes potentially connected to the production of pyomelanin (57, 70). The degradation of 
chorismate is a branch point which can be directed either to the production of pyomelanin or to 
the production of the AQ PQS, therefore the repression or mutation of hmgA in the repression of 
bile may be mechanistically favourable allowing for the enhanced production of AQ (71, 72). 
The persistent Australian Epidemic Strain-1 was shown to down regulate the transcription of 
hmgA though this repression did not result in overproduction of pyocyanin. The downregulation 
rather than mutational inactivation may be employed by clinical isolates providing more 
flexibility for adaptation to changing conditions in the lung (73). Adaptive evolution experiments 
in the presence of the antibiotics piperacillin and ciprofloxacin resulted in the emergence of 
pyomelanin hyper producers (74). Reconciling the link between the genotype and phenotype in 
these studies is essential to determining the functionality of hmgA mutation.  
The expression of the quorum sensing signalling systems by P. aeruginosa has been shown to be 
accompanied by global cellular metabolic changes, with significant changes in observed in TCA, 
therefore the global metabolic changes observed in the presence of bile may be connected to the 
enhanced expression of QS (75). Recent studies have described the evolution of the quorum 
sensing signalling in chronic infection, providing a plausible explanation for the emergence of 
LasR mutants in clinical isolates through a combination of social cheating and reliance on an 
independent RhllR system (33, 76, 77). LasR mutants were demonstrated to induce a pro-
inflammatory response resulting in the recruitment of neutrophils and the production of pro-
inflammatory cytokines (78). Hence, quorum sensing may still play a central role in the 




Phenazine production has been shown to enhance anaerobic survival of P. aeruginosa (79), 
while phenazines have also been shown to influence the physiology of host cells and competing 
organisms. Production of the phenazine pigment PYO was significantly increased in response to 
bile in ASM cultures after 24 h and 96 h. The increased levels of PYO in the cultures were found 
to be toxic to the growth of P. aeruginosa. This key virulence factor contributes to the 
pathogenicity of P. aeruginosa with significant quantities of this redox-active molecule both 
recovered from the lungs of infected CF patients and produced by clinical isolates obtained from 
the lungs (80, 81). The production of PYO is known to be under the regulatory control of the 
quorum sensing signalling systems with its biosynthesis linked to two distantly encoded operons 
(phzA-G), as well as the additional modification genes phzH/M/S. Several studies have reported a 
connection between PYO production and redox and virulence potential within P. aeruginosa (49, 
60, 61). From the host perspective, PYO is capable of causing direct damage to human host cells, 
inhibiting cellular respiration, inducing neutrophil apoptosis and enhancing binding to airway 
epithelial cells (82-85). The importance of PYO to the in vivo success of P. aeruginosa was 
demonstrated in both acute and chronic mouse models, where PYO mutants were less 
competitive than their wild-type counterparts. However, recent evidence has shown that reduced 
autophagy by bronchial epithelial cells is associated with a reduction in pyocyanin production in 
vivo facilitating long term persistence within the host (86). 
 From the bacterial perspective, PYO has been demonstrated to play an important role in the 
establishment of P. aeruginosa biofilms, both through its modulation of signalling of the second 
messenger c-di-GMP and through its contribution to extracellular DNA release as a result of 
cellular auto-poisoning and  subsequent cell death and through it (87). In contrast, PYO is also 




serve as an alternative electron acceptor (49). A recent study by Meirelles et al. has further 
confirmed that PYO production may have both toxic and beneficial consequences to P. 
aeruginosa (49), analogous in some ways to the role proposed for PQS by Haussler and Becker 
(88). Sub-populations of PYO-tolerant cells were shown to emerge from within nutrient-limited 
biofilms, with the PYO-susceptible population sacrificed for eDNA release and structural 
support in a ‘net-benefit’ arrangement for the population. It is possible therefore that the 
emergence of pigmented variants that no longer produce PYO following long term exposure to 
bile is an adaptation within the population to the elevated ‘toxic’ levels encountered in the 
artificial sputum environment. Elevated toxic levels of PYO may select for the emergence of a 
sub-population of PYO defective mutants within the ASM bile microenvironment. Alternatively, 
the emergence of PYO defective mutants could be another form of social cheating akin to that of 
siderophore cheating (89). This would allow the PYO non producers to invade the population of 
producing cells. This cooperation and coexistence could potentially allow the population to 
mitigate the stress of toxic levels of PYO (81, 90, 91). The enhanced production of pyocyanin 
present within a bile positive CF lung should therefore be of consideration regarding the 
evolutionary trajectory of residing P. aeruginosa populations. 
The occurrence of pigmented variants within the lungs of patients with respiratory disease has 
been reported for decades (92, 93). Distinction between red and brown pigmented clinical 
isolates was complicated further by the observation of some isolates that turned from ‘yellowish 
to red’ (94). Advances in sequencing and high throughput screening technologies have 
reinforced the finding that P. aeruginosa populations within the lungs of patients with CF are not 
uniform, but rather display a remarkable level of genotypic and phenotypic heterogeneity (95). 




remains to be understood. In our study, while maintained within the cycled populations in bile 
treated ASM, neither the brown nor the red pigmented mutants ever exceeded more than 10% of 
the population. This would suggest that their function may be crucial in maintaining a PYO 
positive population of P. aeruginosa. Reversion of some colonies following subsequent culturing 
of red pigmented variants would support this hypothesis. Indeed, the frequency of red pigmented 
variants in clinical samples is low, ranging from 3.5-6% (96). Brown pyomelanin pigmented 
variants have been reported at higher frequencies of up to 13% in chronically infected CF 
patients (97). The selective pressure underpinning the emergence of these pigmented variants in 
the lungs, urine, bile and wounds of patients’ remains to be determined. Increased persistence 
through maintenance of redox-balanced populations within biofilms (49), intraspecific 
competition through production of pyocins (98), and tolerance to oxidative stress (57), may all 
contribute to the necessity for these pigmented sub-populations.  
The quorum sensing AQ signalling system is an effective strategy utilised by P. aeruginosa 
allowing a coordinated gene expression response at the population level. This level of regulation 
serves as an additional global mechanism of adaptation to external stimuli and has been 
demonstrated to play a role in both virulence factor production and biofilm formation (99, 100). 
The Pseudomonas Quinolone Signal (PQS) has been shown to exert differential effects on 
individual members of communities of P. aeruginosa capable of both sensitising cells to external 
stresses and inducing effective stress response (88). The presence of high levels of PQS has been 
shown to induce cellular autolysis whilst remaining unaffected cells are triggered to transition to 
a PQS tolerant reduced metabolic state. The synergy between this selective impact on a 
population and the recent findings related to the action of PYO on P. aeruginosa populations is 




central factor in the modulation of population structure and adaptation. The red pigmented 
derivative was shown to be defective in the production of PQS but not its precursor HHQ, 
possibly as a consequence of changes in lasR sequence. As with the loss of PYO production in a 
subpopulation of cells, the global reduction of the PQS signalling molecule may represent a 
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Appendix Figure 1. (A) Biofilm formation in 48 strains isolates from untreated ASM versus 48 strains isolates from 
ASM supplemented with bile. Biofilm is significantly higher in strains isolates from ASM supplemented with bile. 
(B) Biofilm formation in the aforementioned 48 strains isolated from ASM and (C) 48 strains isolates from ASM 
supplemented with bile. Data is the mean of at least three independent biological replicates. Statistical analysis was 




Appendix Figure 2. Swarming motility of colonies recovered from untreated ASM and colonies recovered ASM 




Appendix Table 1; Mutations present in all three pigmented isolates. 








I.D Product Annotation 
72,440 G/C GAG/CAG 
Glutamic 
acid/Glutamine PA14_00740 PA0062  Lipoprotein 
84,664 C/A CCG/CAG Proline/Glutamine PA14_00875 PA0074 ppkA Serine/threonine protein kinase 
96,452 Insertion of A Frameshift  PA14_00970   Hypothetical 
698,265 Insertion of G* Frameshift  PA14_08120 PA0625  Tail length determinator protein 
747,764 G/A GGC/GAC Glycine/Aspartic acid PA14_08760 PA4270 rpoB 
DNA-directed RNA polymerase 
subunit beta 
801,696 C/T CCG/CTG Proline/Leucine PA14_09340 PA4221 fptA 
Fe(III)-pyochelin outer 
membrane receptor 
934,050 G/A GCG/GCA Alanine PA14_10800 PA4109 ampR Transcriptional regulator 
1,016,097 Insertion of G Frameshift  PA14_11730   Protein kinase 
1,228,955 Deletion of G Frameshift  PA14_14400   Hypothetical 
1,243,658 Insertion of G* Frameshift  PA14_14530 PA3825  Hypothetical 
1,244,748 G/T GAG/TAG Glutamic acid/STOP PA14_14570   t-RNA-leucine 
1,269,267 C/T CCG/CTG Proline/Leucine PA14_14940 PA3798  Aminotransferase 
1,744,494 C/T Intergenic      
1,880,872 C/G CGC/AGC Arginine/Serine PA14_21690 PA3272  ATP-dependent DNA helicase 
2,040,973 G/A GCT/ACT Alanine/Threonine PA14_23460 PA3145 orfN Group 4 glycosyl transferase 
2,105,091 A/G AGC/GGC Serine/Glycine PA14_24260   Hypothetical 
2,149,425 A/C CAA/CAC Glutamine/Histidine PA14_24600 PA3054  Carboxypeptidase 
2,209,726 A/G AAG/AGG Lysine/Arginine PA14_25250 PA3001  
Glyceraldehyde-3-phosphate 
dehydrogenase 
2,277,057 G/A Intergenic      
2,339,963 Insertion of G Intergenic      
2,354,159 Deletion of G Intergenic      
2,589,402 C/T Intergenic      
2,790,309 A/G ACG/GCG Threonine/Alanine PA14_32060 PA2519 xylS Transcriptional regulator 
2,864,042 A/G ACG/GCG Threonine/Alanine PA14_32790 PA2462  Hypothetical 
3,107,103 A/G GAC/GGC Aspartic acid/Glycine PA14_34900 PA2298  Oxidoreductase 
3,162,561 T/G GTT/GGT Valine/Glycine PA14_35590 PA2243 pslM FAD-binding dehydrogenase 
3,166,109 T/G CTG/CGG Leucine/Arginine PA14_35620 PA2241 pslK Hypothetical 
3,217,257 C/A GGC/GGA Glycine PA14_36100 PA2212 pdxA 
4-hydroxythreonine-4-phosphate 
dehydrogenase 




3,390,498 A/C TAG/TCG STOP/Serine PA14_38000   Hypothetical 
3,453,679 T/C CTG/CCG Leucine/Proline PA14_38730 PA1993  
Major facilitator superfamily 
transporter 
3,832,407 T/C Intergenic      
3,832,408 C/G Intergenic      
3,874,888 C/A ACG/AAG Threonine/Lysine PA14_43510 PA1625  Hypothetical 
3,879,553 C/G CTC/GTC Leucine/Valine PA14_43570 PA5341  Hypothetical 
4,030,027 G/A GTG/GTA Valine PA14_45180 PA1488  Oxidoreductase 
4,092,528 C/A CGC/AGC Argine/Serine PA14_46010 PA1425  
ABC transporter ATP-binding 
protein 
4,265,772 G/A GGC/GAC Glycine/Aspartic acid PA14_47920 PA1260  
ABC transporter substrate-
binding protein 
4,486,152 A/C CAC/CCC Histidine/Proline PA14_50500 PA2753  Hypothetical 
4,572,692 G/T CCG/CCT Proline PA14_51450 PA0994 cupC3 Usher cupC3 
4,607,562 G/A Intergenic      
4,629,533 Insertion of G Frameshift  PA14_52190 PA0933 rumA 
23S rRNA-methyluridine 
methyltransferase 
4,659,805 A/G Intergenic      
4,659,822 A/G Intergenic      
4,704,034 C/A CCG/ACG Proline/Threonine PA14_53050  aroP2 
Aromatic amino acid transport 
protein 
4,787,386 T/C TTC/CTC Phenylalanine/Leucine PA14_53980 PA0793  Hypothetical 
4,939,410 C/A GCC/GCA Alanine PA14_55480 PA0682 hxcX HxcX 
5,010,234 Insertion of C** Frameshift  PA14_56100   Hypothetical 
5,269,324 T/C GTG/GCG Valine/Alanine PA14_59180   Topoisomerase I-like protein 
5,270,796 Insertion of C Frameshift  PA14_59200   Hypothetical 
5,284,844 T/C CGT/CGC Arginine PA14_59320  pilS2 Type IV B pilus protein 
5,341,373 Insertion of C Frameshift  PA14_59980   Hypothetical 
5,390,088 G/A GCG/GCA Alanine PA14_60470 PA4569 ispB Octaprenyl-diphosphate synthase 
5,444,993 Deletion of G Frameshift  PA14_61050 PA4614 mscL 
Large-conductance 
mechanosensitive channel 
5,698,849 T/G CTC/CGC Leucine/Arginine PA14_63960 PA4837  Outer membrane protein 
5,716,479 T/C TTC/CTC Phenylalanine/Leucine PA14_64140 PA4850 prmA 
50S ribosomal protein L11 
methyltransferase 
5,716,484 G/A CCG/CCA Proline PA14_64140 PA4850 prmA 
50S ribosomal protein L11 
methyltransferase 
5,939,960 A/C GAC/GCC Aspartic acid/Alanine PA14_66570 PA5036 gltB 
Gluatamate synthase subunit 
alpha 
6,070,078 T/C TGA/CGA STOP/Arginine PA14_68010    





















I.D Product Annotation 
32,841 G/T GGC/GTC Glycine/Valine PA14_00360 PA0030  Hypothetical 
61,992 G/T GGC/GTC Glycine/Valine PA14_00620   Hypothetical 
178,759 
Insertion 
of C Frameshift PA14_01970 PA0158  RND efflux transporter 
221,070 C/T GCC/GCT Alanine PA14_02450 PA0195  
NAD(P) transhydrogenase subunit 
alpha part 1 
349,077 C/T CCC/CCT Proline PA14_03870 PA0297 spuA Glutamine amidotransferase 
360,459 A/C CAG/CCG Glutamine/Proline PA14_03980 PA0305  Hypothetical 
397,464 
Deletion 
of C Frameshift PA14_04440 PA0340  Permease 
434,354 C/T ACC/ACT Threonine PA14_04920 PA0375 ftsX Cell division protein 
463,063 
Insertion 
of G Frameshift PA14_05300 PA0406  TonB domain containing protein 
519,061 T/G GTG/GGG Valine/Glycine PA14_05870 PA0450  Phosphate transporter 
632,707 C/T CTG/TTG Leucine PA14_07370 PA0567  Hypothetical 
653,104 C/T GAC/GAT Aspartic acid PA14_07570 PA0580 gcp 
DNA binding/iron 
metalloprotein/AP endonuclease 
783,257 G/T GGC/TGC Glycine/Cysteine PA14_09240 PA4228 pchD Pyochelin biosynthesis protein 
806,392 
Insertion 
of G Frameshift PA14_09400 PA4217 phzS Hypothetical 
814,995 T/G TAC/GAC Tyrosine/Aspartic acid PA14_09500 PA4208 opmD Outer membrane protein 
989,594 C/T Intergenic     
1,070,507 
Deletion 
of GC Frameshift PA14_12420    
1,100,285 A/G ACC/GCC Threonine/Alanine PA14_12820 PA4112  Two component sensor 
1,131,231 A/G CAG/CGG Glutamine/Arginine PA14_13150 PA3921  Transcriptional regulator 
1,238,559 G/A GCG/ACG Alanine/Threonine PA14_14490 PA3829  Hydrolase 
1,327,770 C/T Intergenic     
1,336,935 A/C TAC/TCC Tyrosine/Serine PA14_15720 PA3764  Transglycosylase 
1,346,934 G/T GGG/GTG Glycine/Valine PA14_15790 PA3760  
Phosphoenolpyruvate-protein 
phosphotransferase 




1,475,661 A/G AGC/GGC Serine/Glycine PA14_17210 PA3644 lpxA 
UDP-N-acetylglucosamine 
acyltransferase 
1,611,301 C/T TCG/TTG Serine/Leucine PA14_18720 PA3526  OmpA family membrane protein 
1,642,140 T/G TTC/GTC Phenylalanine/Valine PA14_19020 PA3484 tse3  
1,676,663 T/G CTG/CGG Leucine/Arginine PA14_19390 PA3457  Hypothetical 
1,709,809 C/T Intergenic     
1,863,419 A/G CCA/CCG Proline PA14_21490 PA3290 tle1 Type IV secretion lipase effector 
1,910,808 C/T Intergenic     
2,082,340 G/T GAC/TAC Aspartic acid/Tyrosine PA14_23970 PA3105 xcpQ 
General secretion pathway protein 
D 
2,108,371 C/T AAC/AAT Asparagine PA14_24290 PA3082 gbt Glycine betaine transmethylase 
2,576,533 T/G CTG/CGG Leucine/Arginine PA14_29760 PA4633  Chemotaxis transducer 
2,629,940 C/A CGG/AGG Arginine PA14_30350 PA2610  Hypothetical 
2,772,303 C/T ACC/ACT Threonine PA14_31870 PA2528  
RND efflux membrane fusion 
protein 
2,886,521 C/T ACC/ATC Threonine/Isoleucine PA14_33000 PA2445 gcvP2 Glycine dehydrogenase 





2,983,709 A/T GGA/GGT Glycine PA14_33650 PA2399 pvdD Pyoverdine synthetase D 
2,983,721 C/T GAC/GAT Aspartic acid PA14_33650 PA2399 pvdD Pyoverdine synthetase D 
2,983,898 G/A ACG/ACA Threonine PA14_33650 PA2399 pvdD Pyoverdine synthetase D 
2,984,162 T/G CTT/CTG Leucine PA14_33650 PA2399 pvdD Pyoverdine synthetase D 
2,993,193 G/T TGG/TGT Tryptophan/Cystein PA14_33720 PA2394 pvdN  
3,119,426 T/G CTC/CGC Leucine/Arginine PA14_35030 PA2285  Hypothetical 
3,194,938 C/T GCC/GCT Alanine PA14_35890   
Diamino-2-oxogluturate 
aminotransferase 
3,208,076 T/G TTG/GTG Leucine/Valine PA14_36020   Paraquat-inducible protein B 
3,265,868 A/G GAC/GGC Aspartic acid/Glycine PA14_36660 PA2119  Alcohol dehydrogenase 
3,382,210 
Insertion 
of C Frameshift PA14_37900 PA2057 sppR TonB dependent receptor 
3,392,069 C/T Intergenic     
3,481,455 G/A GTG/GTA Valine PA14_39050 PA1971 braZ 
Branched chain amino acid 
transport carrier 
3,521,696 C/A CCG/ACG Proline/Threonine PA14_39560 PA1930  Chemotaxis transducer 
3,539,750 G/A CCG/CCA Proline PA14_39720 PA1918  Amino acid oxidase 
3,657,223 C/A CCG/CAG Proline/Glutamine PA14_41010 PA1819  Amino acid permease 
3,628,465 G/T GGC/GTC Glycine/Valine PA14_46040 PA1846 cti Cis/trans isomerase 
3,631,015 
Insertion 






of T Intergenic     
3,657,223 C/A CGG/AGG Arginine PA14_41070 PA1814  Hypothetical 
3,813,048 C/A AGC/AGA Serine/Arginine PA14_42900 PA1669 icmF2  
3,842,568 A/C ACC/CCC Threonine/Proline PA14_43130 PA1654  Aminotransferase 
3,917,378 A/C ACC/CCC Threonine/Proline PA14_44010 PA1585 sucA 2-oxoglutarate dehydrogenase E1 
3,944,395 C/T CAG/TAG Glutamine/STOP PA14_44300 PA1561 aer Aerotaxis receptor 
4,049,785 A/C ACC/CCC Threonine/Proline PA14_44500 PA1464  Purine binding chemotaxis protein 
4,159,861 
Insertion 
of two Cs Frameshift PA14_46660 PA1363  
RNA polymerase ECF subfamily 
sigma 70 factor 
4,355,575 T/C Intergenic     
4,371,981 C/A ATC/ATA Isoleucine PA14_49200 PA1178 oprH Outer membrane protein 
4,437,782 G/A GGC/AGC Glycine/Serine PA14_49910 PA1118  Hypothetical 
4,454,838 T/G CTG/CGG Leucine/Arginine PA14_50130 PA1102 fliG Flagellar motor switch protein 
4,460,921 T/G ATG/AGG Methionine/Arginine PA14_50220 PA1097 fleQ Transcriptional regulator 
4,487,961 T/C TTC/CTC Phenylalanine/Leucine PA14_50520 PA1074 braZ 
Branched chain amino acid 
transport protein 
4,521,022 G/A CTG/CTA Leucine PA14_50850 PA1044  Hypothetical 
4,530,389 G/A Intergenic     
4,685,183 G/T GGC/GTC Glycine/Valine PA14_52850 PA0883  Acyl coA lyase subunit beta 
4,717,281 G/A GGC/GAC Glycine/Aspartic acid PA14_53210 PA0855  Hypothetical 
4,941,683 T/C Intergenic     
4,976,703 A/C GAA/GAC 
Glutamic 
acid/Aspartic acid PA14_55750 PA4290  Chemotaxis transducer 
4,993,902 A/C AAC/ACC Asparagine/Threonine PA14_55930 PA4305  Pilus assembly protein 
5,083,361 G/A Intergenic     
5,235,518 G/A GGG/AGG Glycine/Arginine PA14_58750 PA4526 pilB Type 4 fimbrial biogenesis protein 
5,278,478 T/C TTC/CTC Phenylalanine/Leucine PA14_59240  pilL2 Type IV B pilus protein 
5,278,574 
Insertion 
of C Intergenic     
5,291,762 A/G Intergenic     
5,539,405 A/C ACA/CCA Threonine/Proline PA14_60150   tRNA-lysine 
5,376,673 T/C Intergenic     
5,404,653 C/T ACC/ACT Threonine PA14_60630 PA4582  Hypothetical 
5,441,128 G/A Intergenic     
5,445,689 C/A CTC/CTA Leucine PA14_61060 PA4615  Oxidoreductase 
5,447,589 G/A GTC/ATC Valine/Isoleucine PA14_61090 PA4617  Hypothetical 




5,670,468 A/C GAA/GAC 
Glutamic 
acid/Aspartic acid PA14_63605  fdnG 
Formate dehydrogenase-O major 
subunit 
5,676,686 C/T Intergenic     
5,703,909 A/C AGC/CGC Serine/Arginine PA14_63990 PA4839 speA Arginine decarboxylase 
5,742,997 C/T Intergenic     
5,834,228 T/C TCC/CCC Serine/Proline PA14_65500 PA4957 psd Phosphatidylserine decarboxylase 
5,889,326 C/A CCG/ACG Proline/Threonine PA14_66110 PA1390  
Glycosyl transferase family 
protein 
6,003,335 A/C TAC/TCC Tyrosine/Serine PA14_67230 PA5090 vgrG5  
6,098,091 
Deletion 
of C Intergenic     
6,119,371 T/C TGG/CGG Tryptophan/Arginine PA14_68620 PA5194  Hypothetical 
6,188,351 A/G Intergenic     
6,310,168 T/G TAC/GAC Tyrosine/Aspartic acid PA14_70850 PA5368 pstC 
Membrane protein component of 
ABC phosphate transporter 
6,355,746 T/C CTG/CCG Leucine/Proline PA14_71320 PA5402  Hypothetical 
6,437,415 A/G TAC/TGC Tyrosine/Cysteine PA14_72250 PA5474  Hypothetical 
 













I.D Product Annotation 




ACCGAC Frameshift PA14_00980 PA0081 fha1 Fha1 
110,810 G/T GCG/GCT Alanine PA14_01120 PA0092 tsi6 Tsi6 
317,111 C/T CGG/TGG Arginine/Tryptophan PA14_03470 PA0267  Hypothetical 
356,687 C/T CTG/TTG Leucine PA14_03950 PA0303 spuG Polyamine transport protein 
358,353 A/G Intergenic     
482,414 T/G TGC/GGC Cysteine/Glycine PA14_05460 PA0420 bioA 
Adenosylmethionine-8-amino-7-
oxononanoate aminotransferase 
484,343 C/T CCG/TCG Proline/Serine PA14_05480 PA0421  Hypothetical 
588,284 G/T GGC/TGC Glycine/Cysteine PA14_06740 PA0518 nirM Cytochrome c-551 
588,730 T/G TTC/GTC Phenylalanine/Valine PA14_06750 PA0519 nirS Nitrite reductase 




Cs Intergenic     




939,122 T/G GTC/GGC Valine/Glycine PA14_10850 PA4100  Dehydrogenase 
964,247 
Insertion 
of G Frameshift PA14_11100 PA4082 cupB5 Adhesive protein 
974,418 C/T CCG/CTG Proline/Leucine PA14_11190 PA4073  Aldehyde dehydrogenase 
1,126,953 T/C GTG/GCG Valine/Alanine PA14_13130 PA3422  Hypothetical 
1,145,198 T/C GAT/GAC Aspartic acid PA14_13330 PA3910  Hypothetical 
1,193,464 A/C AGC/CGC Serine/Arginine PA14_13890 PA3868  Integrase 
1,202,660 G/T GCC/TCC Alanine/Serine PA14_14020 PA4908  Hypothetical 
1,264,653 C/T GCC/GCT Alanine PA14_14890 PA3802 hisS Histidyl-Trna synthetase 
1,287,749 
Insertion 
of G Frameshift PA14_15200 PA5167  Hypothetical 
1,338,118 G/T GCC/TCC Alanine/Serine PA14_15720 PA3764  Transglycosylase 
1,346,872 G/T GCC/TCC Alanine/Serine PA14_15790 PA3760  
Phosphoenolpyruvate-protein 
phosphotransferase 
1,356,413 G/T GGC/TGC Glycine/Cysteine PA14_15920 PA3749  Major facilitator transporter 
1,400,568 A/G GAG/GGG 
Glutamic 
acid/Glycine PA14_16370 PA3712  Hypothetical 
1,413,327 C/T GCG/GTG Alanine/Valine PA14_16500 PA3702 wspR Two component response regulator 
1,574,661 G/T GGC/GTC Glycine/Valine PA14_18350 PA3554  




1,593,148 T/G TGG/GGG Tryptophan/Glycine PA14_18565 PA3541 alg8 Alginate biosynthesis protein 
1,633,780 G/T CGG/CTG Arginine/Leucine PA14_18950 PA3489  
Na(+)-translocating NADH-
quinone reductase subunit E 
1,651,176 A/G ACC/GCC Threonine/Alanine PA14_19120 PA3477 rhlR Transcriptional regulator 
1,675,303 G/A GGC/AGC Glycine/Serine PA14_19380 PA3458  Transcriptional regulator 
1,682,069 A/G AGG/GGG Arginine/Glycine PA14_19450 PA3453  Hypothetical 
1,690,445 C/T CCC/TCC Proline/Serine PA14_19560 PA2356 ssuD Alkanesulfonate monooxygenase 
1,775,138 C/T GCC/GCT Alanine PA14_20620 PA3360  HlyD family secretion protein 
1,832,860 C/A GCC/GAC 
Alanine/Aspartic 
acid PA14_21190 PA3311  Hypothetical 
1,887,084 T/G TGG/GGG Tryptophan/Glycine PA14_21700 PA3271  Two component sensor 
1,965,600 A/G ATC/GTC Isoleucine/Valine PA14_22590 PA3219  Hypothetical 
1,967,248 G/T GTG/TTG Valine/Leucine PA14_22620 PA3217 cyaB Hypothetical 
1,993,384 A/G AAG/AGG Lysine/Arginine PA14_22980 PA3190  




of G Frameshift PA14_23460  orfN Group 4 glycosyl transferase 




2,089,517 A/G CAC/CGC Histidine/Arginine PA14_24060 PA3098 xcpW General secretion pathway protein J 
2,111,816 C/T Intergenic     
2,265,266 G/A GGC/AGC Glycine/Serine PA14_25970 PA2944 cobN Cobaltchelatase subunit 
2,309,068 C/T GGC/GGT Glycine PA14_26485 PA2906  Oxidoreductase 
2,334,848 C/T GCC/GCT Alanine PA14_26810 PA2882  Two component sensor 
2,439,069 T/C GTG/GCG Valine/Alanine PA14_28170 PA2777  Formate/nitrate transporter 
2,560,944 
Deletion 
of C Frameshift PA14_29520 PA2674  Type II secretion system protein 
2,573,823 C/T CGC/CGT Arginine PA14_29720 PA2658  Hypothetical 




2,716,172 T/G TTT/GTT Phenylalanine/Valine PA14_31240   NrbE like protein 
2,723,025 T/C GGT/GGC Glycine PA14_31310 PA2568  Hypothetical 
2,723,330 A/G TAC/TGC Tyrosine/Cysteine PA14_31310 PA2568  Hypothetical 
2,734,321 T/C Intergenic     
2,821,688 C/A CCC/CAC Proline/Histidine PA14_32450 PA2917  
AraC family transcriptional 
regulator 
2,822,329 A/G Intergenic     
2,937,204 A/G GAA/GAG Glutamic acid PA14_33360   Hypothetical 
2,950,156 G/T GAC/TAC 
Aspartic 
acid/Tyrosine PA14_33530 PA2410  Hypothetical 
2,969,825 A/G CAC/CGC Histidine/Arginine PA14_33610 PA2402  Peptide synthase 
3,021,989 C/A GCC/GCA Alanine PA14_33990 PA2371 clpV3  
3,086,570 A/G CAG/CGG Glutamine/Arginine PA14_34750 PA3935  Taurine catabolism dioxygenase 
3,142,806 T/G TCC/GCC Serine/Alanine PA14_35340 PA2261  2-ketogluconate kinase 
3,299,356 A/C ATC/CTC Isoleucine/Leucine PA14_37030 PA2130 cupA3 Usher 
3,406,931 A/C ACA/ACC Threonine PA14_38190 PA2036  Hypothetical 
3,423,559 T/C GTC/GCC Valine/Alanine PA14_38410 PA2018 amrB Multidrug efflux protein 
3,624,692 T/C ATG/ACG 
Methionine/Threonin




CAACGC Frameshift PA14_42600 PA1695 pscP 
Translocation protein in type III 
secretion 
3,886,462 G/A GGC/AGC Glycine/Serine PA14_43650 PA1613  Hypothetical 
3,904,801 G/T GGC/GTC Glycine/Valine PA14_43850 PA1596 htpG Heat shock protein 90 
4,050,445 C/A CGC/AGC Arginine/Serine PA14_45110 PA1463  CheW-domain containing protein 
4,083,113 A/G CAG/CGG Glutamine/Arginine PA14_45930 PA1433  Hypothetical 




4,279,422 G/T ACG/ACT Threonine PA14_48090 PA1248 aprF 
Alkaline protease secretion outer 
membrane protein precursor 
4,282,181 C/A GCC/GCA Alanine PA14_48115 PA1246 aprD Alkaline protease secretion protein 
4,290,384 C/A CGC/AGC Arginine/Serine PA14_48170 PA1242  Hypothetical 
4,334,674 C/A ATC/ATA Isoleucine PA14_48750 PA1203  Hypothetical 
4,385,780 
Insertion 
of G Intergenic     
4,412,053 T/C CTG/CCG Leucine/Proline PA14_45980 PA1991  
Iron containing alcohol 
dehydrogenase 
4,469,500 T/G CTG/CGG Leucine/Arginine PA14_50300 PA1390  Hypothetical 
4,532,529 
Insertion 
of C Intergenic     
4,533,567 G/T GGG/TGG Glycine/Tryptophan PA14_51020 PA1029  Hypothetical 
4,452,943 T/G CTG/CGG Leucine/Arginine PA14_51120 PA1020  Acyl coA dehydrogenase 
4,573,748 C/A TCC/TCA Serine PA14_51450 PA0994 
cupC
3 Usher cupC3 
4,635,225 
Insertion 
of C Frameshift PA14_52250 PA0929  Two component response regulator 
4,675,304 C/A GGC/GGA Glycine PA14_52750 PA0892 aotP Arginine/ornithine transport protein 
4,678,446 A/C ATC/CTC Isoleucine/Leucine PA14_52780 PA0889 aotQ Arginine/ornithine transport protein 
4,725,064 T/C CTG/CCG Leucine/Proline PA14_53310 PA0847  Hypothetical 
4,786,878 G/A GGC/AGC Glycine/Serine PA14_53970 PA0794  Aconitate hydratase 
4,853,488 
Insertion 
of C Frameshift PA14_54750   Hypothetical 
5,155,582 T/C TCC/CCC Serine/Proline PA14_57930 PA4461  
ABC transporter ATP-binding 
protein 
5,163,385 C/A CCC/CCA Proline PA14_58030 PA4470 fumC Fumarate hydratase 
5,187,968 A/C AAG/ACG Lysine/Threonine PA14_58250 PA4489  Hypothetical 
5,235,921 T/C CTG/CCG Leucine/Proline PA14_58750 PA4526 pilB Type 4 fimbrial biogenesis protein 
5,314,049 G/A GTG/ATG Valine/Methionine PA14_59710  
cupD
1 Fimbrial protein 
5,331,047 T/C GGT/GGC Glycine PA14_59840   Hypothetical 
5,432,474 A/G GAG/GGG 
Glutamic 
acid/Glycine PA14_60870 PA4601 morA Motility regulator 
5,496,057 C/A AGC/AGA Serine/Arginine PA14_61590 PA4656  Hypothetical 
5,501,873 C/A CAC/CAA Histidine/Glutamine PA14_61650 PA4661 pagL Lipid A 3-O-deacylase 
5,597,574 G/A Intergenic     
5,633,276 A/G Intergenic     
5,762,000 C/A CCG/ACG Proline/Threonine PA14_64690 PA4895  Transmembrane sensor 




5,819,003 C/A CGT/AGT Arginine/Serine PA14_65300 PA4943 hflX GTP-binding protein 
5,827,207 G/A GGC/GAC 
Glycine/Aspartic 
acid PA14_65400 PA4950  Iron sulfur cluster binding protein 
5,894,399 C/A CCT/ACT Proline/Threonine PA14_66160 PA1391  Glycosyl transferase family protein 
5,947,261 C/A GCT/GAT 
Alanine/Aspartic 
acid PA14_66620 PA5040 pilQ 
Type 4 fimbrial biogenesis outer 
membrane protein precursor 
5,847,448 A/C ACG/CCG Threonine/Proline PA14_66620 PA5040 pilQ 
Type 4 fimbrial biogenesis outer 
membrane protein precursor 
6,222,145 
Insertion 
of two Cs Frameshift PA14_69760 PA5284  Fimbrial protein 
6,288,100 
Insertion 
of C Frameshift PA14_70580 PA5346  Hypothetical 
 













I.D Product Annotation 
154,905 C/T AGC/AGT Serine PA14_01680 PA0137  ABC transporter permease 
304,728 T/G CTG/CGG Leucine/Arginine PA14_03340   Hypothetical 
375,119 G/T GGC/TGC Glycine/Cysteine PA14_04190 PA0321  Acetylpolyamine aminohydrolase 
400,739 C/A GCG/GAG Alanine/Glutamic acid PA14_04510 PA0344  Hypothetical 
559,260 T/G GTC/GGC Valine/Glycine PA14_06320 PA0485  Hypothetical 
676,385 C/T ACC/ATC Threonine/Isoleucine PA14_07850 PA0602  
ABC transporter substrate binding 
protein 
738,116 T/C Intergenic      
758,103 T/C GCT/GCC Alanine PA14_08830 PA4265 tufA Elongation factor Tu 
1,052,018 G/T GGC/GTC Glycine/Valine PA14_12160 PA3992  Murin transglycosylase 
1,135,419 C/T Intergenic      
1,185,260 T/C TAC/CAC Tyrosine/Histidine PA14_13780 PA3875 narG 
Respiratory nitrate reductase alpha 
subunit 
1,289,849 G/T GCC/TCC Alanine/Serine PA14_15210 PA3788  LysR family transriptional regulator 
1,298,491 T/C TTC/CTC Phenylalanine/Leucine PA14_15310 PA3770 guaB 
Inosine 5'-monophosphate 
dehydrogenase 
1,337,210 G/T GGC/TGC Glycine/Cysteine PA14_15720 PA3764  Transglycosylase 
1,345,617 T/G GTG/GGG Valine/Glycine PA14_15790 PA3760  
Phosphoenolpyruvate-protein 
phosphotransferase 
1,382,883 C/T CAG/TAG Glutamine/STOP PA14_16190 PA3728  Hypothetical 
1,421,131 C/T CCG/CTG Proline/Leucine PA14_16600 PA3695  Alpha/beta hydrolase 
1,518,742 
Deletion 






of G Intergenic      
1,696,730 
Deletion 
of G Intergenic      
1,731,558 T/C CTC/CCC Leucine/Proline PA14_20080 PA3402  Hypothetical 
1,760,186 T/G GTG/GGG Valine/Glycine PA14_20491 PA3368  Acetyltransferase 
1,897,804 
Insertion 
of G Intergenic      
1,955,322 G/T GGG/GTG Glycine/Valine PA14_22460 PA3226  Alpha/beta hydrolase 
1,968,127 T/G TAC/GAC Tyrosine/Aspartic acid PA14_22620 PA3217 cyaB Hypothetical 
2,054,407 C/T CCG/CTG Proline/Leucine PA14_23610 PA3132  Hydrolase 
2,078,818 C/T ACC/ATC Threonine/Isoleucine PA14_23920 PA3108 purF Amidophosphoribosyltransferase 





of GC Frameshift  PA14_25030 PA3018  Hypothetical 
2,199,501 G/A CTG/CTA Leucine PA14_25130 PA3010  Hypothetical 
2,266,101 C/T GCC/GTC Alanine/Valine PA14_25970 PA2944 cobN Cobaltchelatase subunit 
2,488,972 
Insertion 
of G Frameshift  PA14_28830   Hypothetical 
2,563,135 A/G GAT/GGT Aspartic acid/Glycine PA14_29560 PA2670  Hypothetical 
2,636,539 
Insertion 
of G Frameshift  PA14_30440 PA2602  Hypothetical 
2,717,231 
Insertion 
of G Intergenic      
2,823,869 G/T GCC/TCC Alanine/Serine PA14_32490 PA2485  Hypothetical 
2,902,168 A/G AGC/GGC Serine/Glycine PA14_33130 PA2435  Cation transporting P-type ATPase 
2,906,836 
Deletion 
of G Frameshift  PA14_33200   Hypothetical 
2,967,058 A/G AGC/GGC Serine/Glycine PA14_33610 PA2402  Peptide synthase 
2,967,078 C/G GCC/GCG Alanine PA14_33610 PA2402  Peptide synthase 
2,967,133 T/C TTG/CTG Leucine PA14_33610 PA2402  Peptide synthase 
2,967,154 T/C TTG/CTG Leucine PA14_33610 PA2402  Peptide synthase 
2,997,125 T/G TAC/GAC Tyrosine/Aspartic acid PA14_33750 PA2391  Outer membrane protein 
3,104,307 
Insertion 
of G Frameshift  PA14_34870  chiC Chitinase 
3,137,923 
Deletion 
GCG Frameshift  PA14_35290  gnd Gluconate dehydrogenase 
3,298,597 G/T GCC/TCC Alanine/Serine PA14_37030 PA2130 cupA3 Usher 






of C Frameshift  PA14_37680   Hypothetical 
3,436,453 T/C TTC/CTC Phenylalanine/Leucine PA14_38510 PA2009 hmgA Homogentisate 1,2-dioxygenase 
3,566,821 
Insertion 
of G Frameshift  PA14_40020 PA1895  Hypothetical 
3,639,578 G/A GCG/GCA Alanine PA14_40780 PA1837  Hypothetical 







of C Frameshift  PA14_41560 PA1779  Assimilatory nitrate reductase 
3,765,487 
Deletion 
of C Frameshift  PA14_42220   
Membrane sensor domain containing 
protein 
3,799,535 A/C ATC/CTC Isoleucine/Leucine PA14_42710 PA2170  Hypothetical 
3,934,559 T/C CTG/CCG Leucine/Proline PA14_44210 PA1567  Glycine/D amino acid oxidase 
3,943,570 A/G Intergenic      
4,159,861 
Deletion 
of G Frameshift  PA14_46660 PA1363  
RNA polymerase ECF subfamily 
sigma 70 factor 
4,391,772 C/A CCG/ACG Proline/Threonine PA14_49420 PA1158  Two component sensor 
4,460,999 C/A GCC/GAC Alanine/Aspartic acid PA14_50220 PA1097 fleQ Transcriptional regulator 
4,488,205 T/C Intergenic      
4,502,169 T/G GTG/GGG Valine/Glycine PA14_50680 PA1059 shaA  
4,532,506 
Insertion 
of G Intergenic      
4,533,297 T/C Intergenic      
4,595,853 C/A GCG/GAG Alanine/Glutamic acid PA14_51730 PA0971 tolA  
4,636,034 T/C CTG/CCG Leucine/Proline PA14_52260 PA0928  Sensor/response regulator hybrid 
4,787,261 
Deletion 
of two Cs Frameshift  PA14_53980 PA0793  Hypothetical 
4,848,971 T/C CTC/CCC Leucine/Proline PA14_54690 PA0741  Hypothetical 
5,003,595 G/A CGC/CAC Arginine/Histidine PA14_56030 PA4311  Hypothetical 
5,009,310 T/C Intergenic      
5,033,370 T/G GTA/GGA Valine/Glycine PA14_56430 PA4341  Transcriptional regulator 
5,036,924 C/A CTG/ATG Leucine/Methionine PA14_56480 PA2922  Hydrolase 
5,100,605 C/A GCC/GCA Alanine PA14_57240 PA4404  Hypothetical 
5,150,583 C/A ACG/AAG Threonine/Lysine PA14_57850 PA4454  Hypothetical 
5,235,267 G/A GGC/GAC Glycine/Aspartic acid PA14_58750 PA4526 pilB Type 4 fimbrial biogenesis protein 
5,252,021 T/C TCC/CCC Serine/Proline PA14_58910   Chromosome partioning like protein 




5,412,824 A/C AAC/ACC Asparagine/Threonine PA14_60730 PA4589  Outer membrane protein 
5,589,447 G/A Intergenic      
5,709,739 G/A GCC/ACC Alanine/Threonine PA14_64060 PA4844  Chemotaxis transducer 
5,836,844 T/C Intergenic      
5,889,223 C/A ACC/AAC Threonine/Asparagine PA14_66110 PA1390  Glycosyl transferase family protein 





of CG Frameshift  PA14_69040 PA5228  5-formyltetrahydrofolate cyclo-ligase 
6,208,103 T/C CTG/CCG Leucine/Proline PA14_69580 PA5269  Hypothetical 
6,458,917 A/C ATC/CTC Isoleucine/Leucine PA14_72490 PA5493 polA DNA polymerase I 
 











PAO1 Gene I.D Product Annotation 
155,680 C/T GCC/GCT Alanine PA14_01690 PA0138  
ABC transporter 
permease 
1,423,505 A/G GAT/GGT Aspartic acid/Glycine PA14_16640 PA3691  Lipoprotein 
1,635,489 
Insertion 
of C* Intergenic      
1,794,770 A/G GAC/GGC Aspartic acid/Glycine PA14_20850 PA3341  
MarR family 
transcriptional regulator 
2,520,703 A/G GAG/GGG 
Glutamic 
acid/Glycine PA14_29130 PA2707  ATPase 
3,994,253 
Insertion 
of C** Intergenic      
4,085,427 A/C CAT/CCT Histidine/Proline PA14_45960 PA1430 lasR Transcriptional regulator 
4,435,660 G/A GAA/AAA Glutamic acid/Lysine PA14_49890 PA1120 tpbB Diguanylate cyclase 
4,807,520 C/T CTC/CTT Leucine PA14_54180 PA0781  Hypothetical 
4,937,922 G/T GCG/GCT Alanine PA14_55460 PA0684 hxcZ  
5,467,721 C/T CCC/TCC Proline/Serine PA14_61250 PA4628 lysP 
ABC family lysine-
specific permease 
6,457,982 C/A GAC/GAA 
Aspartic 
acid/Glutamic acid PA14_72490 PA5493 polA DNA polymerase I 
* 2 Cs in red       












The successful clinical management of chronic respiratory disease, in particular Cystic Fibrosis 
(CF), has been hindered by the rapid emergence of antimicrobial resistance (1, 2). Uncontrollable 
cycles of infection and inflammation resulting in irreversible lung damage contribute to 
progressive lung function decline (3-6). To date strategies have primarily focused on the 
alleviation of the symptomatic consequences of disease. This includes a combination of chest 
physiotherapy to clear the airways of viscous mucus, anti-inflammatories and antibiotics (7-10). 
However, the chronic colonisation of the CF airways by pathogens, frequently Pseudomonas 
aeruginosa, marks a switch in the emphasis of patient treatment to improving quality of life 
(QoF). Therefore, early and aggressive eradication strategies are essential in the prevention of 
pathogen establishment which have been shown to correlate with improved patient outcomes 
(11-14). Unfortunately, these strategies are not always effective in the prevention of chronic 
infection/inflammation, therefore alternative interventions must be sought (15). The design of 
such strategies requires a comprehensive understanding of the environmental and host factors 
contributing to the progression of chronic respiratory disease. Gastro-oesophageal reflux (GOR) 
is one such host factor which has been implicated as a key comorbidity in CF and a range of 
other respiratory conditions (16-20). Gastro-oesophageal reflux disease (GORD) was shown to 
correlate with increased disease severity and the development of bronchiectasis (21). However, 
the underlying mechanism through which GORD associated lung damage occurs had yet to be 
fully elucidated. It was proposed that GORD derived bile aspiration was the potential underlying 
causative agent responsible, with the focus of this PhD centred on establishing the molecular 
mechanisms through which bile exerts its impact on the biodiversity of the lung microbiota and 




From a clinical perspective, the prevalence of GORD in CF and the resulting aspiration of bile into 
the airways has been confirmed as a significant comorbidity modulating the progression of lung 
disease, with evidence from both in vitro and in vivo studies to support this (12, 22-28). In fact, 
though this thesis has focused on CF, GORD has been described as a key comorbidity for a range 
of other respiratory conditions (as outlined in the general introduction). Therefore, there are far 
reaching consequences for the findings reported here. The microbiology of the CF lung and the 
changes that occur throughout disease progression have been the subject of intensive research 
efforts in the past number of years. These studies have shown that signature diverse microbial 
communities are present in the CF airways with a shift towards pathogen dominated, reduced 
microbial diversity as patients’ transition to adulthood (29-34). Initial studies have predominantly 
focused on the characterisation of the lung microbiota, however the emphasis must now shift to 
the clinical implications of shifts in the microbiota and to the range of factors contributing to the 
restructuring of these communities.  
The longitudinal clinical analysis of an Australian paediatric cohort revealed a correlation between 
the presence of bile acids and pathogen dominated microbiota. There was a shift to a reduced 
biodiversity pathogen dominated microbiota in patients for which bile acids were present. This 
reduction in diversity of the lung microbiota is a hallmark of CF disease progression and has been 
reported in several studies of the CF respiratory microbiota (30, 31, 35-37). Inter patient 
differences in terms of bile acid concentrations were present within the cohort. Interestingly, low 
concentrations of both bile and bile acids have been demonstrated to impact microbial 
communities and bacterial behaviour in vitro (12, 25-27). The differences in bile acid profiles 
between patients is also a subject worthy of further investigation, as individual bile acids have 




that bile acids are capable of influencing the composition of the lung microbiota associated with 
increased disease severity. While these clinical studies are certainly informative, further studies 
and potentially animal models will be required in order to establish causality. 
The observation that bile acid status correlated strongly with CF pathophysiology in paediatric 
patients is highly significant, as bile acid profiling may provide a rapid and effective early 
prognostic biomarker for the identification of high-risk patients predisposed to the onset of chronic 
respiratory infections. Where this is the case, advances in bile acid profiling technologies, possibly 
to the stage where point of care devices are routine in hospitals and clinics, would have significant 
clinical benefit. Most importantly, bile may represent a potential therapeutic target for the 
development of novel therapeutics, providing an opportunity for effective early clinical 
intervention.  
While this research no doubt has clinical implications, the advances in CF molecular therapeutics 
such as Orkambi (39, 40) and to a lesser extent gene therapy which have been revolutionary for 
CF patients, would question the need for such research. However, the availability and 
administration of these therapies is not without its limitations. The primary limitation is the age at 
which patients’ may commence treatment (40). Until recently this stood at 6 years of age with the 
FDA recently approving treatment in paediatric patients as young as two (40). Unfortunately, by 
this time the dysregulated cycles of chronic inflammation and chronic infection which are central 
to the pathogenesis of CF have been initiated with patients as young as 1 already exhibiting 
bronchiectasis (5, 6, 41, 42). Hence, there is a degree of pre-existing lung damage prior to the 
administration of these treatments. Furthermore, the acquisition of pathogens and subsequent 
microbial dysbiosis occurs in infancy, prior to the commencement of these therapies (32, 43). This 




conjunction with these molecular therapeutics with the goal of hindering the progression of lung 
disease.  
It is clear that bile has the potential to play a role in shaping the respiratory microbiota, with 
individual respiratory pathogens shown to respond to bile by modulating the expression of 
virulence related signal transduction systems (26). Deciphering the mechanisms through which 
pathogens such as P. aeruginosa respond to bile is key to the development of targeted strategies 
for the prevention of chronic bacterial infection which cannot be eradicated by conventional 
antibiotic treatment strategies. This research predominantly focused on P. aeruginosa which is the 
primary pathogen associated with morbidity and mortality in CF (21, 44). However, other 
respiratory pathogens such as Staphylococcus aureus and Stenotrophomonas maltophilia were also 
shown to respond to bile by transitioning towards a biofilm lifestyle. It was interesting to note that 
while clinical isolates of these species from the lungs of patients with respiratory disease exhibited 
an increased biofilm state in response to bile, model isolates from culture collections exhibited a 
contrasting phenotype of markedly reduced biofilms. This would suggest a degree of adaptation 
within the challenging ecosystem of the host pulmonary system. Transcriptomic and phenotypic 
analysis of the P. aeruginosa response to bile challenge revealed alterations in virulence, including 
enhanced antibiotic resistance and biofilm formation, potentially linked to alterations in central 
metabolism and redox flux. The connection between virulence potential and metabolic flux has 
been previously reported in a range of pathogens including P. aeruginosa (45, 46), S. aureus (47), 
Salmonella enterica (48) and Listeria monocytogenes (49). A comprehensive understanding of 
the behavioural changes induced by bile will facilitate the design of increasingly effective 




The adaptations of bile tolerant bacteria residing within the GI tract is a valuable source of 
information regarding the mechanisms of bile response systems which may be conserved 
between enteric and respiratory bacteria. There is a wealth of literature describing the numerous 
strategies employed by enteric bacteria to colonise the gut and withstand bile and bile acid stress. 
This includes modification to the outer membrane, the lipopolysaccharide (LPS) moiety in 
particular (50-53). An array of multidrug efflux pumps, such as the AcrAB and EmrAB pumps, 
have been implicated in the bile tolerance of these bacteria, facilitating the removal of bile that 
permeates the outer membrane (53-57). Porin modification has also been shown to contribute to 
bile tolerance by decreasing the ability of bile salts to penetrate the membrane (55, 58). Bile 
acids are also capable of inducing a transcriptional response with generalised and oxidative stress 
responses described in a variety of organisms (59, 60). It is therefore possible that bacteria 
residing in the airway may employ some of these strategies in order to survive and persist in the 
airways.  
The primary phenotype associated with the switch to chronicity is the production of a biofilm 
with bile shown to increase biofilm formation in the P. aeruginosa. Bile has been previously 
shown to induce biofilm in the enteric organisms Salmonella and Vibrio cholerae (61-64)  
Understanding how the pathogen senses and responds to this host factor would facilitate the 
design of novel therapeutic strategies and facilitate the design of targeted molecular therapeutics 
preventing the induction of biofilm. Therefore, the identification of sensory pathways involved in 
the bile induced chronic switch would be a significant advance. This translational research would 
provide many opportunities for the development of novel therapeutics, which could potentially 
target the sensory pathways in these respiratory pathogens orchestrating this critical response to 




in the environment has been previously investigated and is still not fully understood. The two 
component system PhoPQ (65) and transcriptional activators; RpoS and SigB are reported to 
play a role (66, 67). There may also be an indirect detection of bile acids by detection of 
alterations in the bacterial cell membrane.  
The DctB-DctD two component system regulates C4-dicarboxylate uptake in the cell (68) and 
the GtrS-GltR two component system regulates glucose uptake (69). Mutations within these 
genes hindered but did not completely abolish the ability of P. aeruginosa to enhance biofilm 
formation in the presence of bile. Hence, there appears to be a degree of redundancy in the 
regulatory controls underpinning the bile response. Additionally, protein interaction studies 
would be required to investigate the regulation and activation of these systems and whether there 
is any interaction between them. Further elucidation of the hierarchical intricacies of the 
molecular mechanism controlling the response of the pathogen to this key host factor may 
facilitate the design of signal transduction blockers (70, 71). However, the absence of an 
identifiable master regulator controlling the bile response makes the design of molecules to block 
the response much more challenging. 
The combined transcriptomic and phenotypic approach undertaken identified additional signal 
transduction components and the possible molecular mechanism controlling the bile response. 
Though there was components identified in common with a generalised stress response, the 
combination of systems altered appeared to indicate that there is a unique bile specific response. 
This revealed a connection between flux through central metabolism, key metabolic two 
component systems, outlined above, and the mounting of an effective bile response. These 
analyses also indicated that the response to bile may involve several other regulatory systems 




response to bile (72). Further work is required to elucidate the complexity of these systems and 
to decipher how the cell integrates these various regulatory circuits to mount an effective 
response to this emerging host factor which has the ability to modulate the progression of 
chronic respiratory disease. 
Reports of P. aeruginosa acquisition via an aerodigestive route is significant considering the bile 
responsiveness of P. aeruginosa (73, 74). The gastrointestinal tract is known to act as a reservoir 
for P. aeruginosa and other potential respiratory pathogens with acid suppressed of CF patients 
suffering from GORD contributing to bacterial overgrowth (75-77). These isolates may have had 
prior exposure and adaptation to bile within the GI tract with the potential subsequent transmission 
of pre-adapted isolates into the lower airways, equipping these organisms with a further 
competitive advantage within the CF airways (74, 78, 79). Therefore, the wide spread 
administration of acid suppression therapies in these patient cohorts should be re-evaluated for 
their efficacy due to the inadvertent impact on GI tract bacterial overgrowth which may have 
potential negative repercussions on the progression of chronic lung disease (80). The 
administration of probiotics may be a viable strategy to counter these effects (76).  
The fact that bile itself is a complex mixture consisting of a mixture bile acids, phospholipids, fatty 
acids and bilirubin adds a further layer of complexity when deciphering the response of P. 
aeruginosa. Hence, the bacterial response to bile may be a culmination of response to these 
individual components. Bile acids have emerged as a key active component underpinning chronic 
biofilm formation in P. aeruginosa, with CDCA in particular eliciting the strongest response. 
Specificity in the interaction between bile acids and a potential receptor system would enhance the 




the degree to which individual bile acids contribute to antibiotic tolerant biofilm formation in P. 
aeruginosa and other respiratory pathogens. 
Of course, in pursuing a molecular mechanism and in seeking to understand the factors that govern 
chronicity in the lungs of patients with respiratory disease, one must also take note of the genotypic 
and phenotypic heterogeneity that pervades in the lungs (81-83). Several studies have highlighted 
the evolution of P. aeruginosa and other pathogens within the lungs of patients with respiratory 
disease (84-86). These studies have highlighted extensive diversification and adaptation to the CF 
lung environment, underpinned by the emergence of hyper-mutator strains (87) with mutations in 
key quorum sensing genes, such as lasR (88), and antibiotic resistance genes such as the mex genes 
(89) described.  As a result, any intervention would need to target a community of variants rather 
that a single clonal population. The hyper induction of pyocyanin and PQS signalling in response 
to bile was particularly interesting given the central role these systems play in the host-pathogen 
and microbe-microbe interactions, with QS expression demonstrated to cause global metabolic 
changes within the cell, similarly to that observed within the bile transcriptome (90-96). The 
question as to why pigmented variants emerge following long-term bile exposure could potentially 
be attributed to the requirement for the population to manage what are essentially toxic levels of 
pyocyanin and PQS within the community (92). Increasing PYO and PQS upon initial exposure 
may offer a competitive advantage to P. aeruginosa as it seeks to establish itself within the mixed 
microbial community, responding to what it has evolved to recognise as an important host signal 
(97). The pigments themselves may also confer an increased tolerance to stresses encountered 
during colonisation, such as oxidative stress and redox imbalance (98-100). Further work will be 




respiratory microbiomes, and to elucidate the extent to which mutations in these systems are 
propagated within the clinical microbiota. 
Though not in the scope of this thesis, bile has been shown to both directly and indirectly impact 
the initiation of inflammation, indirectly through its promotion of colonisation by pro-
inflammatory pathogens and directly through its impact on the host inflammatory response. The 
presence of bile acids has been correlated with increased levels of neutrophils, neutrophil elastase 
and the pro-inflammatory cytokine interleukin-8 (24, 101, 102). Bile acids have also been shown 
to destabilise the transcription factor HIF-1 required for the resolution of acute inflammation (103, 
104). The dual targeting of airway infection and airway inflammation by bile and bile acids 








Figure 1; Overview of the bile acid-microbiota axis within the CF lung. (A) The accumulation of bile acids within 
the lungs of patients with CF as a consequence of aspiration leads to changes in the structure of the lung microbiota. 
This results in a transition from a high diversity stable community (left lung) to a pathogen dominated low diversity 
population (right lung). (B) The impact of bile acids on the behaviour of the key CF associated pathogen P. aeruginosa 
is consistent with a switch towards a chronic antibiotic tolerant biofilm lifestyle. (C) The dual impact of bile acids on 
the lung microbiota (promoting chronicity) and the inflammatory response (e.g. FXR-dependent induction of pro-
inflammatory cytokines) underscores the unifying principle of bile acids as a major host factor promoting the 
progression of chronic respiratory disease. Modulation of host signalling through the HIF-1 transcription factor by 
bile acids and bile-induced P. aeruginosa derived PQS serve to further promote dysregulated inflammation in this 
patient cohort. 
Early intervention is crucial in the long term prevention of bile induced lung damage, with a 
concerted effort to identify biomarkers for early prognosis. There are many possible therapeutics 
aimed at the control of aspiration. The most common approach currently undertaken is a surgical 




procedures, however, there are associated risks hence there is limited practice of this surgery in 
paediatric patients (107, 108). Therefore, there are calls for less invasive anti-GORD techniques. 
Pro-kinetic macrolides are one such strategy which target bile aspiration at the source by enhancing 
gastric emptying and consequently reducing the frequency of aspiration events (109, 110). The 
administration of inhaled bile acid sequestrants (111) may prove to be a viable alternative which 
could silence the biological effects of bile acids on both bacterial and host cells. As bile acids 
display differential biological activity with the gut microbiota influencing the bile acid profiles 
present, manipulation of the gut microbiota with probiotics may be worthy of further investigation.  
Taken together, the new knowledge presented in this thesis provides a new perspective on the 
factors governing the chronic persistence of P. aeruginosa in the lungs of patients with CF. It 
offers evidence of a correlation between lung bile acids and changes in community structure, both 
from a cross-sectional and longitudinal perspective. The in vitro studies support the hypothesis 
that bile, and bile acids, can shift the behaviour of P. aeruginosa and other respiratory pathogens 
towards a chronic persistent lifestyle. However, further clinical and animal model studies will be 
required to establish a causal link. The aspiration of bile acids is another example of how the role 
of bile, and particularly bile acids, in host cellular physiology extends far beyond the classical 
understanding. With increasing sensitivity, the detection of bile acids at physiologically relevant 
concentrations has expanded our appreciation for their role in previously unforeseen clinical 
conditions. The realisation that microbially derived bile acids can impact on chronic diseases from 
CF to Cancer has opened new horizons in the search for better more effective clinical interventions, 
beyond their classical role in human physiology. The next horizon for bile acid research will be 
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